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Chapter 1
GENERAL INTRODUCTION
Parts of this chapter have been published in:
Stappen op weg naar de uitroeiing van malaria / On the way to eradicating malaria
Nederlands Tijdschrift voor Geneeskunde 2012; 156: A4095
Guido J.H. Bastiaens1, Else M. Bijker1, Robert W. Sauerwein1
1Department of Medical Microbiology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
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Malaria
Malaria is a life-threatening disease caused by the protozoan Plasmodium parasite. It 
accounts for 207 million clinical cases a year worldwide with an estimated 627,000 deaths, 
with children under five years of age in sub-Saharan Africa most severely affected [1]. 
Severe anaemia, cerebral malaria, acute respiratory distress syndrome and organ failure 
are the most common causes of death [2-4]. The malaria parasite Plasmodium falciparum 
that predominates in sub-Saharan Africa is responsible for the vast majority of these 
deaths [1]. Besides P. falciparum, four other Plasmodium parasites (P. vivax, P. ovale, P. 
malariae and P. knowlesi) can cause malaria in humans after bites by infected female 
mosquitoes of more than 30 anopheline species [1,5]. The Plasmodium life cycle is given in 
Figure 1 and shows two distinct parasite phases, an asexual phase where parasites are 
replicating in the human host and a sexual phase where fertilisation of sexual stage 
parasites takes place inside the mosquito midgut. 
 The highest malaria prevalence and transmission intensity is currently found in the 
World Health Organization’s African region where approximately 80% of cases and 90% of 
deaths are estimated to occur [1]. Although here prevalence [6-8] as well as malaria 
mortality is declining [1,9], it remains a huge problem with tremendous economical 
consequences [10,11] particularly affecting the poorest populations and rural areas [1,12].
Malaria control and eradication: the past and present
In 1955 the World Health Organization (WHO) adopted a Global Malaria Eradication 
Programme based on the widespread use of the insecticide DDT (dichlorodiphenyltri-
chloroethane) against Anopheles mosquitoes and the antimalarial drug chloroquine for 
treatment and elimination in humans [13]. Although these efforts were successful over 
large geographical areas including the Netherlands, the campaign was only launched in 
three countries of sub-Saharan Africa [13]. It was not considered feasible in the others 
particularly due to the very high infection pressure and poor (health) infrastructure and 
underperforming health services. Furthermore, the worldwide heterogeneity of malaria 
transmission and disease was underestimated [13-15]. In 1969 global malaria eradication 
was concluded to be unfeasible: for areas where malaria continued to be endemic, the 
focus shifted to control of (severe) malaria disease [16]. This immediately resulted in a 
considerable reduction in financial support to antimalarial programmes, which was 
aggravated by economic and financial crises in the 1970s and 1980s [13,14]. 
 In the 1980s and 1990s malaria started a gradual or sometimes dramatic resurgence, 
which was primarily fuelled by the increase and spread of chloroquine-resistant parasites 
and DDT-resistant anophelines [15,17]. There was at least a doubling of childhood malaria- 
specific mortality from the 1980s compared with the early 1990s in various areas in 
sub-Saharan Africa [17,18] and a rise in the proportion of all childhood deaths attributed to 
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Figure 1  Life cycle of Plasmodium parasites
Female Anopheles mosquitoes inject invasive forms of malaria parasites - sporozoites - when taking a 
blood meal from the human host. These sporozoites migrate via the skin and blood vessels to the liver 
where they mature in hepatocytes without giving clinical symptoms. After ~1 week, an estimated 
40,000 merozoites per infected hepatocyte are released in to the circulation and rapidly invade 
erythrocytes, where they again mature and eventually rupture the erythrocyte while releasing 16–32 
new merozoites into the circulation. These new merozoites again invade erythrocytes, leading to an 
exponential cyclical increase in parasitaemia with clinical symptoms. Each cycle takes ~48 hours to 
complete. The variation in the density of asexual parasites in the bloodstream of infected individuals 
in an area of moderate transmission intensity is shown in red (inset).
A fraction of asexual parasites transforms into sexual stage parasites, gametocytes. The density of 
mature gametocytes in peripheral blood is typically less than 100 gametocytes per μl of blood (light 
blue; inset). Once infectious gametocytes have been ingested by a blood feeding female Anopheles 
mosquito, male and female gametes fuse to form an motile ookinete in the mosquito midgut that 
can penetrate the mosquito midgut wall to form oocysts. The oocyst eventually releases new 
sporozoites that migrate to the mosquito salivary gland, ready to infect a new human. Oocyst 
densities in naturally infected mosquitoes that have fed on either microscopic or submicroscopic 
parasite carriers are typically in the range of 1–10 oocysts (brown; inset). Sporogonic development 
renders mosquitoes infectious to humans after approximately 11–16 days [Meis JF, et al. 1992].
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Microbiology. Bousema T. et al. Asymptomatic 
malaria infections: detectability, transmissibility, and public health relevance 2014 Dec;12(12):833-40, copyright 2014.
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malaria from 18% pre-1960 to 30% during the 1990s [18]. At the end of the 1990s, the 
malaria situation in several settings may have been further deteriorated as a result of civil 
disturbances, increased travel and the HIV epidemic [13,19]. 
 At the beginning of the new millennium, greater recognition of the devastating 
socio-economic effects of malaria stimulated investments in malaria control programmes 
and malaria research. From then on, international disbursements to malaria-endemic 
countries have increased tenfold to US$ 1.71 billion in 2010 and US$ 2.5 billion in 2012 [1]. 
This is an important step forward but still less than half of the estimated US$ 5.1 billion 
required annually to achieve universal access to malaria interventions [1]. 
 The tremendous expansion in the financing and implementation of malaria control 
programmes in the past decade resulted in reductions in malaria case incidence, morbidity 
and mortality [1,8,9]. The number of clinical malaria cases dropped from 226 million in 
2000 to 207 million in 2012 and the number of deaths fell from 985,000 in 2000 to 627,000 
in 2012 [1]. Malaria transmission intensity decreased in several endemic areas and many 
former high-endemic malaria areas are currently characterized by low or decreasing 
malaria transmission [1,8,20-22]. 
 Despite the progress much greater gains could be achieved against malaria, including 
elimination from a number of countries and regions by aggressively scaling up control 
with currently available tools and strategies. Nonetheless, even with maximal effort elimination 
in many areas and global eradication is considered unfeasible [23,24] partly due to 
constant threats to current progress, such as emergence of artemisinin resistance [25-30] 
and vector mosquito resistance to insecticides [31]. Consequently, need for more potent 
tools to contain dissemination of resistant parasite strains and accelerated development 
of vaccines that can impact on malaria incidence, disease, and death remains a high 
priority [32,33].
Improving access and accuracy of diagnosis using 
malaria rapid diagnostic tests
One of the main threats to current progress in decreasing the malaria burden is over -
treatment with antimalarials, which creates artemisinin drug pressure [28,34] that may 
facilitate the spread of artemisinin resistant parasites. Since the 1980s, malaria control has 
incorporated presumptive treatment of fever with antimalarials, treating all febrile 
episodes suspected of malaria with a full therapeutic dose of antimalarials without being 
confirmed by laboratory diagnosis [19]. This approach is no longer justifiable now it is 
realized that treatment decisions are based on clinical signs and symptoms that are neither 
sensitive nor specific [35]; the initial symptoms of malaria may include tachycardia, 
tachypnoea, chills, malaise, fatigue, diaphoresis, headache, cough, anorexia, nausea, 
vomiting, abdominal pain, diarrhoea, arthralgias, and myalgias [36]. The issue of most 
concern for patients with non-malaria severe febrile illness is that treatable alternative 
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diagnoses are being missed, and in febrile children it was shown that mortality due to 
bacterial disease is underestimated [37,38]. 
 Reports from the past decade indicate that many parts of Africa are currently 
characterized by low or decreasing malaria transmission intensity [6-9,20,39]. Particularly in 
these low and moderate transmission areas presumptive treatment practices result in 
extensive overuse of antimalarial drugs, which can contribute to a reduced susceptibility 
of parasites to artemisinins [27,28], the core compound in the world’s most effective 
antimalarial medicines [1,27]. Improving access to and accuracy of diagnosis may thereby 
prove crucial to prevent overtreatment and stimulate the search for alternative causes of 
illness. 
 The gold standard for malaria diagnosis, microscopy, faces challenges particularly in 
rural clinics: microscopes and reagents are often of poor quality and there is a lack of well 
trained microscopists [20,22,40,41]. Malaria rapid diagnostic tests (RDTs) - immunochro-
matographic tests that detect malaria parasite antigens in whole blood samples - pose an 
attractive alternative to routine microscopy: they are sensitive and specific by detecting 
specific P. falciparum or other Plasmodium antigens [42-45], are simple in comparison with 
other malaria diagnostic tests because they do not require electricity or expensive 
equipment, provide results in 15–20 minutes, are relatively inexpensive at $0.30–1.00 per 
test [46], are easy to use, and provide more objective results than microscopy - the test line 
is either present or absent. RDTs are one of the fundamental pillars of the existing global 
strategy to fight malaria [47] and have the potential to reduce the burden of malaria by 
improving parasite-based diagnosis. Improved diagnosis, in turn, can improve treatment 
outcomes, rationalize health care costs by reducing drug consumption [48] and minimize 
drug pressure [28,34], and assist in monitoring disease trends [47]. In theory, the focus on 
RDTs should change presumptive treatment based on signs and symptoms alone, to 
parasite-based diagnosis and treatment based on test results. It is, however, unclear 
whether a change in policy directly affects routine practice or if additional measures are 
needed to improve implementation.
Improving vector control by mosquitocidal drugs
Insecticide-treated bed nets (ITNs) and indoor residual spraying (IRS) were two of the 
conventional key interventions that were rapidly scaled-up in the past decade [49-52] and 
that contributed to the decline in P. falciparum malaria in a number of endemic settings 
throughout sub-Saharan Africa [1,6-9]. Here, the proportion of the population with access 
to an ITN in their household increased dramatically from 2005 to 2011 although the rate 
flattened during the last 2 years, reaching 42% in 2013 [1]. ITNs have been shown to reduce 
malaria transmission by 70–90%, leading to significant reductions in human-vector 
contact, the number of infectious mosquito bites [53,54] and the force of infection [55]. IRS 
targets the vector, the Anopheles mosquito. Despite negative effects on the environment, 
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dichlorodiphenyltrichloroethane (DDT) has been proven to be very successful for disease 
vector control [50,51] and there will be a continued role for DDT in malaria control despite 
its toxicity [56,57]. 
 The efficacy of both interventions is being threatened by Anopheles mosquito 
resistance to insecticides [31]. Furthermore, there are data indicating that mosquitoes can 
increase their biting behaviour from indoors to outdoors [58]. It is therefore debated 
whether up-scaling of conventional malaria control measures like ITNs and IRS will sustain 
declines in malaria or achieve malaria elimination [59] unless augmented by tools that 
specifically aim to reduce transmission. 
 The transmission of malaria from humans to mosquitoes depends on the presence of 
mature gametocytes in the peripheral blood [60]. Gametocytes are relatively insensitive 
to schizonticidal drugs and current first line antimalarial drugs may therefore need to be 
supported by specific transmission-blocking drugs [61]. Traditionally, the search for trans-
mission-blocking drugs has focused on antimalarial drugs with gametocytocidal activities. 
Primaquine has received considerable interest in this because it is the only currently 
available drug that actively clears mature gametocytes, which can persist for several days 
after infected individuals are treated with artemisinin-combination therapy (ACT) [62-65]. 
The average duration of gametocyte carriage after ACT is estimated at 13.4 days although 
gametocyte densities are highest in the first week after initiation of treatment [66]. As a 
result, a substantial proportion of patients can transmit malaria up to 7–14 days after 
successful ACT treatment [65,67-69]. Although addition of primaquine can prevent malaria 
transmission from infected humans to mosquitoes after treatment [70], it is causally 
associated with intravascular haemolysis in glucose-6-phosphate-dehydrogenase (G6PD) 
deficient individuals [71-76], presenting a barrier for primaquine acceptance in combination 
with ACTs [28,77]. 
 An alternative line of thinking to prevent post-treatment malaria transmission was 
recently suggested by several reports on insecticidal capacity of ivermectin (IVM), a drug 
with broad-spectrum activity against nematodes and ectoparasites [78]. It has been 
shown to reduce the lifespan of malaria-transmitting Anopheles mosquitoes that feed on 
humans who have taken IVM [79-81]. In neuronal and neuromuscular tissues of invertebrates 
IVM activates glutamate-gated chloride (GluCl) channels, causing flaccid muscle paralysis 
that can lead to death of the insect [82,83]. GluCl channels are not present in mammals [82] 
therefore IVM has an excellent safety profile and it has been used for decades in mass 
treatment campaigns to reduce the burden of onchocerciasis [84]. This makes IVM a 
potentially attractive component of malaria control efforts, where it could be part of a drug 
combination that not only treats malaria patients but also reduces onward transmission of 
the disease. The duration and the impact of the mosquitocidal effect of IVM is key to its 
potential role as an adjunct malaria therapy. However, few data are available on the exact 
duration and the impact of this effect.
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Protection against malaria by vaccination
Vaccines represent one of the most important global health investments and are the most 
cost-effective tools for public health. According to the World Health Organization, 
immunizations save an estimated 2.5 million lives every year from diphtheria, tetanus 
pertussis and measles [85-88]. An effective vaccine against malaria has long been 
envisaged as a valuable addition to the available tools for malaria control and compulsory 
to achieve malaria eradication. However, the complexity of the malaria parasite makes 
development of a malaria vaccine a very difficult task. Given this, there is currently no 
licensed malaria vaccine, despite decades of intense research and development effort [1]. 
 The agenda for malaria vaccine development is determined by the different stages of 
the parasite’s lifecycle (Figure 1). Due to differences in morphology, composition, 
physiology and patho-physiology of each of the parasite’s stages, stage-specific vaccines 
will have different effects: clinical illness will be prevented by pre-erythrocytic vaccines 
targeting liver-stage parasites [89] or a vaccine that targets the asexual blood-stage of the 
parasite [90,91], while transmission-blocking vaccines will specifically target malaria sexual 
stage antigens, reducing transmission from human to mosquito [63,92]. 
 Vaccine development is hampered by genetic and antigenic diversity of the 
Plasmodium parasite and the complex interaction between parasite and human immune 
system [93]. Around 20 candidate vaccines are currently being evaluated in Phase 1 or 
Phase 2 clinical trials. All are based on one or a limited number of Plasmodium proteins. 
Only one candidate vaccine is currently tested in Phase 3 clinical trials: the RTS,S/
AS01-vaccine which comprises a fusion protein of the sporozoite circumsporozoite 
antigen with hepatitis B surface antigen, and includes the potent AS0 adjuvant. The 
vaccine showed good safety in African children aged 6–12 weeks but only moderate 
efficacy, with 30% protection against clinical malaria and 26% protection against severe 
malaria in the 12 months after the last dose [94]. Previously reported results in slightly 
older children (aged 5–17 months) were better, with 55% protection against all falciparum 
malaria and 35% protection against severe malaria during 14 months [95]. Although 
protection is incomplete, RTS,S could be considered a breakthrough in malaria vaccine 
development. 
 A different approach in malaria vaccine development is based on the whole P. 
falciparum sporozoite. In the 1970s it was shown that immunization of volunteers by bites 
of mosquitoes infected with irradiated P. falciparum sporozoites induces sterile and 
sustained protection [96-100]. More recently, it was shown that exposure of healthy 
malaria-naïve volunteers while taking chloroquine prophylaxis to P. falciparum sporozoites 
via three times 12–15 infected mosquito bites (ChemoProphylaxis and Sporozoites (CPS) 
immunization) induced sterile protection against a homologous challenge infection [101]. 
This protection was found to be long-lasting: after 2.5 years 4/6 volunteers were still 
protected [102]. It is unclear whether immunity induced by CPS targets pre-erythrocytic 
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P. falciparum stages, blood-stages or both. Furthermore, this highly protective CPS immunization 
strategy is currently unsuitable as an implementable vaccine in the field, because it 
depends on inoculation of sporozoites by mosquito bites. Replacing mosquito bites by 
needle and syringe injection is a crucial step in translating CPS immunization into an 
implementable whole sporozoite vaccine approach. For this, considerable technological 
challenges regarding production, formulation and delivery of such a vaccine will have to 
be overcome, as well as the safety aspect that is a considerable issue.
Aims and outline of the thesis
The main objective of this thesis is to evaluate currently available and experimental 
treatment and vaccination strategies that have the potential to support malaria control, 
elimination, and eradication efforts now and in the future. The work described in this 
thesis can be grouped into three main sections. In the first section the implementation of 
malaria rapid diagnostic tests, a current strategy to support diagnosis and accurate 
treatment, is assessed. In the second and third section near future and future strategies are 
tested, respectively, the mosquitocidal effect of ivermectin and the potential of whole 
sporozoite vaccination.
Improving access and accuracy of diagnosis using malaria  
rapid diagnostic tests
Presumptive treatment of suspected malaria cases may no longer be a justifiable approach 
in an era of decreasing malaria transmission and reduced malaria mortality. Malaria rapid 
diagnostic tests (RDTs) have the potential to play an important role in rationalising malaria 
treatment practices but their impact depends on a multitude of aspects including their 
availability and diagnostic practices. In theory, the availability of these tests may allow for 
a switch from presumptive treatment to parasite based diagnosis and treatment based on 
the result of the test. Specific aims regarding implementation of RDTs were:
- to assess the impact of a government policy change, comprising the provision of 
malaria RDTs, on clinical decision-making in district hospitals in Tanzania (Chapter 2)
- to identify technical and operational challenges to achieving at-scale implementation 
of malaria RDTs in sub-Saharan African settings (Chapter 3)
Mosquitocidal additions to current antimalarial treatment to  
prevent transmission
Ivermectin (IVM) is a drug with broad-spectrum activity against nematodes and ectoparasites 
and is widely used in mass treatment campaigns against onchocerciasis. Evidence in 
literature suggests that IVM can reduce the lifespan of malaria-transmitting Anopheles 
mosquitoes, hence onward malaria transmission, after feeding on a host who has taken 
this drug. We addressed the following objectives:
16
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- to acquire a precise estimate of the duration of the mosquitocidal effect of IVM (Chapter 4)
- to determine the safety and efficacy of IVM in combination with conventional malaria 
therapy to prevent malaria transmission from Plasmodium falciparum infected humans 
(Chapter 5)
Protection against malaria by inoculation of whole sporozoites 
Malaria naive volunteers immunized under chloroquine ChemoProphylaxis with Plasmodium 
falciparum Sporozoites (CPS) have shown to develop complete, long-lasting protection 
against subsequent challenge by bites of P. falciparum-infected mosquitoes. It is unclear 
whether immunity induced by CPS targets pre-erythrocytic P. falciparum stages, blood- 
stages or both. Furthermore, mosquito bites will have to be replaced by needle and 
syringe injection in order to translate CPS immunization into an implementable whole 
sporozoite vaccine approach. We explored the following specific objectives relating to 
CPS immunization:
- to assess the life-cycle stage-specificity of CPS-induced protection (Chapter 6)
- to determine the safety and tolerability of intradermal administration of cryopreserved 
sporozoites to volunteers taking chloroquine chemoprophylaxis, and its protective 
efficacy against infectious mosquito bites (Chapters 7 & 8)
17
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Abstract
Introduction
Patterns of decreasing malaria transmission intensity make presumptive treatment of 
malaria an unjustifiable approach in many African settings. The controlled use of 
antimalarials after laboratory confirmed diagnosis is preferable in low endemic areas. 
Diagnosis may be facilitated by malaria rapid diagnostic tests (RDTs). In this study, the 
impact of a government policy change, comprising the provision of RDTs and advice to 
restrict antimalarial treatment to RDT-positive individuals, was assessed by describing 
diagnostic behaviour and treatment decision-making in febrile outpatients <10 years of 
age in three hospitals in the Kagera and Mwanza Region in northern Tanzania. 
Methods
Prospective data from Biharamulo and Rubya Designated District Hospital (DDH) were 
collected before and after policy change, in Sumve DDH no new policy was implemented. 
Diagnosis of malaria was confirmed by RDT; transmission intensity was evaluated by a 
serological marker of malaria exposure in hospital attendees.
Results
Prior to policy change, there was no evident association between the actual level of 
transmission intensity and drug-prescribing behaviour. After policy change, there was a 
substantial decrease in antimalarial prescription and an increase in prescription of 
antibiotics. The proportion of parasite-negative individuals who received antimalarials 
decreased from 89.1% (244/274) to 38.7% (46/119) in Biharamulo and from 76.9% (190/247) 
to 10.0% (48/479) in Rubya after policy change. 
Discussion
This study shows that an official policy change, where RDTs were provided and health care 
providers were advised to adhere to RDT results in prescribing drugs can be followed by 
more rational drug-prescribing behaviour. The current findings are promising for 
improving treatment policy in Tanzanian hospitals.
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Introduction
Malaria accounts for more than 800,000 deaths a year worldwide [1], of which 90% are in 
young African children [2]. It is the leading cause of health service attendance in Tanzania 
and comprises ~40% of all morbidity in Tanzanian outpatients below 5 years of age [3]. 
This poses a considerable burden on health systems.
 Since the 1980s, malaria control has incorporated presumptive treatment of fever 
with antimalarials, treating all febrile episodes suspected of malaria with a full therapeutic 
dose of antimalarials, chloroquine (CQ, until 2001 in Tanzania [4]) or sulphadoxine-pyri-
methamine (SP, until 2007 [5]). This strategy was implemented to effectively treat true 
cases of malaria and may also have had beneficial effects on malaria transmission by 
effectively providing chemoprophylaxis to children in malaria endemic areas [6]. However, 
presumptive treatment may no longer be a justifiable approach in all settings now it is 
realized that many parts of Africa are characterized by low malaria transmission intensity 
[7,8] and transmission intensity is decreasing in many areas in sub-Saharan Africa [9-12]. In 
such settings, presumptive treatment will lead to substantial overtreatment [8], which is 
particularly important now the relatively expensive artemisinin combination therapy 
(ACT) is endorsed as first-line treatment [13-15]. Besides expenses, such practice will lead 
to a reduced susceptibility of parasites to ACT because of the uncontrolled use of 
artemisinins [16]. It is important that diagnosis is established before ACT is prescribed.
 Microscopy is the gold standard method for diagnosis of malaria, but the provision of 
microscopic facilities may not always result in accurate diagnosis [2,8,14,17]. Malaria rapid 
diagnostic testing (RDT) forms an attractive alternative to routine microscopy with good 
sensitivity and specificity profiles [1,18] and more objective results. Wide-scale implementation 
of RDTs may, therefore, improve malaria diagnosis. This was acknowledged by the Tanzanian 
Ministry of Health and Social Welfare. The Kagera Region was the first in Tanzania where a 
policy change was implemented as a pilot to tackle the problem of malaria overdiagnosis. 
Malaria rapid diagnostic testing replaced routine microscopy as the main diagnostic tool 
and clinicians were advised to restrict treatment to RDT-positive individuals only.
 Here, the impact of the policy change was assessed by describing diagnostic behaviour 
and treatment decision-making in febrile outpatients under 10 years of age in three hospitals 
in the Kagera and Mwanza Region in Tanzania. Transmission intensity in these areas, all 
nearby Lake Victoria, was assessed by serological markers of malaria exposure.
Methods
Study site
In this study, common practices in fever diagnosis in the outpatient departments were 
described for three designated district hospitals (DDH) in northern Tanzania: Biharamulo 
DDH and Rubya DDH, both situated in the Kagera Region, and Sumve DDH, situated in the 
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Mwanza Region. Biharamulo is situated at 1,490m, Rubya at >1,500m and Sumve at 1,100m. 
The transmission intensity of the catchment areas is suspected to be different based on 
their distance to Lake Victoria and altitude [19]. However, no formal assessments of 
transmission intensity have been reported. 
 Health care at these outpatient departments was largely provided by clinical officers 
with two to three years’ clinical training. Pneumonia, HIV, tuberculosis, gastrointestinal 
infections, various parasite infections and malaria are common conditions in outpatients 
according to hospital records. Malaria transmission is related to the long rains in March–
April and the less reliable short rains in October–November. The study was approved by 
the Kilimanjaro Christian Medical Centre Research Ethics Committee. Written informed 
consent was obtained from parents or caretakers of all participants.
Prospective data before and after policy change
Data were prospectively gathered from all patients under the age of 10 years presenting 
at the outpatient department of Sumve DDH with reported or measured fever in the 
months September 2009–January 2010. In Biharamulo DDH and Rubya DDH, identical 
data were collected in September–October 2009. This is the period before the policy 
change when microscopy was the only available tool to diagnose malaria. At the end of 
October 2009, the Kagera Region was the first region in Tanzania where a policy change 
was implemented by the National Malaria Control Programme of the Ministry of Health 
and Social Welfare. This policy change comprised the replacement of microscopy as the 
main diagnostic tool for malaria by RDTs (ICT Malaria Pf Cassette Test (ML01), ICT 
Diagnostics) with a sensitivity of 82% at parasite densities of 200 parasites/µL, of 97% for 
parasite densities >2,000 parasites/µL and a false positivity rate of ~1% [20]. Clinical officers 
were now strictly advised to only treat RDT-positive individuals with antimalarials; the 
advice was to look for alternative diagnoses in RDT-negative individuals. The medical 
officers in charge received training from government officials about the implementation 
of the policy change. After this, each medical officer in charge introduced the policy 
change during a two-day workshop to the clinical officers. To evaluate the short-term 
impact of this policy change, data were gathered for a second period in Biharamulo DDH 
(January 2010–February 2010) and Rubya DDH (October 2009–February 2010).
 The same information was collected before and after policy change. The following 
information was collected in a questionnaire: age, gender, month attending the hospital, 
resident or no resident of the area in which the hospital was situated, bed net use, use of 
medication in the previous 2 weeks, axillary temperature, clinical diagnosis made by a 
clinical officer, request for blood slide, result of blood slide, treatment given in the hospital, 
and result of RDT. In Biharamulo and Rubya an additional question ‘request for RDT’ was 
added in the second period. Axillary temperature was measured with digital thermometers; 
blood slides were prepared according to hospital routine, stained with 10% Giemsa 
solution and read by a single experienced microscopist.
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Before the policy change, a finger-prick blood sample was taken for malaria parasite 
detection by RDT (Paracheck Pf Rapid test, Orchid Biomedical Systems) in each patient 
enrolled for an objective assessment of infection with Plasmodium falciparum. The RDT 
was not part of hospital routine, but was used to facilitate objective diagnosis for the 
current study. The RDT was used according to the manufacturer’s instructions and is 
based on the detection of histidine-rich protein 2 (HRP2). This RDT has a sensitivity of 75% 
at parasite densities of 200 parasites/µL, of 100% for parasite densities >2,000 parasites/µL 
and a false positivity rate of ~7% [20]. The results of the RDTs were available for clinical 
officers for diagnosis. 
Transmission intensity
For an objective assessment of exposure to malaria, serum samples were collected using 
a single finger prick (~20 µL) from all individuals, both adults and children, attending these 
three hospitals in Northern Tanzania in November 2009. This group included patients, 
people coming for routine follow-up visits and people accompanying patients. This sampling 
method has previously been validated to obtain a selection of samples representative of 
the general population in the hospital catchment areas [21]. Information was collected on 
age, gender, area of residency, bed net use, and use of medication in the previous 2 weeks.
Assessment of malaria exposure by enzyme-linked  
immunosorbent assay (ELISA)
Serum was eluted from filter papers as described by Corran et al. [22]. Immunoglobulin G 
antibodies against blood-stage antigens were detected by indirect ELISA, as previously 
described in detail [22,23] using recombinant apical membrane antigen 1 (AMA-1). AMA-1 
was suggested as a suitable antigen for areas of moderate or low transmission intensity 
because of its high immunogenicity that results in saturating responses at high endemicity 
but a good discriminating power at low endemicity [24]. To generate an OD cut-off value 
above which samples were deemed antibody positive, the distribution of OD values was 
fitted as the sum of two Gaussian distributions (assuming a narrow distribution of 
seronegatives and a broader distribution of seropositives) using maximum likelihood 
methods [22].
Data analysis
Statistical analyses of data were performed using SPSS version 18.0.0 and Stata 9.2 (Stata 
Corp, College Station TX, USA). Categorical variables were compared between groups by 
the Pearson’s chi-squared test or Fisher’s exact test; odds ratios (OR) with 95% confidence 
intervals (95% CI) were calculated. The main outcomes of the analyses were the proportion 
of individuals treated with antimalarials despite a negative RDT and the proportion of 
individuals who did not receive antimalarials despite a positive RDT. AMA-1 ELISA data 
were used to generate an age-seroprevalence plot. OD values were expressed as percentage 
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of the positive control (normalized OD). The annual seroconversion rate (SCR), λ was 
estimated by fitting a simple model of the acquisition and loss of antibodies to the 
age-specific prevalence of the antibodies using maximum likelihood methods assuming 
a binomial distribution [23]. If visual examination of SCR suggested it was not uniform over 
the whole population (i.e. there was an obvious step in the age-seroprevalence data), 
models allowing for two forces of infection profile and profile likelihood plots were run to 
determine when the most likely time for change in transmission intensity occurred [21,25]. 
These resulted in a predicted time of change in transmission, which was incorporated in 
the catalytic model to generate estimates for previous and current SRC. Models allowing 
for two forces of infection were preferred if the fit compared to the single force model was 
significantly better by likelihood ratio test at a P<0.05.
Results
Collected data
From September 2009–February 2010, a total of 1,608 outpatients below 10 years of age 
presenting with (reported) fever were included. Age, reported bed net use and socio- 
demographic factors were similar between the three clinics (Table 1). The proportion of 
individuals with current fever was lowest in Biharamulo.
Malaria case management before and after malaria treatment  
policy change
Diagnostic behaviour and clinical management in Rubya DDH are summarized in Figures 1 
and 2; the same information for Biharamulo DDH and Sumve DDH is shown in the 
Supporting Information (SI) Figure 1, SI Figure 2 and SI Figure 3. Treatment prescribing 
behaviour before and after the policy change in relation to parasite prevalence is shown 
in Table 2 for all three clinics. There was a striking difference in RDT parasite prevalence 
between the three clinics with the lowest parasite prevalence by RDT in Rubya (1–4%) and 
the highest in Sumve (42%, 152/362). Although the majority of RDT-positive individuals 
received antimalarial treatment, in Biharamulo DDH, 5 malaria-positive individuals did not 
receive antimalarial treatment before policy change (8%, 5/67) compared to 2 (25%, 2/8) 
after policy change. In the other health centres, a positive RDT was followed by antimalarial 
treatment in all instances. In all clinics a substantial proportion of slide-negative patients 
received antimalarial treatment before the policy change (Sumve 67%, Biharamulo 100%, 
Rubya 81.1%) and a substantial proportion of RDT negative patients received antimalarial 
treatment (Sumve 68.1%, Biharamulo 89.1%, Rubya 76.9%). After the policy change this 
decreased to 38.7% in Biharamulo DDH and 10.0% in Rubya DDH. 
 There was also a striking decrease in presumptive treatment of reported fever with 
antimalarials. In Biharamulo DDH 89.0% (284/319) of patients without a slide taken was 
treated with antimalarials before the policy change compared to 27.0% (27/100) of patients 
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without a RDT after the policy change. In Rubya DDH this proportion changed from 67.5% 
(52/77) to 2.0% (2/98), indicating presumptive treatment was largely abandoned after the 
policy change.
Management of non-malaria fevers before and after malaria 
treatment policy change
Together with the decrease in antimalarial prescription, there was an increase in the 
proportion of individuals who received antibiotics. These were mostly broad-spectrum 
antibiotics like co-trimoxazole, ciprofloxacin or amoxicillin. In RDT-negative patients in 
Biharamulo DDH 12.8% received antibiotics before and 59.7% after the policy change. In 
Rubya DDH the number increased from 70.0% to 94.6%.
Figure 3   Age specific seroprevalence plots for apical membrane antigen 1 for Sumve, 
Biharamulo and Rubya
For Biharamulo two forces of infection were fitted, for the other two sites one force of infection 
fitted the data best. The seroconversion rate (SCR, λ) for Sumve was 0.082 (95% CI, 0.063–0.11). For 
Biharamulo the SCR was 0.34 (95% CI, 0.19–0.61) for the period up to 1999 (i.e. for individuals older 
than 10 years of age) but 0.019 (95% CI, 0.011–0.035) for the period 1999–2009. The SCR for Rubya was 
0.041 (95% CI, 0.029–0.058).
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The estimated transmission intensity generated from 
seroprevalence data
From Biharamulo DDH, Rubya DDH, and Sumve DDH, a total of 298, 320 and 304 serum 
samples were successfully tested in the AMA-1 ELISA, respectively. The overall seroprevalence 
of AMA-1 antibodies was 52.0% (158/304), 40.3% (129/320), and 56.7% (169/298); there was 
a clear increase in seroprevalence with age in all sites (Figure 3). The seroconversion rate 
was highest in Sumve (λ=0.082; 95% CI, 0.063–0.11) and lowest in Rubya (λ=0.041; 95% CI, 
0.029–0.058), in line with parasite prevalence rates by RDT. In Biharamulo, malaria 
transmission intensity appeared to have changed over time. While transmission intensity 
used to be intense (λ=0.34; 95% CI, 0.19–0.61), the current SCR was similar to that of Rubya 
(λ=0.019; 95% CI, 0.011–0.035), indicating low transmission intensity.
Discussion
In three study areas in the vicinity of Lake Victoria, a considerable overuse of antimalarials 
was seen prior to a new government policy to incorporate RDTs in the diagnostic process. 
There was no evident association between the actual level of transmission intensity and 
drug-prescribing behaviour across the sites: two thirds of the RDT-negative individuals 
received antimalarial drugs in the area of lowest endemicity. An official policy change, 
where RDTs were provided and health care providers were advised to adhere to RDT 
results in prescribing drugs was followed by lower antimalarial prescription rates and 
higher antibiotic prescription rates in parasite-negative children. This study indicates that 
an official policy change may reduce the overuse of antimalarials, resulting in a more 
rational drug-prescribing behaviour.
 In this study, treatment policies are described in children with reported fever visiting 
outpatient departments of three district hospitals in regions of differing malaria transmission 
intensity. Baseline diagnostic behaviour was similar between hospitals and overtreatment, 
defined as antimalarial treatment of RDT-negative individuals, ranged from 68–90%, 
which is similar to previous studies [8,13,14]. Prior to policy change, these RDT results were 
provided to have an objective indicator of malaria infection for this study. The RDT was not 
requested by the responsible clinical officer who mostly based his or her diagnosis on 
clinical symptoms alone and microscopic results were often ignored in the final deci-
sion-making. Overtreatment was particularly common in Rubya and Biharamulo, areas 
where parasite prevalence by RDT and transmission intensity by serological markers of 
malaria exposure indicated low current levels of malaria transmission intensity. Like other 
recent studies [1,8,14], this study shows a discrepancy between the perceived and actual 
levels of transmission intensity. While there was no evidence for recent changes in 
transmission intensity in Rubya, transmission intensity appeared to have dropped in 
Biharamulo in the last decade. The reason for this change in transmission is unknown, but 
has been observed before in northern Tanzania [21]. 
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Presumptive treatment of fevers with antimalarials may have a beneficial prophylactic 
effect that could also result in a reduction in malaria transmission by reducing the human 
infectious reservoir [6]. However, in a setting like Rubya where transmission intensity is low, 
this beneficial effect is unlikely. The diagnosis of malaria and according treatment may 
simply be a ‘convenient’ clinical strategy avoiding the more complicated search for other 
causes of the presenting illness [26]. Treatment of all febrile episodes as malaria is likely to 
result in underdiagnosis of other fever-causing disorders such as childhood pneumonia 
[2]. In addition, there are financial implications. Overtreatment will often be with the highly 
effective, but expensive, artemether-lumefantrine (AL). In the current study, all malaria 
episodes were treated with AL. AL and other ACTs are 10-times more expensive than 
previously used drugs as sulphadoxine-pyrimethamine [27,28] making reliable diagnosis 
crucial for cost-effective use [29]. Importantly, there is concern for a reduced susceptibility 
of P. falciparum parasites for ACT [30] and the spread of parasites with reduced susceptibility 
to ACT may be enhanced by irrational drug use [31]. Reports on allelic selection after AL 
overuse [32] provide additional warnings against overuse of ACT. 
 Microscopic examination of a blood smear is the gold standard method for the 
diagnosis of malaria, but even if microscopy is used, overdiagnosis of malaria is common 
[17]. In Sumve DDH and Rubya DDH clinicians frequently requested blood slides, but also 
frequently ignored negative results. In these hospitals up to 81% of the slide-negative 
individuals were treated with antimalarials. In Biharamulo DDH 79% of the children were 
treated with antimalarials while no lab-confirmation was sought (i.e. no slide was 
requested). The Tanzanian Ministry of Health and Social Welfare implemented a policy 
change in the Kagera Region to tackle malaria overdiagnosis and overtreatment by 
replacing routine microscopy with RDTs as main diagnostic tool. Although RDTs may not 
be 100% sensitive in detecting (low-density) malaria infections [1], a prospective study 
found that restricting antimalarials to RDT-positive individuals is a safe strategy in low 
endemic areas that does not lead to excess mortality due to false-negative results [33]. 
RDT results are objective and can also be confirmed by the person responsible for the 
clinical decision-making who may not be confident with microscopy. The two different 
RDTs used in this study are both based on HRP-2 for parasite detection and have similar 
sensitivity; we do not expect marginal differences in RDT sensitivity to have influenced the 
treatment-prescribing behaviour. The results of this study indicate an evident short-term 
impact on diagnostic behaviour and treatment decisions, unlike results from a previous 
study in Zambia [34]. In Rubya DDH, the proportion of individuals receiving antimalarials 
despite negative RDTs was reduced 7-fold. This indicates that clinicians appeared willing 
to trust the RDT result in their decision-making, at least shortly after receiving clear 
instructions from the Tanzanian Ministry of Health. Presumptive treatment was not 
completely abandoned but decreased substantially. It is encouraging that antibiotic 
prescription increased in RDT-negative individuals, indicating that alternative diagnoses 
and treatment options are considered.
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The current study was purely observational and no attempts were made to change the 
clinical decision-making process during the study. The new government guidelines were 
explained by the medical officers in charge and information on the sensitivity of RDTs was 
provided. Although an effect of the present study cannot be ruled out completely, similar 
observational studies showed no positive effect on diagnostic and drug-prescribing 
behaviour [8,14]. Therefore, the impact of the current observational study on treatment 
practices will have been negligible compared to the new guidelines provided by the 
government. There are conditions for the policy change to work and keep working. First 
of all, the hospital staff must be well-trained and confident regarding the new policy and 
new diagnostic test and clear guidelines should also be provided on treatment policies for 
RDT-negative individuals. Secondly, RDTs must be available at all times, as well as 
antimalarial drugs and antibiotics. In Rubya DDH, RDTs provided by the Tanzanian 
government were out of stock in the beginning of February 2010. This is also seen in other 
countries [34]. Consequently, this brings the risk of hospital staff returning to their former 
diagnostic and drug-prescribing behaviour. 
Conclusion
This study shows promising data on decrease of antimalarial drug-prescription. Larger 
prospective studies are needed to confirm the current findings, to determine the impact 
of the new policy on morbidity and mortality and to assess the long-term impact of the 
described policy change. The current findings on rational drug-prescribing behaviour in 
Tanzanian hospitals are promising. 
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Abstract
- Scaling up and sustaining access to malaria diagnosis and treatment in all public sector, 
for-profit, and informal health facilities across sub-Saharan Africa is central to current 
global strategies for malaria control and elimination. 
- The use of malaria rapid diagnostic tests (RDTs) aims to eliminate reliance on signs and 
symptoms to diagnose and treat malaria but evidence shows health workers do not 
always test the right patients, nor provide treatment based on the results of the test. 
- Expanding access to malaria RDTs on the scale needed to achieve universal coverage 
requires retraining of public, private, and retail sector providers as well as sustained 
supplies and quality assurance.
- Barriers to rational use of tests and drugs may be overcome through appropriate policy 
design for the local health service setting, which addresses health worker practice and 
patient perceptions.
- Innovative methods have been used to increase access to the most effective antimalarial 
drugs in the last five years, but these efforts will be incomplete and unsustainable 
without similar efforts to incorporate RDTs into practice.
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Introduction
An estimated 627,000 malaria deaths occurred in 2012, mostly in African children and 
many of them preventable with prompt diagnosis and treatment [1]. Access to diagnosis 
remains poor—in half of endemic African countries, over 80% of malaria treatments are 
applied without diagnostic testing [2]. Improving diagnosis and treatment of malaria will 
improve treatment outcomes, rationalize health care costs by reducing drug consumption 
[3], minimize drug pressure that can contribute to resistance [4,5], and assist in monitoring 
disease trends [2]. 
 In April 2012, the World Health Organization’s (WHO) Global Malaria Programme 
launched a highly ambitious new initiative: T3: Test. Treat. Track [1,2]. T3 aims to address the 
widespread problem of poor access to diagnostic testing and antimalarial treatment, and 
to enhance case-reporting. It sets a target of universal access to diagnostic testing in the 
public and private health care sector by 2015 [1,2]. Achieving this goal will centre on the 
use of malaria rapid diagnostic tests (RDTs).
 In this Policy Forum article we examine the operational challenges to implementing 
the T3 strategy of scaling up and maintaining RDT coverage. We identify gaps in planning 
for at-scale implementation in policy design and implementation, the local health care 
setting, and the attitudes and demands of patients. While focussed on malaria diagnosis 
and treatment, the challenges illustrated here are not unique to malaria and may apply to 
health care provision across resource-poor settings. 
Policy design and implementation
By 2012, 41 out of 44 endemic countries in the WHO African Region had adopted the 
policy of providing malaria diagnostic testing for all age groups before treatment [2]. RDT 
procurement increased worldwide from 45 million units in 2008 to 205 million in 2012 
although supply remains far short of requirements [1,2]. In theory, the availability of reliable 
easy-to-use tests should result in a switch from presumptive treatment based on signs 
and symptoms alone, to parasite-based diagnosis and treatment based on test results. 
Diagnostic processes and treatment decisions are, however, often irrational and health 
staff do not always test the right patients, nor provide treatment based on the results [6-8].
 RDTs will be introduced in health facilities and among community health workers 
(CHWs) who work at local levels. To translate the change in policy to a change in routine 
practice where tests are appropriately used by providers, unambiguous messages and 
guidelines that are adapted to the local context are needed [6,9,10]. This targeted 
information must counter the widespread and long-held guidelines that promoted 
presumptive treatment of malaria in cases of fever [11]. Appropriate information and 
training will improve implementation at the community level [12]. Recent evidence shows 
that CHWs reliably provided Integrated Management of Childhood Illnesses to children 
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after training and incorporation of RDTs into the algorithm [13,14]. In one study, malaria 
and pneumonia were appropriately classified in 94%–100% of children, and supply 
management of medications and RDTs was excellent [13]. Replicating these effects outside 
the trial setting requires national level training to ensure safety and quality of services.
 Mobilising sufficient resources for the training and monitoring required to sustain the 
new policy is the key to success. A reliable system for RDT delivery needs to include 
re-training of staff and consistent quality assurance at all levels. The quality of services is 
likely to wane over time and can be aggravated by high staff turnover, which occurs in 
many health service settings. Ensuring programme quality and sustainability therefore requires 
constant rolling interventions and local evidence for the best models of implementation.
The local health care setting
In the local health care setting, two problems persist: firstly, parasite-based testing is 
generally unavailable [1,2] with treatment decisions based on clinical signs and symptoms 
that are neither sensitive nor specific [15]; and secondly, if tests are available, health 
workers often do not apply treatment according to the result of the test [10,16-18]. Both 
situations result in extensive overuse of antimalarial drugs, especially in low transmission 
settings [19,20]. 
 When RDTs are introduced in presumptive treatment settings significant reductions 
in the overprescription of antimalarials have been seen in almost all studies published 
(Supporting Information Table 1). However, when they are introduced in settings that have 
used microscopic examination of blood smears, the advantages of RDTs are harder to 
define. Substantial numbers of patients may still be treated with an antimalarial drug 
despite a negative RDT or blood smear result, so the evidence of any clinical advantage of 
RDTs over microscopy is unclear in some settings (Supporting Information Table 2). 
 Often, the irrational use of tests and drugs is based on perceived shortcomings of the 
tests. A common concern amongst health staff is that negative tests do not definitively 
rule out malaria [21], but trials that withheld antimalarials in febrile children with negative 
test results have shown no additional malaria risk to patients in moderate-to-high 
transmission settings. In one trial in Uganda, 13/1,602 (0.8%) blood smear-negative patients 
who were not given antimalarial drugs developed clinical malaria over 7 days of follow-up 
and all 13 were detected by the health service and treated [22]. Similar findings were seen 
in Tanzania (3/603 [0.5%] of RDT-negative patients developed malaria within 7 days) [23]. 
These studies indicate that withholding antimalarial therapy in febrile children with 
negative test results is likely to be safe and results in a considerable reduction in antimalarial 
drug consumption. 
 Improvements in antimalarial prescription often coincide with increases in prescription 
of antibiotics amongst test-negative patients. All studies where antimalarial prescription 
rates were reduced in malaria-negative patients show an increase in antibiotic prescriptions 
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(Tables S1 and S2) [16,19,24-26]. There is little data on the spectrum of infections in patients 
presenting with symptoms of suspected malaria but most of these are probably self- 
limiting [23,27], and evidence that supports the prevailing practice of widespread antibiotic 
use in malaria-negative patients is lacking. 
 Identifying patients at risk of progressing to severe disease in which antibiotic 
treatment and/or referral would have a clinical advantage, while withholding antibiotic 
treatment in other patients, is a considerable challenge. Affordable rapid diagnostics for 
bacterial infections or markers of severe infections would support the rational prescription 
of both antimalarials and antibiotics.
Patient load and malaria diagnosis
A high patient load in many clinics creates challenges in implementing new policies and 
motivating staff [28,29]. In Tanzania, health workers identified high patient load and 
shortage of staff as key factors that hindered use of RDTs [28]. Most staff felt RDTs placed 
additional strain on normal operations and believed more staff were needed to conduct 
the tests [28]. Although these considerations apply to all diagnostic procedures and are 
not unique to RDTs, understanding the realities of routine practice is required because 
introducing extra staff into facilities will have an impact on cost. 
Sustained supply of RDTs in public and private sectors
Sustaining the supply of RDTs is a substantial challenge. In rural areas, where access to 
services is often low but demand for services may be highest [1], drug stock-outs are 
common [30,31] and supply is one of the biggest challenges facing the health system. The 
T3 recommendations imply that a constant supply of both artemisinin-based combination 
therapies (ACTs) and RDTs is needed. The shelf-life and performance of both diagnostics 
and drugs depends on their storage conditions; RDTs are degraded by high temperatures 
and humidity and the entire supply chain must ensure that RDTs remain within 
manufacturers’ recommended limits. WHO testing of a range of commercially available 
RDTs demonstrated consistent detection of malaria at tropical temperatures [21], but 
actual field data on storage conditions affecting RDT stability are scarce. 
 The private for-profit sector plays an important role in delivering services across most 
of Africa and the majority of suspected malaria episodes are initially treated by private 
health workers [32,33]. Data from a limited number of countries suggest neither microscopy 
nor RDTs have penetrated the private health care sector [1,34] but more than 50% of 
patients purchase drugs from unregistered shops and peddlers [32,33]. This occurs 
especially amongst lower income groups [35]. Improving diagnostic and treatment 
practices in the private sector could have a substantial impact on access to diagnosis 
before treatment but models of implementation have yet to be fully assessed in 
operational trials [35,36]. 
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Affordability and cost-effectiveness of RDT-based diagnosis
To improve access to drugs in sub-Saharan Africa, the Affordable Medicines Facility - malaria 
provided subsidised ACT drugs in a multi-country pilot [37]. This study demonstrated 
improved access and market share of ACTs in 5 out of 7 pilot countries driven mainly by 
improvements in the private for-profit sector [38]. In 2012, 331 million courses of ACTs were 
procured by the public and private sectors in endemic countries, up from 182 million in 
2010 [1]. Although the pilot rapidly improved availability, affordability, and market share of 
quality-assured ACTs at the point of use, no equivalent increase in RDTs has been observed 
[1,38]. As diagnosis is seldom available and ACT orders are more than double that of RDTs, 
overtreatment is likely to be common in retail outlets. ACTs are approximately 10 times 
more costly than previously used monotherapies [19,31] so the use of RDTs prior to 
treatment may improve cost-effectiveness. Data from a willingness-to-pay study in private 
drug shops in Uganda indicated that there was a demand for RDTs in the private sector 
but this was far below the price of delivery [39]. Subsidised supply of RDTs, similar to the 
ACTs subsidy, should be assessed to examine the impact on the uptake of RDTs in the 
private retail sector. 
 In high and very high transmission areas, presumptive treatment has cost-effectiveness 
advantages given the imperfect sensitivity of tests under field conditions [3]. RDTs in 
settings with up to 62% Plasmodium falciparum prevalence were cost-effective compared 
to presumptive treatment, assuming that prescribers adhered fully to test results [31]. 
When treatment is consistent with the results of a test, cost savings of between 50% and 
100% can be achieved compared with presumptive treatment [3]. Conversely, if treatment 
is inconsistent with the result of the test, cost-effectiveness is reduced, an association that 
varies with the malaria transmission setting [3,31]. Other factors that can reduce cost-ef-
fectiveness are stock-outs, poor accuracy of RDTs, and poor quality assurance for drugs 
and diagnostics [31]. 
 In low-endemic settings, RDTs and microscopy remain attractive compared to presumptive 
treatment even when there is poor adherence to negative test results [3]. RDTs can be 
more cost-effective than microscopy because they are more accurate under real-life 
conditions [31] and continuous (re-)training of microscopists is particularly important if 
fewer malaria-positive slides with low parasite levels are encountered in low-endemic 
settings. Despite these advantages of RDTs over presumptive treatment, adherence to 
microscopy and RDT test results remains a key factor for cost-effective diagnosis and 
treatment [3,40].
Malaria diagnosis in elimination programmes
Currently available RDTs will not detect all infections with low parasite loads. These 
submicroscopic infections frequently occur in low-endemic areas [41], are probably not 
associated with clinical risks [42], but do play a role in onward malaria transmission [43]. 
Diagnostics with a sensitivity that is higher than currently available RDTs will be needed to 
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identify all malaria infections in elimination efforts [44]. Operational approaches may 
involve screening by RDT to identify geographic or demographic clusters of infections 
[45,46] that can be targeted following molecular diagnosis of infection or by focal mass 
drug administration [47,48].
Attitudes and demands of patients
Patients can influence the diagnostic and treatment practices of health workers [7,8] and 
patient pressure on providers contributes to overtreatment [7]. There is a persistent 
perception that all fever episodes in malaria endemic areas are due to malaria [49] and, 
until recently, a global policy of presumptive treatment for malaria in cases of fever has 
been in place [2]. These factors have created entrenched demand for malaria treatment 
without first testing for malaria [29,50,51]. Efforts to change demands to promote malaria 
testing are particularly important in the private and informal sector, where few patients 
presently receive a diagnostic test. A change in public perceptions brought about by 
effective communication is needed to widen demand for testing before treatment. 
Conclusions
Meeting the global target of universal coverage with parasite-based diagnosis by 2015 is 
a huge undertaking requiring sufficient resources. The cost-effectiveness of the 
intervention will hinge on the accurate use of RDTs in guiding treatment. Probably the 
biggest challenge in RDT implementation will be to provide adequate and sustained 
supplies of RDTs and appropriate training to all health workers in endemic areas. With 
increased access to malaria diagnosis, there will also be increased use of antibiotics, and 
interventions to guard against even greater overuse are needed to prevent worsening 
antimicrobial resistance. The Affordable Medicines Facility - malaria initiative demonstrated 
that large increases in access to ACTs were possible. Increasing access to RDTs is equally 
important. ACTs and RDTs should be seen as a package to improve management of febrile 
cases, and improving access to both of these in the public and private sectors has the 
potential to provide valuable returns. 
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SI Table 1   Patients treated with antimalarials and antibiotics in studies comparing  
clinical diagnosis with malaria rapid diagnostic tests
Study, year Country Study design Treatment with antimalarials Treatment with antibiotics
Clinical diagnosis RDT Clinical diagnosis RDT
% (95% CI), n/N % of RDT-positives % of RDT-negatives % of RDT-negatives
Williams et al., 2008 Tanzania Pilot implementation study 61.3 (57.4–65.3), 365/595 98.4 (97.7–99.0), 1329/1351 24.7 (22.3–27.2), 289/1168 NR NR
Msellem et al., 2009 Tanzania Cross-over validation trial 85.3 (82.9–87.6), 752/882 35.9 (33.0–38.9), 361/1005 26.6 (23.7–29.6), 235/882 37.0 (34.0–40.0), 372/1005a
Bisoffi et al., 2009 Burkina Faso Randomized, multi-centre,  
open clinical trial
87.2 (85.3–89.2), 969/1111 97.7 (96.4–98.9), 543/556 81.0 (77.5–84.4), 400/494 54.8 (51.9–57.7), 609/1111 56.9 (52.5–61.2), 281/494 
Kyabayinze et al., 2010 Uganda Quasi-experimental  
implementation study
54.3 (53.9–54.7), 29117/53629 32.9 (32.5–33.2), 24591/74784a NR NR
Ansah et al., 2010 Ghana Randomized controlled  
open label trial
92.7 (91.5–94.0), 1598/1723 99.6 (99.1–100.0), 703/706 49.5 (46.4–52.5), 501/1013 22.3 (20.3–24.3), 384/1723 35.0 (32.1–38.0), 355/1013
Chinkhumba et al., 2010 Malawi Cross-sectional survey NR 98.0 (97.1–98.9), 985/1005 57.9 (53.0–62.9), 223/385 NR NR
Masanja et al., 2010 Tanzania Observational study NR 97.1 (96.7–97.6), 5331/5488 4.0 (3.4–4.5), 205/5162 NR NR
Yeboah-Antwi et al., 2010 Zambia Cluster randomized  
controlled trial
99.1 (98.7–99.5),
2066/2084
27.5 (24.7–30.3), 265/963b NR NR
Chanda et al., 2011 Zambia Prospective pilot study NR 100.0, 2318/2318 0.6, 13/NR and 0.0, NRc NR NR
Mubi et al., 2011 Tanzania Randomized cross-over trial 96.5 (95.6–97.5), 1422/1473 99.7 (99.3–100.0), 731/733 6.1 (4.3–7.8), 44/724 NR NR
Ishengoma et al., 2011 Tanzania Longitudinal study 98.6 (98.3–98.9), 4448/4511 31.8 (31.1–32.6), 4440/13942 NR NR
Uzochukwu et al., 2011 Nigeria Cross-sectional study NR 100.0, 92/92 74.1, (65.8–82.3) 80/108 NR NR
Mukanga et al., 2012 Burkina Faso Open cluster randomized trial 99.8 (99.5–100.0),
575/576
99.2 (98.4–100.0), 388/391 3.7 (0.5–6.9), 5/134 NRd 59.0 (50.6–67.3), 79/134 
Mukanga et al., 2012 Ghana Open cluster randomized trial 95.3 (93.5–97.0),
563/591
100.0, 492/492 3.3 (0.0–6.9), 3/92 64.3 (60.4–68.2), 380/591 69.6 (60.2–79.0), 64/92
Mukanga et al., 2012 Uganda Open cluster randomized trial 100.0,
965/965
99.9 (99.7–100.0), 856/857 7.6 (2.8–12.4), 9/118 NRd 59.3 (50.5–68.2), 70/118
Kyabayinze et al., 2012 Uganda Cross-sectional survey 60.1 (59.3–60.9), 8432/14024 32.7 (32.0–33.5), 4892/14940 NR NR
RDT, malaria rapid diagnostic test; NR, not reported.
a99% of RDT-positives received antimalarials, 30% of febrile RDT-negatives received antimalarials.
b3 out of 704 RDT-negatives received antimalarials. 
cData of two districts.
dAntibiotics not available as treatment.
Search strategy: on 24 April 2013 we searched the PubMed electronic database to locate relevant RDT-implementation 
studies from sub-Saharan Africa, focusing on intervention and observational studies of non-RDT versus RDT and pre- 
versus post-RDT implementation. We used the following combination of search terms: 
Search #1: (“case management”[Text Word]) AND (“malaria”[Text Word]) AND (“rapid diagnostic test”[Text Word])
Search #2: (“treatment practices”[Text Word]) AND (“malaria”[Text Word]) AND (“rapid diagnostic test”[Text Word])
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SI Table 1   Patients treated with antimalarials and antibiotics in studies comparing  
clinical diagnosis with malaria rapid diagnostic tests
Study, year Country Study design Treatment with antimalarials Treatment with antibiotics
Clinical diagnosis RDT Clinical diagnosis RDT
% (95% CI), n/N % of RDT-positives % of RDT-negatives % of RDT-negatives
Williams et al., 2008 Tanzania Pilot implementation study 61.3 (57.4–65.3), 365/595 98.4 (97.7–99.0), 1329/1351 24.7 (22.3–27.2), 289/1168 NR NR
Msellem et al., 2009 Tanzania Cross-over validation trial 85.3 (82.9–87.6), 752/882 35.9 (33.0–38.9), 361/1005 26.6 (23.7–29.6), 235/882 37.0 (34.0–40.0), 372/1005a
Bisoffi et al., 2009 Burkina Faso Randomized, multi-centre,  
open clinical trial
87.2 (85.3–89.2), 969/1111 97.7 (96.4–98.9), 543/556 81.0 (77.5–84.4), 400/494 54.8 (51.9–57.7), 609/1111 56.9 (52.5–61.2), 281/494 
Kyabayinze et al., 2010 Uganda Quasi-experimental  
implementation study
54.3 (53.9–54.7), 29117/53629 32.9 (32.5–33.2), 24591/74784a NR NR
Ansah et al., 2010 Ghana Randomized controlled  
open label trial
92.7 (91.5–94.0), 1598/1723 99.6 (99.1–100.0), 703/706 49.5 (46.4–52.5), 501/1013 22.3 (20.3–24.3), 384/1723 35.0 (32.1–38.0), 355/1013
Chinkhumba et al., 2010 Malawi Cross-sectional survey NR 98.0 (97.1–98.9), 985/1005 57.9 (53.0–62.9), 223/385 NR NR
Masanja et al., 2010 Tanzania Observational study NR 97.1 (96.7–97.6), 5331/5488 4.0 (3.4–4.5), 205/5162 NR NR
Yeboah-Antwi et al., 2010 Zambia Cluster randomized  
controlled trial
99.1 (98.7–99.5),
2066/2084
27.5 (24.7–30.3), 265/963b NR NR
Chanda et al., 2011 Zambia Prospective pilot study NR 100.0, 2318/2318 0.6, 13/NR and 0.0, NRc NR NR
Mubi et al., 2011 Tanzania Randomized cross-over trial 96.5 (95.6–97.5), 1422/1473 99.7 (99.3–100.0), 731/733 6.1 (4.3–7.8), 44/724 NR NR
Ishengoma et al., 2011 Tanzania Longitudinal study 98.6 (98.3–98.9), 4448/4511 31.8 (31.1–32.6), 4440/13942 NR NR
Uzochukwu et al., 2011 Nigeria Cross-sectional study NR 100.0, 92/92 74.1, (65.8–82.3) 80/108 NR NR
Mukanga et al., 2012 Burkina Faso Open cluster randomized trial 99.8 (99.5–100.0),
575/576
99.2 (98.4–100.0), 388/391 3.7 (0.5–6.9), 5/134 NRd 59.0 (50.6–67.3), 79/134 
Mukanga et al., 2012 Ghana Open cluster randomized trial 95.3 (93.5–97.0),
563/591
100.0, 492/492 3.3 (0.0–6.9), 3/92 64.3 (60.4–68.2), 380/591 69.6 (60.2–79.0), 64/92
Mukanga et al., 2012 Uganda Open cluster randomized trial 100.0,
965/965
99.9 (99.7–100.0), 856/857 7.6 (2.8–12.4), 9/118 NRd 59.3 (50.5–68.2), 70/118
Kyabayinze et al., 2012 Uganda Cross-sectional survey 60.1 (59.3–60.9), 8432/14024 32.7 (32.0–33.5), 4892/14940 NR NR
Search #3: (“implementation”[Text Word]) AND (“malaria”[Text Word]) AND (“rapid diagnostic test”[Text Word])
Search #4: (“treatment outcome”[Text Word]) AND (“malaria”[Text Word]) AND (“rapid diagnostic test”[Text Word])
Search #5: (“adherence”[Text Word]) AND (“malaria”[Text Word]) AND (“rapid diagnostic test”[Text Word])
The search yielded 189 records from which 57 duplicates were removed. After screening the records for relevant 
studies, 106 records were excluded. Of the remaining 26 records, 5 records were excluded because these did not 
provide data on non-RDT versus RDT settings (Abdelgader et al. BMC Public Health 2012, 12:11; Mangham et al. Trop Med 
Int Health 2012, 17(3): 330-42; Manirakiza et al. BMC Public Health 2012, 12:482; Rowe et al. Mal J 2009, 8:275; Ukwaja et al. 
Ethiop J Health Sci 2010, 20(3):179-83). Results of the remaining 21 records are described here, showing studies 
performed in presumptive treatment (SI Table 1) and microscopy settings (SI Table 2), respectively.
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SI Table 2   Patients treated with antimalarials and antibiotics in studies comparing  
microscopy with malaria rapid diagnostic tests
Study, year Country Study design Treatment with antimalarials Treatment with antibiotics
Microscopy RDT Microscopy RDT
% of slide positives 
(95% CI), n/N
% of slide-negatives % of RDT-positives % of RDT-negatives % of slide-negatives % of RDT-negatives
Hamer et al., 2007 Zambia Cross-sectional,  
cluster sample survey
100.0, 64/64 58.4 (47.7–69.4),
45/77 
96.6 (93.6–99.5),
140/145 
35.5 (28.6–42.5),
65/183 
NR NR
Reyburn et al., 2007 Tanzania Randomized trial 98.3 (96.3–100.0), 171/174 50.8 (47.7–53.8),
523/1030 
98.9 (97.5–100.0),
186/188
53.7 (50.6–56.8),
540/1005
51.0 (47.9–54.0),
525/1030 
51.6 (48.6–54.7),
519/1005
Skarbinsky et al., 2009 Kenya Pre-post cluster  
randomized  
controlled trial
59.2 (47.7–70.6), 42/71a 3.8 (1.0–6.6), 7/183a 56.7 (44.1–69.2), 34/60b 6.2 (2.9–9.4), 13/210b NR NR
Ansah et al., 2010 Ghana Randomized controlled  
open label trial
98.3 (97.2–99.3),
565/575 
49.5 (46.8–52.2),
656/1325 
98.2 (97.1–99.2),
587/598 
46.0 (43.3–48.7),
597/1298 
28.6 (26.2–31.0),
379/1325 
28.8 (26.3–31.3),
374/1298 
Bastiaens et al., 2011 Tanzania Observational study 100.0, 12/12 82.5 (77.0–88.0),
151/183 
100.0, 26/26 16.6 (13.0–20.2),
67/404 
62.8 (55.8–69.8),
115/183 
92.8 (90.3–95.3),
375/404 
D’Acremont et al., 2011 Tanzania Cross-sectional surveysc 99, NR/370 53, NR/215 99, NR/126 7, NR/628 54, NR/215 78, NR/628 
Masanja et al., 2012 Tanzania Cross-sectional surveys 60.0 (51.9–68.1), 84/140d 14.6 (10.2–19.1), 35/239d 71.8 (64.0–79.5), 94/131e 7.0 (4.2–9.9), 22/313e NR NR
Yukich et al., 2012 Zambia Cross-sectional study 66.1f NA 26.6f NA NR NR
RDT, malaria rapid diagnostic test; BS, blood slide; NR, not reported; NA, not applicable.
aCombined intervention and comparison arms, and blood slide and RDT-results pre-RDT and bpost-RDT implementation.
cData derived from before-and-after analysis based on repeated cross-sectional surveys.
dCombined blood slide and RDT-results pre-RDT implementation and epost-RDT implementation.
fAntimalarial drug treatments per facility-month.
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SI Table 2   Patients treated with antimalarials and antibiotics in studies comparing  
microscopy with malaria rapid diagnostic tests
Study, year Country Study design Treatment with antimalarials Treatment with antibiotics
Microscopy RDT Microscopy RDT
% of slide positives 
(95% CI), n/N
% of slide-negatives % of RDT-positives % of RDT-negatives % of slide-negatives % of RDT-negatives
Hamer et al., 2007 Zambia Cross-sectional,  
cluster sample survey
100.0, 64/64 58.4 (47.7–69.4),
45/77 
96.6 (93.6–99.5),
140/145 
35.5 (28.6–42.5),
65/183 
NR NR
Reyburn et al., 2007 Tanzania Randomized trial 98.3 (96.3–100.0), 171/174 50.8 (47.7–53.8),
523/1030 
98.9 (97.5–100.0),
186/188
53.7 (50.6–56.8),
540/1005
51.0 (47.9–54.0),
525/1030 
51.6 (48.6–54.7),
519/1005
Skarbinsky et al., 2009 Kenya Pre-post cluster  
randomized  
controlled trial
59.2 (47.7–70.6), 42/71a 3.8 (1.0–6.6), 7/183a 56.7 (44.1–69.2), 34/60b 6.2 (2.9–9.4), 13/210b NR NR
Ansah et al., 2010 Ghana Randomized controlled  
open label trial
98.3 (97.2–99.3),
565/575 
49.5 (46.8–52.2),
656/1325 
98.2 (97.1–99.2),
587/598 
46.0 (43.3–48.7),
597/1298 
28.6 (26.2–31.0),
379/1325 
28.8 (26.3–31.3),
374/1298 
Bastiaens et al., 2011 Tanzania Observational study 100.0, 12/12 82.5 (77.0–88.0),
151/183 
100.0, 26/26 16.6 (13.0–20.2),
67/404 
62.8 (55.8–69.8),
115/183 
92.8 (90.3–95.3),
375/404 
D’Acremont et al., 2011 Tanzania Cross-sectional surveysc 99, NR/370 53, NR/215 99, NR/126 7, NR/628 54, NR/215 78, NR/628 
Masanja et al., 2012 Tanzania Cross-sectional surveys 60.0 (51.9–68.1), 84/140d 14.6 (10.2–19.1), 35/239d 71.8 (64.0–79.5), 94/131e 7.0 (4.2–9.9), 22/313e NR NR
Yukich et al., 2012 Zambia Cross-sectional study 66.1f NA 26.6f NA NR NR
RDT, malaria rapid diagnostic test; BS, blood slide; NR, not reported; NA, not applicable.
aCombined intervention and comparison arms, and blood slide and RDT-results pre-RDT and bpost-RDT implementation.
cData derived from before-and-after analysis based on repeated cross-sectional surveys.
dCombined blood slide and RDT-results pre-RDT implementation and epost-RDT implementation.
fAntimalarial drug treatments per facility-month.
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Abstract
Introduction
Ivermectin (IVM) reduces the life span of malaria-transmitting mosquitoes after feeding 
on humans treated with IVM. If this effect is sufficiently long and strong, IVM could form 
part of a drug combination that not only treats malaria patients but also reduces onward 
transmission. Limited data are available on the exact duration of the mosquitocidal effect 
of IVM; daily mosquito feeding assays are required for this. 
Methods
We determined mortality rates of Anopheles stephensi mosquitoes that took a blood meal 
on Swiss mice, Wistar rats and Cynomolgus monkeys that received IVM orally at 200–400 
µg/kg. Mosquito feeding assays were performed on 5 consecutive days after IVM 
administration. Mosquito mortality was determined in the first 72 hours after feeding.
Results
Mosquito mortality was 70–100% when mosquitoes fed on any of the animals 1–2 days 
after the last IVM administration. After this time-point the mosquitocidal effect was still 
evident in most animals but it became more variable. 
Discussion
Our findings of a pronounced but short-lived mosquitocidal effect makes the timing of 
IVM administration crucial to form a useful addition to antimalarial drugs. 
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Introduction
The search for malaria transmission-blocking drugs has so far focused on drugs that clear 
gametocytes, the sexual stage Plasmodium parasites that are responsible for the transmission 
of malaria to mosquitoes. An alternative or supplementary approach to prevent malaria 
transmission after treatment would be a strategy that aims to kill mosquitoes before they 
become infectious after feeding on a gametocytaemic blood meal. Ivermectin (IVM) may 
fulfil a role in such a strategy. IVM is a drug with broad-spectrum activity against nematodes 
and ectoparasites, and is widely used in mass treatment campaigns against onchocerciasis 
[1]. It has recently received much attention because of the reduced life span of malaria- 
transmitting mosquitoes after feeding on humans and cattle treated with IVM [2-5]. This 
makes IVM a potentially attractive component of malaria control efforts, where it could be part 
of a drug combination that not only treats malaria patients but also reduces onward transmission 
of the disease. The duration of the mosquitocidal effect of IVM is key to its potential role as 
an adjunct malaria therapy. Few data are available on the exact duration of this effect. 
 Fritz and colleagues showed previously that addition of IVM to bovine blood that is 
directly fed to An. gambiae sensu stricto and An. arabiensis mosquitoes reduces their 
survivorship and fecundity [5], and that IVM is already lethal to An. arabiensis at low 
concentrations (LC50 of 7.9 parts per billion) [6]. Work in rodents and cattle suggests a 
long-acting effect of IVM on anophelines, mosquito survival rates being affected as long 
as 10 days after feeding on an IVM-treated animal [5,7]. Chaccour and colleagues directly 
fed An. gambiae mosquitoes on healthy human volunteers 1 and 14 days post-IVM 
administration and observed an increased mortality at only the first time-point [2]. In a 
study from Papua New Guinea, blood-fed mosquitoes were collected from the huts of 
people 1–3 days and 28 days after an IVM mass treatment campaign. An. punctulatus or An. 
koliensis caught 1–3 days post-treatment showed 70% mortality in the first 24 hours after 
capture compared to 2% caught 28 days post-treatment [8]. A study from Senegal similarly 
determined survival in An. gambiae s.s. blood fed mosquitoes sampled from houses after 
IVM mass treatment campaigns and found that survival rates were lower for mosquitoes 
that were caught 1–6 days post-treatment; the effect for the individual days was not 
reported [4]. A study where An. farauti mosquitoes were allowed to feed on the skin of a 
single Indonesian volunteer 0, 7, 10, 14, 26 and 44 days after administration of 250 µg/kg 
IVM suggested that the mosquitocidal effect may last for 14 days [3]. 
 In short, precise estimates of the duration of the mosquitocidal effect of IVM are 
unavailable and studies have been hampered by logistical and ethical challenges in 
performing frequently repeated mosquito feeding experiments. We aimed to support the 
discussion on the best strategy of IVM deployment by analyzing previously conducted 
and unpublished experiments on the mortality rate of An. stephensi mosquitoes after 
feeding on different animals treated with IVM at doses within the range that is recommended 
for use in humans (200–400 μg/kg). 
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Methods
Experiments were performed at the Radboud University Nijmegen Medical Centre animal 
facility in the period May 1986–October 1987, where the test animals and mosquitoes 
were housed according to local and national guidelines. Permission to conduct the 
experiments in this study was given under approval number DGVGZ/VVP-83262. 
 Swiss mice (Mus musculus; n=10) weighing ~25 g each were given forage containing 
2 mg/kg IVM. Oral take-up of 5 g of forage per day resulted in a total take-up of 10 μg IVM 
per day per mouse, or a daily dose of 400 μg/kg IVM. Four to 5 days old An. stephensi 
mosquitoes were allowed to feed directly on the skin of all animals exactly 1, 2, 3, 4 and 5 
days after IVM treatment. After each feeding experiment fully engorged mosquitoes were 
selected. The median number of fully engorged mosquitoes per mouse per feeding day 
was 10 (interquartile range [IQR], 10–13.25; total number of mosquitoes, 503). Mosquito 
mortality for each of the 5 mosquito feeding days was compared with 15 mosquito 
feeding experiments on untreated Swiss mice; an entirely separate group of animals. Mice 
were given IVM treatment for 1–5 days prior to the first feeding experiment. The total dose 
of IVM therefore differed between animals. However, we observed no effect of longer 
treatment on mosquito mortality after the last dose of IVM (Table 1; P=0.87) and animals 
were therefore combined and analysed as a group.
 Wistar rats (Rattus norvegicus, n=5) weighing ~120 g each were given Ivomec® solution 
orally. Ivomec® solution containing 10 μg/mL IVM was diluted to 100 μg/mL IVM using 
distilled water, and administered orally by syringe to reach a daily dose of 400 μg/kg IVM. 
Mosquito feeding assays were performed as above. The median number of fully engorged 
mosquitoes per rat per feeding day was 26 (IQR, 20–30; total number of mosquitoes, 673). 
Mosquito mortality for each of the five mosquito feeding days was compared with 15 
mosquito feeding experiments on a completely separate group of untreated Wistar rats. 
While IVM was given 1–5 days prior to mosquito feeding, we observed no effect of longer 
treatment on mosquito mortality after the last dose of IVM (P=0.83) and animals were 
therefore combined and analysed as a group. 
 Cynomolgus monkeys (Macaca fascicularis, n=3) were given an orange containing 
Ivomec® solution at a single dose of 200 (n=2) or 400 μg/kg bodyweight (n=1). Mosquito 
feeding assays were performed as above. The median number of fully engorged 
mosquitoes per monkey per feeding day was 14 (IQR, 10.5–16.5) and was not recorded for 
all experiments. For some experiments only the proportion of surviving mosquitoes was 
recorded; this did not affect the statistical analysis where we used a single estimate per 
mosquito feeding experiment (see below) but limited the information that could be given 
for individual experiments on Cynomolgus monkeys (Table 1). Mosquito mortality for each 
of the 5 mosquito feeding days was compared with 21 mosquito feeding experiments on 
a separate group of untreated Cynomolgus monkeys.
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Figure 1   Mosquito mortality within 72 hours after feeding on different animals treated 
with ivermectin
Mosquito feeding experiments were conducted on 5 consecutive days following IVM treatment. 
Mosquito mortality was calculated for the first 72 hours after each mosquito feeding experiment. 
Plotted on the x-axis is the day since the last IVM dose, plotted on the y-axis is the proportion of all 
fully fed mosquitoes that died within 72 hours after their blood meal. Swiss mice (n=10) and Wistar 
rats (n=5) received IVM 400 μg/kg for 1–5 days (A and B). Cynomolgus monkeys (n=3) received a 
single dose of IVM at 200 (n=2) or 400 μg/kg (n=1) (C). Dots indicate the median mosquito mortality 
and error bars indicate the interquartile range; for IVM-treated monkeys this interquartile range 
equals the total range because only 3 monkeys received IVM. Lines are drawn between the estimates 
of the median and do not represent fitted or smoothed curves.
*statistically significant after adjusting p-values for multiple comparisons.
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For each of the 5 time-points after IVM, the proportion of mosquitoes that died within 72 
hours after their blood meal was compared with control experiments using STATA version 
12.0 (StataCorp LP, Texas, US). Because the number of animals was deemed too small to 
reliably estimate clustering of individual mosquito observations that fed on the same 
animal, we chose the most conservative analytical approach: each feeding experiment 
contributed one observation of the proportion of mosquitoes that died within 72 hours 
after this feeding experiment. This continuous variable was compared between test and 
control experiments using a nonparametric Wilcoxon rank-sum test; a Bonferroni 
correction was used to counteract the problem of multiple comparisons.
Results
In mice, the proportion of mosquitoes that died within 72 hours after their blood meal 
was strongly elevated when feeding 1 or 2 days after IVM (Table 1; Figure 1a). On these 
days 70–100% of mosquitoes died within 72 hours after feeding on any of the IVM-treated 
mice compared to 0–10% in control mice (P<0.0001 for both days). Beyond day 2, higher 
mosquito mortality was still observed in some animals but we no longer found evidence 
for a statistically significantly elevated mosquito mortality compared to control mice. For 
rats, mosquito mortality was also most pronounced for mosquitoes feeding one or two 
days after IVM: 85–100% of all mosquitoes died within 72 hours after feeding on any of the 
IVM-treated rats compared to 2–28% in control rats (Table 1; Figure 1b; P=0.001 for day 1 
and P=0.0009 for day 2). Mosquito mortality decreased after this time-point but remained 
statistically significantly elevated up to day 4 after IVM treatment (P=0.008). Similar as in 
rats and mice, mosquito mortality in experiments with Cynomolgus monkeys was highest 
when feeding one or two days after IVM (Table 1; Figure 1c; 77–100% mosquito mortality 
within 72 hours after feeding, P=0.002 for both days). On the third day after treatment, 
mosquito mortality was more variable (38–86%) although still statistically significantly 
higher than control experiments (P=0.002). 
Discussion
We observed a pronounced effect of IVM on mosquito mortality rates in all animal models. 
The strong but short-lived mosquitocidal effect of IVM that we observed supports several 
previous observations [2,4,8] with more detailed daily assessments and a larger number of 
mosquito observations. 
 A strength of our study is that we have performed daily mosquito feeding experiments 
in 3 animal species and thereby are able to add an estimate of mortality on different days 
post-IVM to the available literature. Since the mosquitocidal effect of IVM was previously 
shown to be highly dependent on the concentration of IVM in plasma [9], we interpret our 
finding that the mosquitocidal effect becomes more variable after 2 days, as an indication 
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for inter-individual variation in IVM metabolism. Since we did not determine IVM plasma 
concentrations in our study animals, we were unable to address this further. This is a 
shortcoming of the current study. We found no evidence in literature that the plasma 
disposition of IVM differs between our animal models and humans. Since our findings are 
consistent between the different animals, we consider it plausible that also in humans the 
mosquitocidal effect of IVM is limited to the first days after treatment. 
 Our findings have implications for the next steps in evaluating IVM as a tool for use in 
malaria control. The strong but short-lived mosquitocidal effect makes IVM less attractive 
as a stand-alone drug for mass drug administration (MDA) campaigns that aim to reduce 
malaria transmission. IVM may, however, be a potent addition to antimalarial drugs in MDA 
campaigns or to prevent transmission shortly after treatment of symptomatic malaria 
cases. Current therapy for malaria patients is based on treatment with artemisinin 
combination therapy (ACT). Whilst ACTs are highly effective against asexual parasite 
stages and immature gametocytes, mature gametocytes persist for several weeks after 
treatment [10]. As a result, there is a pronounced but incomplete reduction of malaria 
transmission in the first 7–14 days after treatment [11-13]. Primaquine (PQ) is the only 
currently available drug that can play a role in reducing the infectious period after ACT by 
actively clearing mature gametocytes. Addition of PQ to ACT reduces the duration of 
gametocyte carriage 4-fold compared to ACTs alone [14]. However, a single dose of PQ at 
the currently recommended concentration (0.75 mg/kg) is associated with haemolysis in 
glucose-6-phosphate-dehydrogenase (G6PD) deficient individuals [15,16]. This sub-optimal 
safety profile hinders wide-scale use of PQ in malaria control [17]. There are currently no 
safe alternatives to PQ available, although dose-finding studies to determine a lower but 
efficacious dose of PQ are ongoing and the gametocytocidal activity and safety profile of 
the drug candidate methylene blue are promising [18].
 Adding IVM to ACTs may be a promising strategy to further reduce post-treatment 
malaria transmission. For this, the timing of IVM administration has to be optimized to 
cover the period when an individual is most infectious, which is plausibly the first week 
after initiation of treatment with ACTs [11,19]. An attractive element of IVM as a ‘targeted 
vector control tool’ is that it acts against both indoor and outdoor biting vectors and 
targets different effector molecules compared to indoor residual spraying with insecticides 
and insecticide treated nets [20,21]. An additional benefit in terms of integrated disease 
management would be the curative effect of IVM on intestinal strongyloidiasis, onchocerciasis 
and scabies [1]. Several important safety and tolerability data of an ACT-IVM drug combination 
are needed to confirm its potential, as well as pharmacokinetic data to ensure there are no 
drug interactions that may reduce the efficacy of the ACT or partner drug component.
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Abstract
Introduction
Artemisinin combination therapy effectively clears asexual malaria parasites and immature 
gametocytes but does not prevent post-treatment malaria transmission. Ivermectin (IVM) 
may reduce malaria transmission by killing mosquitoes that take blood meals from IVM 
treated humans.
Methods
In this double-blind, placebo-controlled trial, 120 asymptomatic Plasmodium falciparum 
parasite carriers were randomized to receive artemether-lumefantrine (AL) plus placebo 
or AL plus a single or repeated dose (200 µg/kg) of ivermectin (AL-IVM1 and AL-IVM2, 
respectively). Mosquito membrane feeding was performed 1, 3, and 7 days after initiation 
of treatment to determine Anopheles gambiae and Anopheles funestus survival and 
infection rates. 
Results
The AL-IVM combination was well tolerated. IVM resulted in a 4- to 7-fold increased 
mortality in mosquitoes feeding 1 day after IVM (P<0.001). Day 7 IVM plasma levels were 
positively associated with body mass index (r=0.57, P<0.001) and were higher in female 
participants (P=0.003), for whom An. gambiae mosquito mortality was increased until 7 days 
after a single dose of IVM (hazard rate ratio, 1.34 [95% confidence interval, 1.07–1.69]; 
P=0.012). Although we found no evidence that IVM reduced Plasmodium infection rates 
among surviving mosquitoes, the mosquitocidal effect of AL-IVM1 and AL-IVM2 resulted 
in 27% and 35% reductions, respectively, in estimated malaria transmission potential 
during the first week after initiation of treatment.
Discussion
We conclude that IVM can be safely given in combination with AL and can reduce the 
likelihood of malaria transmission by reducing the life span of feeding mosquitoes.
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Introduction
The transmission of Plasmodium from humans to mosquitoes depends on the presence of 
mature transmission stages, gametocytes. Once ingested, gametocytes may render 
mosquitoes infectious within 11–16 days after a blood meal [1]. Artemisinin combination 
therapy (ACT) forms the current first-line treatment for uncomplicated falciparum malaria. 
ACT rapidly clears asexual parasites and developing gametocytes but leaves mature P. 
falciparum gametocytes largely unaffected; a proportion of patients may transmit malaria 
after successful ACT treatment [2]. Strategies to prevent malaria transmission after ACT 
have received a sense of urgency with the emergence of artemisinin-resistance in 
Southeast Asia [3,4] and have mainly focused on supplementing ACT with gametocytocidal 
compounds [5-7]. An alternative approach to prevent post-treatment malaria transmission 
is to reduce the likelihood that mosquitoes that feed on gametocytaemic human hosts 
survive long enough to become infectious to other humans. Ivermectin (IVM) reduces 
the lifespan of Anopheles mosquitoes that feed on humans who have taken IVM [8,9] by 
activating glutamate-gated chloride (GluCl) channels in neuronal and neuromuscular 
tissues of invertebrates, thereby causing flaccid muscle paralysis [10]. IVM has an excellent 
safety profile in humans, allowing IVM to be used in mass drug administration campaigns to 
reduce the burden of onchocerciasis and lymphatic filariasis in Africa. IVM has never been 
tested in a clinical trial setting in malaria-infected individuals or in combination with ACT. 
 In this study, we report a randomized, double-blind, placebo-controlled clinical trial 
to determine the safety and impact of IVM, administered as single or repeated dose, in 
combination with artemether-lumefantrine (AL) in reducing the proportion of mosquitoes 
that survive sufficiently long to complete the sporogonic cycle of malaria.
Methods
Study design and participants
This trial was conducted from January until March 2013 in Balonghin, Burkina Faso. Individuals 
aged 15–25 were eligible if found to be infected with P. falciparum by microscopy and 
otherwise healthy. Exclusion criteria were: ≥20,000 malaria parasites/µL; severe malaria; 
fever (axillary temperature ≥37.5°C); haematological or biochemical abnormalities; body 
mass index (BMI) <16 or >32 kg/m2; haemoglobin concentration <11 g/dL; use of IVM 
within the previous 3 months; Loa loa or other filariasis infection; travel history to L. 
Loa-endemic areas; pregnancy or lactation; current tuberculosis or antiretroviral treatment; 
family history of congenital QTc interval prolongation or sudden death; use of drugs that 
influence cardiac function or prolong QTc interval; or electrolyte imbalance. Written 
informed consent was obtained. The trial was approved by the Interventions Research 
Ethics Committee of the London School of Hygiene and Tropical Medicine (reference 
number 6154), Comité d’Ethique pour la Recherche en Santé, Ministère de la Santé du 
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Burkina Faso (reference number 2012-5-026) and Comité Technique d’Examen des Demandes 
d’Autorisation d’Essais Cliniques, Ministère de la Santé du Burkina Faso (reference number 
50001020125EC00000). 
Randomization and masking
Included subjects (n=120) were randomly assigned to 1 of 3 treatment arms and 1 of 2 
membrane feeding schedules. A first set of 40 sealed envelopes contained cards indicating 
treatment with AL alone (AL, n=20) or AL with a single dose of IVM (AL-IVM1, n=20). After 
reviewing safety data, 80 additional participants were randomized to AL (n=20), AL-IVM1 
(n=20), or AL with a repeated treatment dose of IVM (AL-IVM2, n=40). Half of each treatment 
arm was allocated to membrane feeding on days 1 and 7, others to days 3 and 7.
Procedures
All subjects received 6 doses of 4 tablets of AL (Coartem [20 mg artemether and 120 mg 
lumefantrine], Novartis Pharma AG, Basel, Switzerland) at enrolment and after 8 hours (day 0), 
24 and 36 hours (day 1), and 48 and 60 hours (day 2) (±90 minutes). In the AL arm, the first 
and fifth dose of AL were given together with placebo tablets (Albochin, Pharmachemie 
BV, Haarlem, The Netherlands); in the AL-IVM1 arm, the first dose of AL was given with IVM 
(Stromectol, Merck Sharp & Dohme BV, Haarlem, The Netherlands) and the fifth AL dose 
together with placebo. In the AL-IVM2 arm, both the first and fifth AL dose were given 
together with IVM. IVM was given as 3-mg tablets aiming for a dose of 200 µg/kg. All 
treatment was administered under direct supervision, with 1 sachet of Nestle NIDO 
powder milk (containing 7.28 g of milkfat) dissolved in water to enhance bio-availability of 
AL [11]. 
 Participants were examined clinically on days 1, 2, 3, and 7 after enrolment. Blood 
samples were taken for microscopy (days 0, 3, and 7), standard haematological and 
biochemical parameters (days 0 and 7), membrane feeding assays (days 1 and 7 or days 3 
and 7), pharmacological assessment (days of membrane feeds) and gametocyte detection 
by Pfs25 messenger RNA quantitative nucleic acid sequence-based amplification 
(QT-NASBA; days 0, 3, and 7) [7]. 
 Membrane feeding assays were conducted as described elsewhere [12] using 
100–150 locally reared 4 to 5-day-old female Anopheles gambiae sensu stricto mosquitoes 
and 50–70 4 to 5-day-old Anopheles funestus mosquitoes. Because of mosquito husbandry 
limitations, experiments with An. funestus were done with a smaller number of mosquitoes 
and on days 1 and 3 only. Fully fed mosquitoes were kept on glucose for 10 days at 
27°C–29°C to monitor daily mosquito mortality. Anopheles gambiae mosquitoes that 
survived until day 10, when residual DNA from the blood meal is highly unlikely [13,14], 
were individually homogenised and processed for detection of P. falciparum oocysts or 
sporozoites by polymerase chain reaction (PCR) [14]. On day 7, lumefantrine plasma 
concentrations were determined for 20 randomly selected individuals per treatment arm 
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[15]; on days 1, 3, and 7, IVM plasma concentrations were determined for all individuals 
participating in membrane feeding experiments using high-performance liquid chroma-
to graphy with fluorescence detection and a sensitivity of 0.2 ng IVM/mL [16].
Outcome measures
The study objective was to determine the safety and efficacy of IVM in combination with 
AL in reducing the proportion of mosquitoes that survive long enough to complete the 
sporogonic cycle of P. falciparum. The primary efficacy endpoint was the survival of An. 
gambiae and An. funestus mosquitoes after taking a blood meal 1, 3 or 7 days after initiation 
of treatment. Plasma concentrations of AL and IVM after treatment and mosquito infection 
rates were secondary outcome measures. The associations of IVM plasma concentrations 
with sex and BMI were not initially defined in the study protocol.
Statistical analysis
For the primary efficacy outcome, individual mosquito data were analysed by Cox 
proportional hazard models with shared frailty to allow for the correlation between 
mosquito observations from the same donor. Cumulative mosquito mortality by day 10 
after feeding was determined for each individual membrane feeding experiment, 
log10-transformed, and compared with the AL reference arm using t test. IVM (days 1, 3, 7) 
and lumefantrine plasma concentrations (day 7) were compared between groups using 
nonparametric Wilcoxon-rank sum test. Proportions were compared between arms by χ2 
test, associations between continuous variables were determined by Spearman correlation 
coefficients, and the association between sex and IVM plasma concentrations was 
determined by Wilcoxon rank-sum test. 
 The impact of IVM on transmission from patients during the first week after initiation 
of treatment was estimated using data from a clinical trial with detailed gametocyte 
quantification after AL [7], a meta-analysis of the association between gametocyte 
concentration and An. gambiae mosquito infection rates [17], and An. gambiae mosquito 
survivorship in relation to IVM concentration. Assuming that a similar number of 
mosquitoes would feed on individuals from treatment arms and on all days of follow-up, 
the impact of IVM at reducing the number of infectious mosquitoes can be calculated as 
where gi, is the gametocyte prevalence at each day of follow-up (i) after treatment, pi is the 
proportion of mosquito infection in feeding assays with gametocyte levels at day i, and μi 
is the proportion of mosquito survival up to day 10.
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Sample size calculation
This study was designed as a superiority trial, testing mosquito mortality in the 2 IVM arms 
against the AL comparator arm. The study sample size was based on 80–100 fully fed An. 
gambiae sensu stricto mosquitoes and ≤20% mortality in the control arm [12]. Including 
20 individuals per time-point would allow us to detect an increase in mortality to ≥50% 
after 1 or 2 doses of IVM compared to the control arm (k=0.5; Zα/2=1.96; Zβ=0.84). For day 
7, we expected the smallest difference in mortality and aimed for 40 experiments per 
treatment arm.
Results
Trial profile and baseline characteristics
Of 120 randomized individuals, 117 completed follow-up (Figure 1). Baseline asexual 
parasite densities ranged from 8 to 7063 parasites/µL (Table 1); all participants cleared their 
asexual parasites by day 3. Gametocyte prevalence by QT-NASBA declined from 91.9% 
(102/111) at baseline to 54.9% (62/113) by day 3 and 41.8% (43/103) by day 7 with no 
significant difference between treatment arms (P≥0.81).
Safety results
Twenty-two adverse events (AEs) occurred; 10 AEs were ranked as mild and 12 as moderate 
in intensity (Table 2). None of the AEs were definitively associated with treatment and no 
serious AEs were seen. Platelet counts declined in 2 subjects during follow-up. In 1 subject 
of the AL group, platelets decreased from 327,000/µl at enrolment to 82,800/µl on day 7. 
This subject refused to return to the clinic for extra follow-up and was followed passively. 
In 1 subject of the AL-IVM1 group, platelets decreased from 191,000/µl at enrolment to 
68,500/µl on day 7, and returned to 218,000/µL when measured 20 days later. There were 
no other clinically significant haematological and biochemical abnormalities.
Efficacy results
The median number of fully fed An. gambiae mosquitoes was 94 per experiment 
(interquartile range [IQR], 92–96) and not different between treatment arms (P=0.15), 
giving 22,818 mosquito observations from 233 experiments conducted on days 1, 3, and 
7 post-treatment. The median number of fully fed An. funestus mosquitoes was 23 per 
experiment (IQR, 23–25) and not different between treatment arms (P=0.19), giving 2,469 
mosquito observations from 102 experiments conducted on days 1 and 3. Anopheles 
gambiae mortality was significantly increased on day 1 after single-dose IVM (hazard rate 
ratio [HRR], 3.86 [95% confidence interval {CI}, 3.29–4.52]; P<0.001), day 3 after single-dose 
IVM (HRR, 1.37 [95% CI, 1.14–1.65]; P=0.001), day 3 after repeated-dose IVM (HRR, 4.07 [95% 
CI, 3.41–4.87]; P<0.001), and day 7 after repeated-dose IVM (HRR, 1.30 [95% CI, 1.10–1.53]; 
P=0.002), but not day 7 after single-dose IVM (HRR, 0.93 [95% CI, 0.79–1.11]; P=0.43) 
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(Figure 2A). Similarly, An. funestus mosquito mortality was significantly increased on day 1 
after single-dose IVM (HRR, 7.12 [95% CI, 4.45–11.39]; P<0.001), day 3 after single-dose IVM 
(HRR, 2.98 [95% CI, 1.62–5.48]; P<0.001), and day 3 after repeated dose IVM (HRR, 9.07 [95% 
CI, 5.06–16.25]; P<0.001)(Figure 2B). Geometric mean cumulative An. gambiae mosquito 
mortality by day 10 after membrane feeding was 21.2% (95% CI, 18.5%–24.3%) in the AL 
arm; 59.1% (95% CI, 53.3%–65.6%; P<0.001) on day 1 after single-dose IVM, 31.1% (95% CI, 
26.5%–36.5%; P=0.001) on day 3 after single-dose IVM; 66.2% (95% CI, 58.5%–74.9%; 
P<0.001) on day 3 after repeated-dose IVM; 21.7% (95% CI, 18.5%–25.4%, P=0.82) on day 7 
Figure 1   Trial profile
Membrane feeding participation rates are reported for Anopheles gambiae.
AL, artemether-lumefantrine; BMI, body mass index; IVM1, single-dose ivermectin; IVM2, repeated-dose ivermectin.
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Table 1  Baseline characteristics of enrolled subjects
Treatment Group
Characteristic AL (n=40) AL-IVM1 (n=40) AL-IVM2 (n=40)
Age, y, median (IQR) 18.5 (16.0–21.3) 16.0 (15.0–20.0) 17.0 (16.0–18.5)
Sex, male, % (n/N) 65.0% (26/40) 45.0% (18/40) 70.0% (28/40)
Haemoglobin, g/dL,  
median (IQR)
13.3 (12.0–14.4) 13.2 (12.3–13.9) 12.9 (12.3–13.8)
Parasitaemia by microscopy, 
parasites/µL, median (IQR)
109.5 (38.3–222.0) 87.0 (28.0–203.5) 134.0 (45.0–406.0)
Gametocyte prevalence  
by microscopy, % (n/N)
20.0 (8/40) 12.5 (5/40) 12.5 (5/40)
Gametocyte prevalence  
by QT-NASBA, % (n/N)
97.2% (35/36) 86.8% (33/38) 91.9% (34/37)
AL, artemether-lumefantrine; IQR, interquartile range; IVM1, single-dose ivermectin; IVM2, repeated-dose 
ivermectin; QT-NASBA, quantitative nucleic acid sequence-based amplification.
Table 2  Adverse events of any severity in the different treatment arms
Treatment Group
Adverse Event AL (n=38) AL-IVM1 (n=39) AL-IVM2 (n=40)
Abdominal pain 2
Abscess on hand 1
Abscess on leg 1
Bronchitis 1
Conjunctivitis 1
Cough 1 1
Dental pain 1
Diarrhoea 1
Fever 1
Headache 1 1 4
Orchitis 2
Painful swelling of leg 1
Pharyngitis 1
Urinary tract infection 1
AL, artemether-lumefantrine; IVM1, single-dose ivermectin; IVM2, repeated-dose ivermectin.
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after single-dose IVM; and 26.7% (95% CI, 23.2%–30.7%; P=0.013) on day 7 after repeated- 
dose IVM. Geometric mean cumulative An. funestus mosquito mortality was 5.0% (95% CI, 
3.2%–7.8%) in the AL arm; 40.0% (95% CI, 26.8%–59.8%; P<0.001) on day 1 after single-dose 
IVM; 10.9% (95% CI, 5.4%–22.0%; P=0.033) on day 3 after single-dose IVM, and 51.4% (95% 
CI, 37.7%–69.9%; P<0.001) on day 3 after repeated-dose IVM.
Figure 2   Mosquito survival rate in relation to treatment arm for Anopheles gambiae and 
Anopheles funestus
The proportion of An. gambiae (A) or An. funestus (B) that survive in 10 days following membrane 
feeding in various treatment arms at days 1, 3, and 7 was combined for artemether-lumefantrine 
(AL); day 1 was combined for AL with single-dose ivermectin (IVM1) and AL with repeated-dose 
ivermectin (IVM2) as this was before the second dose of ivermectin.
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Median lumefantrine concentration was 685 ng/mL (IQR, 474–894 ng/mL) in the AL arm, 
634 ng/mL (IQR, 420–818 ng/mL) in the AL-IVM1 arm, and 449 ng/mL (IQR, 385–734 ng/
mL) in the AL-IVM2 arm (P=0.28). IVM plasma concentrations declined quickly after the last 
dose of IVM (Figure 3a) and were significantly higher in female than in male participants 
when measured on day 3 after single-dose IVM (P=0.02), and day 7 after single-dose 
(P=0.007) or repeated-dose IVM (P=0.003). IVM accumulates in fat tissue [18] and the 
proportion of body fat is positively associated with BMI. BMI was associated with IVM 
plasma concentration on day 3 (IVM1: n=18, r=0.64, P=0.004; IVM2: n=20, r=0.19, P=0.42), 
and day 7 (IVM1: n=37, r=0.73, P<0.0001; IVM2: n=40, r=0.49, P=0.001; Figure 3b) but not on 
day 1. Female participants had a higher mean BMI than male participants (difference of 
means, 1.12 kg/m2 [95% CI, 0.54–1.71 kg/m2]; P=0.0002). IVM plasma concentrations were 
strongly associated with cumulative mortality by day 10 after the blood meal for An. 
gambiae (r=0.75, P<0.0001; Figure 4) and An. funestus (r=0.48; P<0.0001). When stratified by 
sex, the lethal effect of IVM on An. gambiae was more pronounced and longer in women 
(Table 3). The number of An. funestus observations was 9-fold lower than for An. gambiae 
and considered too limited to allow robust sex-stratified analysis. 
Individual An. gambiae mosquitoes from 68 membrane feeds performed on days 1 and 7 
on Pfs25 QT-NASBA-confirmed gametocyte carriers were successfully analysed by PCR. 
Remaining assays failed because of freeze-thaws of mosquito samples, giving non- 
interpretable results. In total, only 0.8% (13/1,619) of the successfully assayed mosquitoes 
were P. falciparum positive: 0.7% (4/560) in the AL-arm, 0.5% (3/556) in the AL-IVM1 arm, and 
Table 3   Hazard rate ratios for Anopheles gambiae mortality on different days after 
initiation of treatment
Male participants Female participants
Treatment Hazard rate ratio P-value Hazard rate ratio P-value
No ivermectin 1 (ref ) 1 (ref )
Day 1, IVM1 & IVM2 3.29 (2.67–4.07) <0.001 5.03 (4.00–6.31) <0.001 
Day 3, IVM1 1.39 (1.04–1.85) 0.025 1.67 (1.31–2.13) <0.001
Day 3, IVM2 3.54 (2.81–4.46) <0.001 5.23 (4.01–6.83) <0.001
Day 7, IVM1 0.70 (0.55–0.89) 0.003 1.34 (1.07–1.69) 0.012
Day 7, IVM2 1.14 (0.92–1.42) 0.23 1.61 (1.25–2.08) <0.001
Hazard rate ratios were determined relative to the artemether-lumefantrine placebo arm and adjusted for 
the correlation between observations from the same individual.
IVM1, single-dose ivermectin; IVM2, repeated-dose ivermectin.
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Figure 3   Ivermectin plasma concentrations in relation to the sex of participants and 
body mass index
(A) Sex-stratified IVM plasma concentration for the different treatment arms and time-points of 
follow-up. (B) Association between BMI and day 7 IVM plasma concentrations for male (gray dots; 
n=45; r=0.52, P=0.0002) and female (n=32; r=0.37, P=0.037) participants. The limit of detection of the 
assay was 0.2 ng/mL (dashed line); plasma samples with undetectable IVM concentrations are given 
below the line.
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1.2% (6/503) in the AL-IVM2 arm. Supporting in vitro experiments found no apparent 
effect of sublethal IVM concentrations on P. falciparum development in An. stephensi and 
An. gambiae mosquitoes (Supporting Information 1). 
 We combined our longitudinal data on IVM concentrations (Figure 3), our data on the 
association between IVM concentration and An. gambiae mosquito survivorship (Figure 4), 
previously published data on gametocyte prevalence and density following treatment of 
symptomatic malaria patients [7], and a meta-analysis of the association between 
gametocyte density and mosquito infection rates [17] to estimate the potential impact of 
IVM on onward malaria transmission in the first week after initiation of treatment 
(Supporting Information 2). Despite the incomplete and short-lived mosquitocidal effect 
of IVM, mosquito survivorship is significantly reduced in the first days after treatment 
when gametocyte concentrations are highest and onward transmission is most likely. 
Compared to the AL-only arm, we estimated that individuals in the AL-IVM1 and AL-IVM2 
arms had a 27.2% and 35.4% reduction, respectively, in their contribution to transmission 
in the first week after initiation of treatment (Figure 5).
Figure 4   Ivermectin plasma concentrations in relation to cumulative mortality of 
Anopheles gambiae
The association between IVM plasma concentrations (all time-points combined) and cumulative 
An. gambiae mosquito mortality by day 10 (d10) after taking a blood meal. r=0.75, P<0.0001.
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Discussion
In this study, the AL-IVM combination was safe and significantly reduced the survival of 
2 major malaria vectors in sub-Saharan Africa, An. gambiae and An. funestus. The 
mosquitocidal effect of IVM was apparent 3–7 days after a single dose depending on 
volunteer sex, with a more pronounced effect when mosquitoes fed on blood from 
female participants. 
Figure 5   The estimated impact of treatment with ivermectin on Plasmodium falciparum 
transmission for malaria patients during the first week after treatment with 
artemether-lumefantrine
Bars indicate the percentage of mosquitoes that become infected and survive for 10 days after their 
blood meal for the different treatment arms and days after treatment (left y-axis). The assumptions 
underlying these estimates are outlined in the Supporting Information and are based on gametocyte 
prevalence and density estimates from Ugandan children aged 1–10 years [7], a meta-analysis of 
mosquito feeding experiments [17], and IVM pharmacokinetics and mosquito survival rates 
presented in the current manuscript. Lines indicate mosquito survival rates for the different 
treatment arms (right y-axis) and were either directly estimated or based on the best fit of IVM 
 pharmacokinetic data (Figure 2a) and the association between IVM plasma concentration and 
mosquito infection rates (Figure 3). Mosquito mortality in the AL-only arm (21% over 10 days) is 
considered to reflect natural mortality over this period and is assumed to be unrelated to the 
ingestion of gametocytes.
IVM1, single-dose ivermectin; IVM2, repeated-dose ivermectin.
1 2 3 4 5 6 7 9
0
1
2
3
4
5
6
7
8
9
10
0
10
20
30
40
50
60
70
80
90
100
AL
AL -IVM1
AL -IVM2
average
Days
Pe
rc
en
ta
ge
 m
os
qu
ito
es
 in
fe
ct
ed
an
d 
su
rv
iv
in
g 
un
til
 d
ay
 1
0
Percentage m
osquito survival until day 10
86
Chapter 5
The continued move toward malaria elimination has reinvigorated the search for strategies 
to prevent the spread of malaria, bolstered by a sense of urgency from the threat of 
artemisinin resistance [4]. Our findings confirm that IVM reduces the life span of different 
malaria vectors [19], including 2 dominant and important vectors in sub-Saharan Africa, 
An. gambiae and An. funestus. Mosquito mortality was 4- to 7-fold increased in mosquitoes 
that took a blood meal 1 day after IVM. Mosquito mortality was associated with IVM 
plasma concentrations that decreased markedly during the week after IVM treatment [20]. 
The waning of the mosquitocidal effect of a single or repeated dose of IVM was slower 
for female participants, in line with a higher IVM bioavailability in females [21]. The 
accumulation of IVM in fat tissue [18] and the strong association between BMI and day 7 
IVM plasma concentrations suggests that body fat may act as a slow-release reservoir 
that results in a longer effective half-life of IVM in female participants. 
 Our findings indicate that higher, repeated doses or sustained presence of drug may 
be needed for maximal effect. Although IVM is currently recommended as single dose of 
200 µg/kg with an excellent safety profile [22], there have been reports where IVM was 
used repeatedly at higher concentrations [23,24]. We confirmed the tolerability of repeated 
IVM dosing in a small group of malaria-infected individuals and found no evidence that 
co-administration of IVM affects the bioavailability of lumefantrine. The primary safety 
concern for IVM is encephalopathy in individuals heavily infected with microfilariae of 
L. Loa [25] and precludes the use of IVM without prior screening for L. loa in endemic areas 
of Central and West Africa. 
 Even in individuals with the highest IVM plasma concentrations, the mosquitocidal 
effect of IVM was not complete and a proportion of mosquitoes survived until day 10. 
Plasmodium falciparum parasites were detected in a small proportion of these surviving 
mosquitoes. Although our findings do not rule out a sporontocidal effect of IVM, which 
would require a larger study that is powered for infectivity outcomes, it indicates that 
malaria transmission potential is not completely abrogated by the AL-IVM combination. If 
IVM has no impact on gametocytes or their infectivity, its transmission-blocking effect is 
restricted to its capacity to reduce malaria survivorship in the days immediately following 
treatment. We estimated that single and repeated doses of IVM may lead to 27% and 35% 
reductions in post-treatment malaria transmission from symptomatic malaria patients 
in the first week after treatment with an effective antimalarial. This effect reflects the 
contribution of an individual patient to malaria transmission and does not reflect population- 
 level impacts that need to take into account effects of IVM on total vector density [8,9,26], 
reduced mosquito re-feeding rates, and recovery following a blood meal containing 
sub-lethal doses of IVM [19] and may therefore be larger than reported here. Future studies 
should further quantify the importance of IVM accumulation in fat tissue for (the duration 
of) IVM efficacy and be adequately powered to study subtle effects of IVM on sporogonic 
development. Most important, community trials with repeated doses of IVM are needed 
to confirm that IVM forms a useful adjunct to reduce and interrupt transmission [27]. 
87
Ivermectin to prevent malaria transmission after treatment
5
In conclusion, our study indicates an incomplete but pronounced effect of IVM on the 
survival of malaria vectors after IVM ingestion. This effect can be extended by repeated 
dosing and is associated with the BMI of treated individuals. We observed no evidence for 
a sporontocidal effect of IVM at mosquito sublethal concentrations in P. falciparum-infect-
ed individuals. The transmission-blocking properties of IVM may therefore be restricted to 
its mosquitocidal effects. 
Acknowledgements
We thank the study participants and members of the field team, clinical team, and 
entomology team at the Centre National de Recherche et de Formation sur le Paludisme, 
Ouagadougou, Burkina Faso. We further acknowledge the work of Geert-Jan van Gemert, 
Marga van de Vegte-Bolmer, Wouter Graumans, Rianne Siebelink-Stoter (Radboud University 
Medical Center, Nijmegen, The Netherlands) and Koen Dechering (TropIQ Health Sciences, 
Nijmegen, The Netherlands) for supporting in vitro work.
88
Chapter 5
References
1. Meis JF, Wismans PG, Jap PH, Lensen AH, Ponnudurai T (1992) A scanning electron microscopic study of the 
sporogonic development of Plasmodium falciparum in Anopheles stephensi. Acta Trop 50: 227-236.
2. Sawa P, Shekalaghe SA, Drakeley CJ, Sutherland CJ, Mweresa CK, et al. (2013) Malaria transmission after arte-
mether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. J Infect Dis 207: 1637-1645.
3. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, et al. (2009) Artemisinin resistance in Plasmodium falciparum 
malaria. N Engl J Med 361: 455-467.
4. Dondorp AM, Fairhurst RM, Slutsker L, Macarthur JR, Breman JG, et al. (2011) The threat of artemisinin-resistant 
malaria. N Engl J Med 365: 1073-1075.
5. White NJ (2013) Primaquine to prevent transmission of falciparum malaria. Lancet Infect Dis 13: 175-181.
6. Coulibaly B, Zoungrana A, Mockenhaupt FP, Schirmer RH, Klose C, et al. (2009) Strong gametocytocidal effect 
of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial. PLoS 
One 4: e5318.
7. Eziefula AC, Bousema T, Yeung S, Kamya M, Owaraganise A, et al. (2014) Single dose primaquine for clearance 
of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, 
controlled, double-blind, dose-ranging trial. Lancet Infect Dis 14: 130-139.
8. Chaccour C, Lines J, Whitty CJ (2010) Effect of ivermectin on Anopheles gambiae mosquitoes fed on humans: 
the potential of oral insecticides in malaria control. J Infect Dis 202: 113-116.
9. Sylla M, Kobylinski KC, Gray M, Chapman PL, Sarr MD, et al. (2010) Mass drug administration of ivermectin in 
south-eastern Senegal reduces the survivorship of wild-caught, blood fed malaria vectors. Malar J 9: 365.
10. Kane NS, Hirschberg B, Qian S, Hunt D, Thomas B, et al. (2000) Drug-resistant Drosophila indicate gluta-
mate-gated chloride channels are targets for the antiparasitics nodulisporic acid and ivermectin. Proc Natl 
Acad Sci U S A 97: 13949-13954.
11. Borrmann S, Sallas WM, Machevo S, Gonzalez R, Bjorkman A, et al. (2010) The effect of food consumption on 
lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible 
tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria. Trop Med Int Health 15: 434-441.
12. Ouedraogo AL, Guelbeogo WM, Cohuet A, Morlais I, King JG, et al. (2013) A protocol for membrane feeding 
assays to determine the infectiousness of P. falciparum naturally infected individuals to Anopheles gambiae. 
Malaria World Journal 4: 16.
13. Bell AS, Ranford-Cartwright LC (2004) A real-time PCR assay for quantifying Plasmodium falciparum infections 
in the mosquito vector. Int J Parasitol 34: 795-802.
14. Stone WJ, Eldering M, van Gemert GJ, Lanke KH, Grignard L, et al. (2013) The relevance and applicability of 
oocyst prevalence as a read-out for mosquito feeding assays. Scientific reports 3: 3418.
15. Wahajuddin, Singh SP, Jain GK (2009) Determination of lumefantrine in rat plasma by liquid-liquid extraction 
using LC-MS/MS with electrospray ionization: assay development, validation and application to a pharmaco-
kinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 877: 1133-1139.
16. Kitzman D, Wei SY, Fleckenstein L (2006) Liquid chromatographic assay of ivermectin in human plasma for 
application to clinical pharmacokinetic studies. J Pharm Biomed Anal 40: 1013-1020.
17. Bousema T, Dinglasan RR, Morlais I, Gouagna LC, van Warmerdam T, et al. (2012) Mosquito feeding assays to 
determine the infectiousness of naturally infected Plasmodium falciparum gametocyte carriers. PLoS One 7: 
e42821.
18. Baraka OZ, Mahmoud BM, Marschke CK, Geary TG, Homeida MM, et al. (1996) Ivermectin distribution in the 
plasma and tissues of patients infected with Onchocerca volvulus. Eur J Clin Pharmacol 50: 407-410.
19. Chaccour CJ, Kobylinski KC, Bassat Q, Bousema T, Drakeley C, et al. (2013) Ivermectin to reduce malaria 
transmission: a research agenda for a promising new tool for elimination. Malar J 12: 153.
20. Bastiaens GJ, van Gemert GJ, Hooghof J, Lindsay SW, Drakeley C, et al. (2012) Duration of the mosquitocidal 
effect of ivermectin. Malaria World Journal 3: 10.
21. Vanapalli SR, Chen Y, Ellingrod VL, Kitzman D, Lee Y, et al. (2003) Orange juice decreases the oral bioavailability 
of ivermectin in healthy volunteers. Clinical Pharmacology & Therapeutics 73: 94.
22. Olsen A (2007) Efficacy and safety of drug combinations in the treatment of schistosomiasis, soil-transmitted 
helminthiasis, lymphatic filariasis and onchocerciasis. Trans R Soc Trop Med Hyg 101: 747-758.
89
Ivermectin to prevent malaria transmission after treatment
5
23. Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, et al. (2002) Safety, tolerability, and pharmacokinetics of 
escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol 42: 1122-1133.
24. Awadzi K, Opoku NO, Addy ET, Quartey BT (1995) The chemotherapy of onchocerciasis. XIX: The clinical and 
laboratory tolerance of high dose ivermectin. Trop Med Parasitol 46: 131-137.
25. Gardon J, Gardon-Wendel N, Demanga N, Kamgno J, Chippaux JP, et al. (1997) Serious reactions after mass 
treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 350: 18-22.
26. Kobylinski KC, Sylla M, Chapman PL, Sarr MD, Foy BD (2011) Ivermectin mass drug administration to humans 
disrupts malaria parasite transmission in Senegalese villages. Am J Trop Med Hyg 85: 3-5.
27. Slater HC, Walker PG, Bousema T, Okell LC, Ghani AC (2014) The Potential Impact of Adding Ivermectin to a 
Mass Treatment Intervention to Reduce Malaria Transmission: a Modelling Study. J Infect Dis [in press].
90
Chapter 5
Supporting information 1
The Plasmodium falciparum sporonticidal effect of sublethal 
concentrations of ivermectin in Anopheles stephensi and An. gambiae 
mosquitoes
The clinical trial with artemether-lumefantrine alone or in combination with a single or 
repeated dose of ivermectin (IVM) observed P. falciparum positive mosquitoes that 
survived until day 10 after feeding on a gametocytaemic blood meal with sublethal 
concentrations of IVM. Below, we provide supporting information from in vitro experiments 
where we i) determined the concentration of IVM at which approximately 25% or 10% of 
An. stephensi mosquitoes died within 3 days after feeding (the LC25 and LC10); ii) determined 
oocyst development in An. gambiae and An. stephensi mosquitoes that were offered cultured 
gametocytes in combination with ivermectin at a concentration representing the 
estimated LC25 and LC10 values. 
Methods and Results
Anopheles stephensi (Sind-Kasur Nijmegen strain) and An. gambiae (Ngousso strain) were 
reared at 30°C and 70–80% humidity, while exposed to a 12/12 hour day/night cycle as 
described elsewhere [1]. In initial experiments, mosquitoes were offered IVM in the 
absence of gametocytes, as described by Kobylinski et al. [2] Powdered IVM [Sigma-
Aldrich] was diluted in dimethyl sulfoxide (DMSO) to obtain a 10mM stock (250 mg in 28.57 
mL DMSO). This stock concentration was serially diluted in DMSO and subsequently in 
human serum to reach a final DMSO concentration of 0.1%. The serum containing the 
diluted compound was mixed with human red blood cells to reach a haematocrit of 50% 
and fed to Anopheles mosquitoes using a glass membrane feeder. After three days, the 
numbers of dead and live mosquitoes were counted. LC25 and LC10 values were determined 
in triplicate experiments (SI Figure 1). 
For An. stephensi the LC25 and LC10 were estimated at 3.65x10
-9 M and 2.2x10-9 M by logistic 
regression. These concentrations were subsequently added to gametocyte culture. For 
this, mature P. falciparum (NF54) gametocytes (14 day culture, 0.3–0.5% gametocytes, 2% 
haematocrit) were obtained from an automated tipper system and prepared as previously 
described [3] and offered to mosquitoes using a glass membrane midi-feeder system 
containing 1.25 mL of the P. falciparum culture mix with IVM. Unfed and partially fed 
mosquitoes were removed after feeding and fully blood-fed females were maintained at 
26°C and 70–80% humidity until day 7 post-feeding. Routine staining of midguts was 
done in 1% mercurochrome after which oocyst densities were quantified. In triplicate 
replicates in An. gambiae and duplicate replicates in An. stephensi, there was no difference 
in oocyst density between surviving mosquitoes in control feeds and feeds with IVM at 
LC25 or LC10 (SI Figure 2).
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These results indicate that sublethal concentrations of IVM may not affect the development 
of P. falciparum oocysts in surviving mosquitoes. 
SI Figure 1   The kill curve of ivermectin in Anopheles stephensi (left) and An. gambiae 
mosquitoes (right)
SI Figure 2   Oocyst densities in Anopheles stephensi (left) and An. gambiae (right) 
mosquitoes using in vitro experiments with NF54 Plasmodium falciparum 
gametocytes and ivermectin
IVM was added to feeders at LC25 and LC10 concentrations; – indicates control feeds with gametocytes 
but no IVM.
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Supporting information 2 
The estimated net impact of treatment with ivermectin on  
Plasmodium falciparum transmission potential to Anopheles gambiae 
mosquitoes for malaria patients during the first week after treatment 
with artemether-lumefantrine
In the AL-IVM1 and AL-IVM2 arms, IVM plasma concentrations for 12-hour time windows 
were estimated based on the dynamics of IVM concentration in the human blood using 
the following equations,
where G is the concentration of IVM in the gut, B is the concentration of IVM in the blood, 
a is the rate at which IVM passes from the gut to the blood and c is the rate at which it is 
cleared from the blood. This model has previously been used to estimate the pharmaco-
kinetic properties of a drug for a range of treatments [1]. We have initial conditions  (where 
is the IVM dose) and . 
For the first round of treatment this model has the following analytic solutions,
Parameters a, c, and  are estimated by fitting Equation 1 to all the data from IVM1 and to 
the observations from the first day of IVM2 (Figure S3A). The pharmacodynamics for hours 
48–168 in the AL-IVM2 arm are estimated by fitting the analytical solution,
to the day 3 and day 7 data presented in SI Figure 3B where  is the concentration of IVM in 
the blood as predicted by the first model. Models were fit using maximum likelihood 
methods.
94
Chapter 5
From these fits, the average IVM concentration was determined for 12-hour time periods 
after single or double-dose IVM (SI Table 1). This was combined with estimates of the 
relationship between mosquito survival and IVM concentration (as shown by the linear 
association in SI Figure 4) to generate a prediction of mosquito survival for each time-period 
following treatment. 
SI Figure 3   The temporal dynamics of ivermectin concentration in the human blood  
for a single (A) and double (B) dose regimen
Points depict observational data whilst lines show the best fit model outlined in Equation 1 and 2 
(with parameter values a = 0.01976 c = 0.38535 and G0=200 µg/kg for A and the initial 48 hours of B, 
and a=0.01970, b=0.34719, G0 =200 µg/kg and B0= 4.187 µg/kg for the latter part of B). Vertical dashed 
line in (B) signifies the timing of the second treatment. Care should be taken interpreting the early 
pharmacodynamics of the drug prior to the first data point as this is driven by the structure of the 
model and has not been confirmed with observational results.
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SI Table 1   Modelled mean ivermectin plasma concentrations and predicted 
mosquito survival in the 10 days following a blood meal
It is assumed that IVM is given first thing in the morning and that mosquitoes start feeding  
12 hours later (at a constant rate for the next 12-hour period).
IVM1 IVM2
Hours Concentration Mosquito 
survival 
Concentration Mosquito  
survival 
0–12 Start treatment 7.24 7.24
12–24 Average 1st night 7.51 43.5% 7.51 43.5%
24–36 5.95 5.95
36–48 Average 2nd night 4.69 55.4% 4.69 55.4%
48–60 3.70 7.82
60–72 Average 3rd night 2.92 62.9% 8.38 39.9%
72–84 2.30 6.65
84–96 Average 4th night 1.82 67.5% 5.25 53.0%
96–108 1.43 4.14
108–120 Average 5th night 1.13 70.4% 3.27 61.4%
120–132 0.89 2.58
132–144 Average 6th night 0.70 72.2% 2.04 66.6%
144–156 0.56 1.61
156–168 Average 7th night 0.44 73.3% 1.27 69.8%
IVM, ivermectin.
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These data were combined to estimate the transmission-reducing effect at the level of 
individual patients (SI Table 2, see explanation in the main text). For this we used 
gametocyte prevalence and density data from a clinical trial in symptomatic malaria 
patients [2]. The likelihood that mosquitoes become infected after feeding on a 
blood-meal with the given gametocyte density was based on a meta-analysis of mosquito 
feeding data. The analysis was repeated for 2 other datasets [3,4] and did not lead to 
different conclusions on the comparative effect of IVM1 and IVM2 in comparison with AL 
monotherapy (data not shown).
SI Figure 4   The association between cumulative mosquito mortality and ivermectin 
plasma concentration
The association between IVM concentration and cumulative mosquito mortality during the 10 days 
following a blood meal was best described by the equation: mosquito mortality = 0.0421 (IVM 
concentration) + 0.2486 (blue line, R2 0.628). Non-linear functions did not improve the fit of IVM 
concentration and mosquito mortality (green and red line).
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Abstract
Introduction
Volunteers immunized under chloroquine chemoprophylaxis with Plasmodium falciparum 
sporozoites (CPS) develop complete, long-lasting protection against homologous sporozoite 
challenge. Chloroquine affects neither sporozoites nor liver-stages, but kills only asexual 
forms in erythrocytes once released from the liver into the circulation. Consequently, CPS 
immunization exposes the host to antigens from both pre-erythrocytic and blood stages, 
and induced immunity might target either of these stages. We therefore explored the life 
cycle stage specificity of CPS-induced protection. 
Methods
Twenty-five malaria-naive volunteers were enrolled in a clinical trial, 15 of whom received 
CPS immunization. Five immunized subjects and 5 controls received a sporozoite challenge 
by mosquito bites, whereas 9 immunized and 5 control subjects received an IV challenge 
with P. falciparum-infected erythrocytes. The latter approach completely bypasses pre- 
erythrocytic stages, enabling a direct comparison of protection against either life cycle stage. 
Results
CPS-immunized subjects (13 of 14) developed anticircumsporozoite antibodies, whereas 
only one volunteer generated minimal titers against typical blood-stage antigens. IgG 
from CPS-immunized volunteers did not inhibit asexual blood-stage growth in vitro. All 
CPS-immunized subjects (5 of 5) were protected against sporozoite challenge. In contrast, 
9 of 9 CPS-immunized subjects developed parasitaemia after blood-stage challenge, with 
identical pre-patent periods and blood-stage multiplication rates compared with controls. 
Intravenously challenged CPS-immunized subjects showed earlier fever and increased 
plasma concentrations of inflammatory markers D-dimer, IFN-γ, and monokine induced 
by IFN-γ than IV challenged controls. 
Discussion
The complete lack of protection against blood-stage challenge indicates that CPS-induced 
protection is mediated by immunity against pre-erythrocytic stages. However, evidence 
is presented for immune recognition of P. falciparum-infected erythrocytes, suggesting 
memory responses unable to generate functional immunity.
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Introduction
Malaria remains one of the most common and severe infectious diseases, with an estimated 
216 million cases and 655,000 deaths annually [1]. The malaria parasite Plasmodium falciparum 
is responsible for most of these cases, particularly in sub-Saharan Africa. Plasmodium 
falciparum sporozoites are transmitted to humans by the bites of infected Anopheles 
mosquitoes. Sporozoites migrate from the skin to the liver, where they invade hepatocytes, 
develop, and multiply. Approximately 6 days after invasion, hepatocytes rupture and merozoites 
are released into the bloodstream, where they multiply in 48-hour cycles of erythrocyte 
invasion, replication, erythrocyte rupture, and release of infectious merozoites. These 
asexual blood-stage parasites cause the clinical symptoms of malaria. To fight malaria, an 
effective vaccine is urgently needed. Development of vaccines generally has been stage-
oriented, specifically targeting pre-erythrocytic or asexual blood stages of the parasite [2]. 
 In the controlled human malaria infection model, we previously showed that 
immunization of healthy malaria-naive volunteers while they are taking chloroquine 
prophylaxis with P. falciparum sporozoites via infected mosquito bites (ChemoProphylaxis 
and Sporozoites [CPS] immunization) induces long-lasting sterile protection against a 
homologous challenge infection [3,4]. The unprecedented efficacy of the CPS 
immunization model is represented by the low dose sufficient to induce protection, i.e., 
3 times 12–15 infected mosquito bites, compared with 1,000 bites required in the irradiated 
sporozoite approach [5]. 
 Chloroquine kills only developing blood stages of P. falciparum, without affecting 
sporozoites or liver stages [6]. This results in transient low-level blood-stage parasitaemia 
during CPS immunization [3]. Consequently, the host’s immune system will be exposed to 
a relatively broad repertoire of antigens, including sporozoite, liver-stage, and early 
blood-stage antigens. Humoral and cellular immune responses are induced against both 
sporozoites and blood stages [3,7]. In addition, many antigens are shared between these 
stages [8], leaving open the possibility that the observed protection may be mediated by 
immune responses against either of these parasite life cycle stages or a combination 
thereof [9]. The absence of parasitaemia after challenge infection and the predominant 
induction of pre-erythrocytic antibodies suggest that pre-erythrocytic immunity primarily 
is responsible for protection, although a possible requirement for immune responses 
against asexual stages cannot be ruled out [3]. Indeed, previously it was shown that 
exposure to very low densities of blood stages may induce protection in the controlled 
human malaria infection model [10]. In this study, protected subjects displayed strong 
parasite-specific T-cell proliferation and IFN-γ production [10]. Moreover, CPS-immunized 
volunteers also exhibited strong IFN-γ responses upon in vitro restimulation with infected 
erythrocytes [7].
 To explore the possible role of immunity against the pre-erythrocytic and/or blood 
stage in protection, CPS-immunized volunteers were subjected to either a P. falciparum 
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sporozoite or an asexual blood-stage challenge. Because the latter approach completely 
bypasses the liver stages, any protection seen would indicate that blood-stage immunity 
may contribute to CPS-induced protection.
Methods
Study design
We conducted this single-center, open-label study at the Radboud University Nijmegen 
Medical Centre (Nijmegen, The Netherlands) from April 2011 until March 2012 following 
approval by the Central Committee for Research Involving Human Subjects of The 
Netherlands (CCMO NL34273.091.10). The study team complied with the Declaration of 
Helsinki and Good Clinical Practice, including monitoring of data. The trial is registered at 
ClinicalTrials.gov (NCT01236612). Written informed consent of all volunteers was obtained 
before screening. 
 Twenty-five healthy subjects (age 18–35 years) without a history of malaria or 
residence in a malaria-endemic area in the 6 months before study entry were included 
(Supporting Information [SI] Materials and Methods, Screening of Study Subjects) and 
randomly assigned to 4 groups (groups 1, 2, 3, and 4; Figure S1). Fifteen subjects received 
CPS immunization (groups 1 and 2) as described in detail in SI Materials and Methods. Ten 
controls (groups 3 and 4) received only chloroquine chemoprophylaxis. 
 Seventeen weeks after discontinuation of chloroquine prophylaxis, corresponding to 
21 weeks after the last immunization, all subjects received a challenge infection. Group 1 
(n=9; 1 lost to follow-up) and control group 3 (n=5) were challenged by IV administration 
of 1,962 viable 3D7 P. falciparum-infected erythrocytes (blood-stage challenge), which 
were derived from a stock produced at the Queensland Institute of Medical Research as 
described previously [11] and used in numerous studies [10-15]. Group 2 (n=5) and group 
4 (n=5) were exposed to the bites of 5 3D7 P. falciparum-infected Anopheles stephensi 
mosquitoes (sporozoite challenge). Subjects and investigators were aware of the study 
group, whereas primary outcome assessors were kept blinded to the allocation. All 
volunteers were treated with a curative regimen of antimalarial drugs at the time of thick 
smear positivity, or presumptively on day 21 after challenge if thick smears remained 
negative. 
Study outcomes
The primary study outcome was time to parasitaemia after challenge, as assessed by 
microscopy (SI Materials and Methods). The pre-patent period was defined as the period 
between challenge and the first positive thick smear. Volunteers were defined as protected 
from challenge if they remained thick smear negative until day 21. Additionally, 
parasitaemia was measured retrospectively by quantitative real-time polymerase chain 
reaction (qPCR) [16]. Blood-stage parasite multiplication rate was calculated as described 
107
Protection against malaria by preerythrocytic immunity
6
previously [17]. Assessment of in vitro growth inhibition and measurements of antibodies, 
haematological parameters, MIG, and IFN-γ are described in detail in SI Materials and 
Methods. 
Statistical methods
Statistical analysis was performed using GraphPad Prism 5. The difference in AEs among 
groups was calculated by unpaired Student t test on the accumulative duration of AEs. 
Differences among groups on the first day of fever (≥37.5°C), first day of D-dimer increase 
above 2 times the upper limit of normal (≥1,000 ng/mL), and first day of detectable IFN-γ 
and MIG were tested by unpaired Student t test. Differences among groups in pre-patent 
periods by thick smear and qPCR and blood-stage parasite multiplication rates were 
tested by the Mann-Whitney test. Differences in antibody levels and in vitro growth 
inhibition between time-points were tested by paired t test. 
 Analysis of lymphocyte kinetics after challenge was performed with SPSS version 18 
and based on data obtained at days 5, 6, and 7 (pre-treatment). Two regression-type 
models were fitted to the data. The dependent variable was lymphocyte number, and 
independent variables were time, treatment, the interaction between time and treatment, 
and the baseline observation of the dependent variable. The longitudinal character of the 
data was accommodated using general least-squares estimation; a heterogeneous, 
unstructured covariance matrix was assumed.
Results
Twenty-five of 42 screened subjects (median age 21 years; range 19–32 years) were 
included in the study (SI Figure 1). Fifteen volunteers were immunized according to the 
CPS protocol as described previously [3]. Briefly, while taking chloroquine prophylaxis, 
volunteers (groups 1 and 2) were exposed to bites of 15 P. falciparum infected mosquitoes 
(8 mosquitoes with the NF54 strain and 7 mosquitoes with the 3D7 clone) at monthly 
intervals for a period of 3 months. Control volunteers (groups 3 and 4) received chloroquine 
prophylaxis only. One subject in group 1 withdrew consent after the third immunization 
for reasons unrelated to the trial. 
 After the first immunization, 14 of 15 subjects (groups 1 and 2) developed transient 
low blood-stage parasitaemia, as retrospectively detected by qPCR. The geometric mean 
of peak parasitaemia was 1,378 parasites/mL (95% confidence interval [CI], 456–4,165 
parasite/mL; Figure 1). Thick smears remained negative, except in two subjects (one each 
in groups 1 and 2) who developed a positive thick smear on day 7. Their peak parasitaemia 
was 14,454 and 6,761 P. falciparum/mL. Both the severity and frequency of adverse events 
(AEs) were similar to those in the other subjects, and chloroquine plasma concentrations 
were within the prophylactic range (53 and 56 μg/L). These 2 subjects were treated 
promptly with atovaquone/proguanil and continued study participation according to 
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protocol. All subjects in groups 1 and 2 reported solicited AEs (mean duration, 1.0 ± 0.11 
days) after the first immunization. The most common AEs were headache (13/15 subjects), 
and fever and nausea (both in 8/15 subjects). Four subjects experienced a grade 3 AE 
(headache n=2, malaise n=2; mean duration 1.8 ± 0.6 days), which all occurred between 
days 7 and 10 after the first immunization and were considered probably related to the 
immunization. 
 After the second immunization, 4 subjects developed parasitaemia by qPCR (geometric 
mean peak parasitaemia, 351 parasites/mL; 95% CI, 43–2,857; Figure 1), whereas thick 
smears remained negative. Two subjects experienced mild or moderate AEs. After the 
third immunization, only 1 subject showed blood-stage parasitaemia (178 parasites/mL; 
Figure 1) and 3 subjects experienced mild AEs. No serious AEs occurred during the trial. 
 Antibody levels against the circumsporozoite protein (CSP), apical membrane antigen 
1 (AMA-1), and glutamate-rich protein (GLURP) were measured before CPS immunization 
and before challenge. CPS-immunized subjects (13/14) showed induction of anti-CSP 
antibodies (at least a 2-fold increase in antibody titer), whereas only a single subject (group 1) 
showed a minimal increase in AMA-1 and GLURP antibody titers (Table 1). Immunoglobulin 
G (IgG) was isolated from plasma of all immunized subjects at baseline and before 
challenge infection. In vitro blood-stage growth inhibition assay (GIA) did not show an 
inhibitory effect of purified IgG on blood-stage parasite growth in any of the subjects 
(Table 1). 
Figure 1   Blood-stage parasitaemia during CPS immunization
Blood-stage parasitaemia was measured from day 6 until day 10 after the first (I), second (II), and third 
(III) immunization by qPCR. Each line represents an individual subject (n=15); values shown as 10 on 
the logarithmic scale were negative.
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The minimum therapeutic plasma chloroquine concentration is 30 μg/L [18], and its 
reported half-life varies from 5 to 58 days [18,19]. To ensure sufficient clearance of 
chloroquine in view of the very low blood-stage challenge dose, the challenge infection 
was conducted 17 weeks after the last chloroquine dose, corresponding to 21 weeks after 
the last immunization. Group 1 (n=9) and group 3 (n=5) received a blood-stage challenge 
by IV administration of 3D7 asexual parasites. Group 2 (n=5) and group 4 (n=5) were 
subjected to a sporozoite challenge using 5 mosquitoes infected with 3D7 sporozoites 
[20]. There was no difference in parasitaemia between CPS-immunized group 1 and 
control group 3; both groups became thick smear positive, with a median pre-patent 
period of 8.0 days (range 7.0–8.3 days and 8.0–8.3 days, respectively; P=0.83). Likewise, the 
pre-patent period by qPCR was similar in both groups (median 5.0 days; range 3.0–5.3 
days and 2.0–6.3 days, respectively; P=0.41; Table 2). Furthermore, there was no statistically 
significant difference in multiplication rates of blood-stage parasites between the 
CPS-immunized subjects and naive controls (median 8 [range 6–18] and 14 [range 7–24], 
respectively; P=0.19; Table 2 and Figure 2). 
 In group 2, challenged with sporozoites, 4 of 5 CPS-immunized subjects remained 
negative throughout the follow-up period by both thick smear and qPCR. One 
CPS-immunized subject, however, showed a positive qPCR at day 21 post-challenge (457 
parasites/mL, determined retrospectively). Controls in group 4 all became thick smear 
positive, with a median pre-patent period of 12.3 days (range 9.3–12.3; multiplication rate 
10, range 5–23). Parasitaemia in group 4 (sporozoite-challenged controls) developed 
approximately 4 days later compared with group 3 (blood-stage-challenged controls; day 
5 vs. 9 by qPCR, P=0.01; and day 8 vs. 12.3 by thick smear, P=0.01; Table 2). The range in 
pre-patent periods was significantly smaller in group 3 (8.0–8.3 days) than in group 4 
(9.3–12.3 days). The parasite multiplication rate in the blood of control subjects was similar 
Table 1   Antibody titers and in vitro growth inhibition
Test I- 7 C-1 Δ [(C-1) - (I-7)] P-value
Antibody titer, AU
CSP 0.91 (0; 2.15) 24.3 (15.2; 48.5) 24.3 (10.8; 47.3) 0.006
AMA-1 0.12 (0.08; 0.17) 0.11 (0.09; 0.17) 0.00 (-0.03; 0.01) 0.35
GLURP 1.23 (1.01; 2.39) 1.06 (0.90; 3.39) -0.13 (-0.35; 0.14) 0.46
Growth inhibition, (%) -3.3 (-7.1;-1.1) -8.6 (-10.0; -5.46) -4.4 (-6.0; 1.8) 0.03
Antibody titers against CSP, AMA-1 and GLURP, and in vitro growth inhibitory activity of isolated IgG in all 
CPS-immunized subjects, before immunization (I-7) and on the day before challenge (C-1). Data are expressed 
as median (25;75 percentile). Differences between time-points were tested using a paired t test. AU, arbitrary 
units.
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Figure 2   Parasitaemia after challenge as assessed by qPCR 
Geometric mean parasite density ± 95% CI from day of inoculation until the day of treatment after 
blood-stage challenge [black line, group 1, CPS-immunized (n=9); dashed dark gray line, group 3, 
controls (n=5)] or sporozoite challenge [light gray line, group 2, CPS-immunized (n=5); dashed light 
gray line, group 4, controls (n=5)]. Values shown as 10 on the logarithmic scale were negative.
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Immunized Sporozoite 5/5 100 N/A N/A* N/A
Blood-stage 0/9 0 8.0 (7.0–8.3) 5.0 (3.0–5.3) 8 (6–18)
Control Sporozoite 0/5 0 12.3 (9.3–12.3) 9.0 (7.0–10.0) 10 (5–23)
Blood-stage 0/5 0 8.0 (8.0–8.3) 5.0 (2.0–6.3) 14 (7–24)
*One subject became qPCR positive on day 21 after challenge. N/A, not applicable.
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in those receiving either a blood-stage or sporozoite challenge (14 [7–24] vs. 10 [5–23], 
respectively; P=0.57). 
 All 19 unprotected volunteers reported solicited AEs considered possibly or probably 
related to the challenge (mean number of AEs per subject, 6.4; mean duration, 1.4 ± 0.1 
days), including headache, fever, and nausea as the most common symptoms (SI Table 1). 
The peak of AEs occurred later in subjects who received a sporozoite challenge, concordant 
with the later onset of parasitaemia, but there was no difference in accumulative duration 
of AEs compared with blood-stage-challenged controls (Figure 3a1 and a2; P=0.24). In 
contrast, protected subjects showed significantly fewer AEs: 3 of 5 experienced mild or 
moderate AEs (mean number/subject, 1.4; mean duration, 0.3 ± 0.1 days; P=0.002 
compared with unprotected subjects; Figure 3a2). 
 Lymphocyte counts decreased after challenge in all unprotected subjects (Figure 4A), 
as did platelet counts (Figure 4B), with the exception of 1 volunteer. Platelet counts 
declined below the lower limit of normal (150×109/L) in 9 of 19 unprotected subjects 
Figure 3   Adverse events and temperature after challenge  
Adverse events (AEs) and body temperature were recorded daily after challenge. Blood-stage 
challenge (A1) and sporozoite challenge (A2): mean number of possibly or probably related solicited 
AEs per subject. Blood-stage challenge (B1) and sporozoite challenge (B2): temperature (mean ± SEM). 
Black line, group 1 (CPS-immunized, blood-stage challenge; n=9); dashed dark gray line, group 3 
(controls, blood-stage challenge; n=5); light gray line, group 2 (CPS-immunized, sporozoite 
challenge; n=5); dashed light gray line, group 4 (controls, sporozoite challenge; n=5).
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(mean lowest value 132 ± 10 ×109/L). D-dimer concentrations were elevated in all thick 
smear-positive subjects (n=19; mean peak concentration, 3,908 ± 650 ng/mL; Figure 4C). 
All abnormal laboratory values normalized without complications; bleeding or thrombotic 
complications were not detected in any of the subjects. 
Figure 4   Haematological and inflammatory markers after challenge   
(A) Peripheral lymphocyte counts (×109/L). (B) Platelet counts (difference from value at inclusion, 
×109/L). (C) D-dimer (ng/mL). (D) IFN-γ (pg/mL). (E) MIG (pg/mL). Black line, group 1 (CPS-immunized, 
blood-stage challenge; n=9); dashed dark gray line, group 3 (controls, blood-stage challenge; n=5); 
light gray line, group 2 (CPS-immunized, sporozoite challenge; n=5); dashed light gray line: group 4 
(controls, sporozoite challenge; n=5). Data are shown as mean ± SEM.
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There was a remarkable difference in occurrence of fever and AEs between blood-stage-
challenged groups 1 and 3, although curves of developing parasitaemia were identical 
(Figures 2 and 3). CPS-immunized subjects in group 1 developed fever at a significantly 
earlier time-point than controls in group 3 (mean first day of temperature ≥37.5°C, day 7.25 
vs. day 8.5; P=0.002; Figure 3B1), concordant with an earlier mean decline in lymphocytes 
(Figure 4a; P<0.01) and increase in D-dimer concentrations (mean first day of D-dimer, 
>1,000 ng/mL, day 8.0 vs. day 9.0; P=0.05; Figure 4c). 
 We next investigated plasma concentrations of IFN-γ, a key mediator of cellular 
immunity in malaria [21], and monokine induced by IFN-γ (MIG), a downstream mediator 
in the IFN-γ pathway [22]. Figure 4 D and E shows distinct increases in both IFN-γ and MIG 
plasma concentrations upon blood-stage challenge at 2–3 days earlier in group 1 compared 
with group 3 (P<0.001).
Discussion
This study shows that sporozoite immunization by P. falciparum infected mosquito bites of 
human subjects while taking chloroquine chemoprophylaxis (CPS immunization) does 
not protect against an IV administered blood-stage challenge infection. The presence of 
transient low-level parasitaemia during CPS immunization is sufficient to induce immune 
recognition of asexual forms, as indicated by an earlier increase of IFN-γ and MIG after 
blood-stage challenge. However, these responses apparently are insufficient to confer any 
functional blood-stage immunity. In contrast, complete protection is obtained against a 
sporozoite challenge by mosquito bites as described before [3,4]. 
 The previously observed absence of detectable parasitaemia in CPS-immunized 
subjects after mosquito challenge suggested predominance of pre-erythrocytic 
immunity, but asexual stage immunity might have contributed to protection [3]. In the 
present study, however, the complete lack of any sign of clinical and/or parasitological 
protection against even an unphysiologically low blood-stage infection (<2,000 ring 
forms, i.e., 20-fold lower than an estimated average of 40,000 merozoites released from a 
single infected hepatocyte [23]), suggests the complete absence of any functional 
blood-stage immunity. This is supported by the lack of antibodies against blood-stage 
antigens after CPS immunization in all but 1 volunteer, and the absence of in vitro 
growth-inhibitory activity of IgG isolated from CPS-immunized subjects. The single 
volunteer who developed detectable, although very low, AMA-1 and GLURP antibody 
levels was the only subject who experienced qPCR-detectable blood-stage parasitaemia 
after all three immunizations. One immunized subject developed parasitaemia on day 21 
after sporozoite challenge, as retrospectively detected by qPCR. The blood-stage parasite 
multiplication rate after controlled human malaria infection in malaria-naive subjects is 
10.9 on average, but may be as low as 2 [17]. With a multiplication rate of 2, a load of 457 
parasites/mL on day 21 would be the result of an estimated 9,000 merozoites released 
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from the liver (i.e., one infected hepatocyte). Given the total lack of in vivo protection from 
blood-stage challenge and in vitro growth-inhibitory activity of IgG in all immunized 
subjects, the delayed pre-patency in this volunteer most likely was caused by either a 
profound reduction in liver-stage burden or a prolonged liver stage and therefore delayed 
release of merozoites into the blood. 
 Although clinical immunity and control of blood-stage parasitaemia are acquired 
with repeated parasite exposure in endemic populations, the occurrence of sterile protection 
mediated by sporozoite/liver stages alone has not been confirmed [24]. Hence, this study 
is a unique and unambiguous demonstration of induction of sterile pre-erythrocytic 
immunity generated against non-attenuated wild-type P. falciparum sporozoites. Sterile 
protection induced by immunization with irradiated sporozoites that arrest early after liver 
cell invasion also most likely is based on pre-erythrocytic immunity [5]. In this situation, 
asexual forms never occur, and the apparent lack of blood-stage immunity was shown 
in the 1970s in a single irradiated sporozoite-immunized volunteer challenged with 
blood-stage parasites [25]. 
 Blood-stage-challenged subjects in our study showed neither a delay in the 
pre-patent period nor a reduction in asexual multiplication rate compared with naive 
controls. This is remarkable because several studies have shown that protective immunity 
to P. falciparum blood stages can be induced readily after very few infections [10,26]: (i) 
Adult patients treated with prolonged P. falciparum infections for neurosyphilis in the 
1920s and 1930s showed clear evidence of clinical and parasitological immunity during a 
second asexual blood-stage infection by a decrease in frequency of fever and parasitaemia 
[26]. (ii) Repeated administration of ±30 P. falciparum-infected erythrocytes followed by 
early treatment with atovaquone/proguanil induced protection against blood-stage 
challenge [10] in 3 of 4 subjects, although a potential effect of residual atovaquone blood 
levels could not be ruled out [27]. A plausible explanation for the absence of blood-stage 
protection might be the short duration and low grade of parasitaemia as a result of the 
use of chloroquine and hence insufficient exposure to blood-stage antigens. Induction of 
protective immunity against blood stages requires several cycles of parasite replication 
and sufficient duration of parasitaemia [26,28]. Even in the trial by Pombo et al. [10], in 
which subjects were immunized with unphysiologically low numbers of blood-stage 
parasites, treatment was initiated only after 8 or 14 days, allowing at least 4 replication 
cycles and therefore sufficiently long exposure to blood-stage antigens. This stands in 
contrast to the CPS immunization protocol, in which prophylactic levels of chloroquine 
constantly are present, preventing a full blood-stage replication cycle of parasites. Thus, 
although the occurrence of low parasitaemia during CPS immunization might benefit the 
induction of pre-erythrocytic immunity as a result of the expression of cross-stage 
antigens, it clearly is insufficient to induce a functional protective immune response 
against blood stages. 
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Notwithstanding the absence of protection against blood-stage challenge, we do find 
evidence for immune recognition of blood stages. Previously, we showed that 
P. falciparum-infected erythrocytes elicit release of IFN-γ, mainly from innate cells including 
natural killer and γδT cells [7,29,30]. This innate response may be enhanced through and 
supplemented by adaptive memory T cells producing cytokines [31]. In addition, effector 
memory T cells produce IL-2 and IFN-γ upon in vitro restimulation with P. falciparum- 
infected erythrocytes [7]. In the present study, CPS-immunized subjects, while unprotected 
against a blood-stage challenge, showed an earlier in vivo peak of plasma IFN-γ in the 
course of blood-stage infection than naive controls, despite identical kinetics of 
developing parasitaemia. Early recognition of blood stages by memory cells in these 
immunized subjects apparently led to an accelerated and enhanced production of IFN-γ 
and further downstream mediators, including the chemokine MIG [22]. MIG may have 
contributed to the observed earlier lymphocyte recruitment out of the peripheral 
circulation. The clinical and laboratory signs/symptoms in the unprotected CPS-immunized 
and blood-stage-challenged volunteers (group 1) most likely represent a shift of 
inflammatory responses common to malaria [32] to earlier time-points compared with the 
challenged controls. Thus, immune recognition represented by these markers took place 
at an earlier time-point in CPS-immunized individuals compared with naïve volunteers, 
suggesting the presence of memory responses to asexual blood stages despite the 
absence of protection. 
 Mechanisms and target antigens for protective immunity induced by CPS immunization 
remain to be unravelled. Although mainly antibodies are important in controlling 
blood-stage parasitaemia [33], rodent and primate studies indicate that CD8+ T-cell 
responses against parasite liver stages are critically involved in pre-erythrocytic immunity 
[34-36]. Therefore, detailed analysis of T-cell responses will be the subject of future studies. 
 Furthermore, this efficient immunization model will enable studies of antigen 
specificity of cellular and humoral immune responses for identification of potential new 
antigens or combinations thereof for subunit vaccine candidates. Malaria vaccine 
development to date has been stage oriented, aimed at targeting either the pre-erythro-
cytic or asexual blood-stage of the parasite. Vaccines against asexual blood-stage antigens 
likely will not prevent infection, but instead may reduce parasite densities and provide 
protection against clinical disease. Pre-erythrocytic immunization strategies such as CPS 
immunization, however, induce sterile protection, thereby preventing blood-stage 
infection [37]. 
 In conclusion, sporozoite immunization by the CPS protocol may induce sterile 
protection entirely mediated by immune responses against the pre-erythrocytic stages of 
P. falciparum. These findings support a continued focus on vaccine development toward 
pre-erythrocytic stages, particularly whole-sporozoite approaches.
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Supporting information - Materials and methods
Screening of study subjects 
Forty-two subjects without a history of malaria or residence in a malaria-endemic area in 
the 6 months before study entry were screened for eligibility based on medical and family 
history, physical examination, and general haematological and biochemical tests. Serologic 
analyses for HIV, hepatitis B, hepatitis C, and Plasmodium falciparum were negative in all 
subjects. Urine toxicology screening was negative, and none of the volunteers was 
pregnant or lactating. All subjects had an estimated 10-year risk of developing a cardiac 
event lower than 5%, as estimated by the systematic coronary evaluation system [1].
Preparation of P. falciparum-infected mosquitoes for chemoprophylaxis 
and sporozoites immunization
Anopheles stephensi mosquitoes were reared at our insectary and infected by allowing 
them to feed on cultured gametocytes of P. falciparum parasites according to standard 
procedures as described previously [2]. We intended to immunize the subjects with 3D7 
parasites only, because this P. falciparum strain was to be used for the challenge infections. 
Initial stocks of 3D7 parasites for immunization and challenge were kindly provided by 
Adrian Hill, Oxford. However, because of difficulties in culturing 3D7 parasites during the 
immunization period, we immunized each volunteer with seven 3D7-infected plus eight 
NF54-infected mosquito bites per immunization instead. The 3D7 strain is a clone of NF54, 
and both are sensitive to chloroquine. The percentage of infected mosquitoes in the 
batches used for immunization 1, 2, and 3 was 75, 85, and 90 for 3D7 and 95, 90, and 100 
for NF54, respectively. Mosquitoes were infected with an average of 5,042 and 109,000 
sporozoites for 3D7 and NF54, respectively.
Chemoprophylaxis and sporozoites immunization procedure
Chloroquine was administered to all subjects according to a standard prophylactic 
regimen for a period of 14 weeks (98 days) as described previously by Roestenberg et al. 
[3]. While receiving chloroquine, groups 1 and 2 (15 subjects) were immunized 3 times at 
monthly intervals, starting 8 days after the first chloroquine dose. Immunization was 
performed by exposure to the bites of exactly 15 P. falciparum-infected mosquitoes for 15 
minutes, briefly interrupted twice. Following each feeding session, the salivary glands of 
all blood-engorged mosquitoes were dissected to confirm the presence of sporozoites. 
All 10 control subjects (groups 3 and 4) received chloroquine prophylaxis only, but no 
mosquito bites. On days 6–10 after each immunization, we checked all 15 immunized 
subjects once daily at our outpatient clinical research department. Blood was drawn for 
thick blood smears, standard haematological markers, and retrospective assessment of 
blood-stage parasitaemia by qPCR using P. falciparum standard curves prepared by DNA 
extraction from titrated samples of ring-infected cells [4]. All signs and symptoms were 
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recorded by the attending physician as mild (grade 1, easily tolerated), moderate (grade 2, 
interferes with normal activity), or severe (grade 3, prevents normal activity), or in the case 
of fever, grade 1 (>37.5–38.0°C), grade 2 (>38.0–39.0°C), or grade 3 (>39.0°C). For safety 
reasons related to a previously reported cardiac event [5], we measured cardiovascular 
markers throughout the trial (highly sensitive troponin, platelets, D-dimer, and lactate 
dehydrogenase). Whenever abnormal, blood samples were checked for the presence of 
fragmentocytes and von Willebrand-cleaving protease activity, according to previous 
protocols [6].
Challenge infections
Seventeen weeks after discontinuation of chloroquine prophylaxis, corresponding to 21 
weeks after the last immunization, all subjects received a challenge infection. Group 1 
(n=9; 1 lost to follow-up) and control group 3 (n=5) subjects were challenged by IV 
administration of 3D7 P. falciparum-infected erythrocytes (blood-stage challenge), 
whereas group 2 (n=5) and group 4 (n=5) were exposed to the bites of 5 3D7 P. falci-
parum-infected An. stephensi mosquitoes (sporozoite challenge). Subjects were checked 
daily on an outpatient basis for symptoms and signs of malaria, thick blood smears, 
hematologic tests, and cardiovascular markers. Subjects who received a blood-stage 
challenge were checked from the first day after challenge onward, sporozoite-challenged 
subjects from day 5 onward. All signs and symptoms (solicited and unsolicited) were 
recorded as described for the chemoprophylaxis and sporozoites (CPS) immunization. 
At the time of thick smear positivity, each subject was treated with a curative regimen of 
1,000 mg atovaquone and 400 mg proguanil once daily for 3 days according to Dutch 
national guidelines. Subjects who remained thick smear negative until day 21 after 
challenge were treated presumptively with the same curative regimen. Complete cure 
was confirmed by 2 consecutive parasite-negative blood smears after treatment.
Blood-stage inoculum
Inocula for blood-stage challenge were derived from a stock of 3D7 P. falciparum-infected 
erythrocytes (blood group O, rhesus negative) produced at the Queensland Institute of 
Medical Research, as described previously [7]. The donor was seronegative or PCR 
negative, or both, for a panel of parenterally transmissible viruses at the time of donation 
and 1 year later, but was IgG positive for EBV and CMV [7]. The blood-stage inoculum was 
cryopreserved in Glycerolyte 57 and stored in liquid nitrogen under temperature-moni-
tored conditions. To prepare the inocula for IV administration, an aliquot of the seed stock 
was thawed and washed under sterile conditions as described previously [8] using 
solutions licensed for clinical use and sterile, single-use consumables. Bacterial culture 
plates of the hood and both aerobic and anaerobic blood culture of the inoculum did not 
show any bacterial growth. The inoculum was prepared by diluting to the appropriate 
dose and dispensed aseptically into 5-mL syringes for administration. Based on microscopic 
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estimates of the donor’s parasite density before freezing of blood samples, each inoculum 
contained 4,289 infected erythrocytes. The inocula were kept on ice during preparation. 
Alternating between CPS-immunized and control subjects, all volunteers were inoculated 
IV between 103 and 111 minutes after thawing of the inocula. The number of viable 
parasites in the inoculum was verified in retrospect by limiting dilution culture and qPCR 
detection as previously described [4,8], and the inoculum was calculated to contain 
1,962/4,289 (46%) viable/total parasites per subject. This recovery of viable parasites was in 
the range of what has been reported for the inoculum elsewhere [8-10].
Sporozoite challenge
Anopheles stephensi mosquitoes fed on cultured gametocytes of P. falciparum strain 3D7 
were 100% infected with an average of 100,000 sporozoites per mosquito. A total of 10 
volunteers from group 2 (n=5) and group 4 (n=5) were exposed to bites of 5 infected 
An. stephensi mosquitoes for 10 minutes, as described previously [3]. One feeding session 
was sufficient for 5 volunteers, whereas a second session was required in the remaining 
5 volunteers to obtain an infectious challenge by exactly 5 infected mosquitoes in all 
10 subjects.
Study outcomes
The primary study outcome was time to parasitaemia after challenge, as assessed by 
microscopy. Sampling started on a daily basis for groups 1 and 3 (blood-stage challenge) 
on days 1–4 and continued for all groups post-challenge twice daily on days 5 and 6, 
thrice daily on days 7–11, again twice daily on days 12–15, and finally once daily on days 
16–21. Thick blood smears were made from 15 μL of EDTA-anticoagulated blood spread 
over the standardized surface of 1 well of a 3-well glass slide according to harmonized 
standard protocol for Controlled Human Malaria Infections (Laurens MB, Roestenberg M, 
and Moorthy VS; manuscript in preparation). After drying, wells were stained with Giemsa 
for 30 minutes. Slides were read at 1,000x magnification by assessing 200 high-power 
fields, equal to about 0.5 μL of blood. The smear was deemed positive if 2 unambiguously 
identifiable parasites were found. Lymphocyte and platelet counts were determined in 
EDTA-anticoagulated blood with the Sysmex XE-5000. D-dimer concentrations were 
assessed in citrate plasma by STA-R (Roche).
Immunological measurements
Concentrations of malaria antigen specific antibodies were determined in serially diluted 
citrate plasma by standardized ELISA in Nunc MaxiSorp plates (Thermo Scientific) coated 
with 1 μg/mL full-length circumsporozoite protein (CSP), apical membrane antigen 1 
(AMA-1; FVO-allele) [11], or glutamate-rich protein (GLURP) [12] diluted in PBS. ELISAs were 
developed using biotinylated polyclonal goat antihuman IgG (1/2,500), streptavidin- 
conjugated HRP (1/2,000), and tetramethylbenzidine (all from Mabtech). Spectrophoto-
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metrical absorbance was measured at 450 nm. Levels of antibody reactivity were analyzed 
in relation to a pool of sera from adults living in a highly endemic area in Tanzania [3], 
which was defined to contain 100 arbitrary units (AU) of IgG directed against an antigen. 
Antibody responses were considered positive when they had increased at least 2-fold 
after immunization, compared with baseline. Antibodies for growth inhibition assay (GIA) 
were isolated from citrate plasma collected the day before the start of chloroquine 
prophylaxis and the day before challenge infection. IgG was purified using protein G 
columns (HiTrapTM Protein G HP, GE Healthcare). Eluted samples were exchanged into 
RPMI-1640 on a Vivaspin 20 30-kDa molecular mass cut-off ultrafiltration unit (Sartorius), 
concentrated to 20 mg/mL, filter sterilized, and stored at −20°C until used. IgG protein 
concentrations were measured using a NanoDrop ND-1000 spectrophotometer (NanoDrop 
Technologies). The GIA was performed as previously described [11]. Briefly, the effect of 
IgG on in vitro parasite growth was evaluated at an IgG concentration of 10 mg/mL. 
Samples were run in triplicate using alanine-synchronized cultures of P. falciparum 3D7 
schizonts at an initial parasitaemia of 0.7%. After 40–42 hours, parasite growth was 
assessed by measuring parasite lactate dehydrogenase levels in culture supernatants with 
the lactate diaphorase 3-acetylpyridine adenine dinucleotide substrate system. EDTA (4 mM) 
was included in every test plate as a positive control. Induction of growth inhibitory 
activity by CPS immunization was assessed by subtracting for each volunteer the pre- 
immunization percentage of growth inhibition from the post-immunization value. 
Monokine-induced-by-IFN-γ (MIG) and IFN-γ concentrations in frozen and stored EDTA 
anticoagulated plasma samples were determined retrospectively. MIG was measured 
using a DuoSet ELISA (R&D Systems) and IFN-γ was measured using a Ready- SET-Go! ELISA 
kit (eBioscience) according to the manufacturer’s recommendations.
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Figure S1  Study flow diagram with relevant baseline data
Fifteen subjects were CPS-immunized by the bites of 3 × 15 P. falciparum- infected mosquitoes while 
taking chloroquine prophylaxis (groups 1 and 2). Ten control subjects received chloroquine 
prophylaxis but no infected mosquito bites (groups 3 and 4). One subject withdrew informed 
consent after the immunization for reasons unrelated to the trial. Seventeen weeks after discontinuation 
of chloroquine prophylaxis, nine immunized (group 1) and five control volunteers (group 3) received 
a blood-stage challenge, whereas five immunized (group 2) and five control volunteers (group 4) 
received a sporozoite challenge by mosquito bites.
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Abstract
Introduction
Our previous studies in the Controlled Human Malaria Infection (CHMI) model show that 
volunteers develop complete, long-lasting protection against a standard homologous 
Plasmodium falciparum (Pf) infection when immunized under chloroquine chemo-
prophylaxis by bites of sporozoite (SPZ)-infected mosquitoes. Here, we studied the safety, 
tolerability and induction of protective efficacy against homologous Pf CHMI after 
intradermal (ID) immunization with aseptic, purified, cryopreserved, infectious PfSPZ 
(NF54 strain) in volunteers taking weekly chloroquine chemoprophylaxis (PfSPZ-CVac).
Methods
Thirty healthy malaria-naive volunteers were enrolled in a double-blind, placebo controlled 
trial. All volunteers received chloroquine chemoprophylaxis during the immunization 
period. Vaccine group 1 (n=10) received 3 immunizations at 4 week intervals with 75,000 
PfSPZ (total 225,000) administered by 6 ID 10 µL injections at each session while control 
group 2 (n=5) received normal saline administered in the same fashion. Protective efficacy 
was tested by CHMI at 60 days after the last immunization. Vaccine group 3 (n=8) received 4 
rounds of ID immunizations with 75,000 PfSPZ (total 300,000) with group 4 (n=5) as normal 
saline control; 4 subjects of both group 3 and 4 were subjected to CHMI at 137 days after the 
last immunization.
Results
Similar percentages of PfSPZ-CVac recipients (11/20, 55%) and vaccine controls (6/10, 60%) 
reported mild to moderate probably/possibly solicited adverse events (AEs) and no 
serious AEs during immunization. A total of 23 volunteers were subjected to CHMI; 2/10 
subjects in group 1 remained aparasitaemic by microscopy but not by qPCR during the 
follow-up period of 21 days, and a parasite killing effect of residual chloroquine levels 
cannot be excluded. All other volunteers that received CHMI (n=21) developed 
parasitaemia with no significant difference in pre-patent period between both vaccine 
groups 1 (n=8) and 3 (n=4) as well as control groups 2 (n=5) and 4 (n=4). One subject in 
vaccine group 1 developed a cardiac serious adverse event (SAE) after CHMI as reported 
elsewhere. Only weak humoral responses assessed by PfSPZ immunofluorescence assay 
and specific ELISAs for PfCSP, PfLSA1 and PfMSP1 were induced in vaccine group 1 and 3, 
while there were no in vitro cellular re-call responses against NF54 parasites as determined 
by flow cytometry.
Discussion
ID immunization with up to a total of 300,000 PfSPZ-CVac was safe and well tolerated, but 
induced only minimal immune responses and subsequent protection if any against a 
homologous CHMI. Dose and/or route of PfSPZ-CVac administration were insufficient and 
unable to induce the immune responses required for protection.
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Introduction
Malaria accounts for 207 million clinical cases a year worldwide and an estimated 627,000 
deaths, with children under 5 years of age in sub-Saharan Africa most severely affected [1]. 
Significant advances have been made in malaria control with the number of confirmed 
cases steadily reducing and mortality rates dropping by 49% in the World Health 
Organization (WHO) African Region between 2000 and 2012 [1]. To ensure these positive 
trends and maintain gains achieved over the past decade, current control and preventive 
measures such as artemisinin-based combination therapies (ACTs), rapid diagnostic tests 
(RDTs), long-lasting insecticidal nets (LLINs) and indoor residual spraying (IRS) should be 
supported by a highly-effective malaria vaccine. Emergence of artemisinin-resistant malaria 
in Southeast Asia [2,3] and widespread insecticide resistance in malaria transmitting 
anopheline mosquitoes [4] further increase this need. Combining various control and 
preventive measures including large-scale vaccination will ultimately offer the best prospect 
for success.
 Progress in the clinical development of efficient immunization strategies as a forerunner 
of an effective malaria vaccine has been facilitated by controlled human malaria infections 
(CHMIs). CHMIs involve small groups of malaria-naive volunteers exposed to the bites 
of Plasmodium falciparum (Pf) sporozoite (SPZ)-infected laboratory-reared Anopheline 
mosquitoes. We have previously shown that healthy malaria-naive volunteers can be fully 
protected against a mosquito CHMI with a homologous Pf strain for more than two years 
after three immunizations under chloroquine prophylaxis by bites from 12-15 PfSPZ- 
infected mosquitoes at monthly intervals (ChemoProphylaxis and Sporozoites, CPS) [5,6]. 
Protection is mediated by immunity against pre-erythrocytic stages [7].
 While a strong proof of concept, this protocol is unsuitable for direct practical application 
as long as PfSPZ are inoculated by mosquito bites. Sanaria Inc. (Rockville, USA) has 
developed a process for manufacturing infectious, aseptic, purified, vialed, cryopreserved 
PfSPZ (PfSPZ Challenge) in compliance with all regulatory standards [8-11]. To date, single 
doses of cryopreserved PfSPZ have been administered at different doses up to 125,000 
PfSPZ in 184 human subjects by the intradermal (ID) (n=84), intramuscular (IM) (n=70), or 
direct venous inoculation (IV) (n=30) routes using a needle and syringe in order to assess 
safety, tolerability and infectivity [8,9,11].
 Here, we report the first phase 1 trial of CPS immunization with cryopreserved PfSPZ, the 
PfSPZ-CVac (PfSPZ-Chemoprophylaxis Vaccine) approach to assess, safety, immunogenicity 
and protection against CHMI with Pf-infected mosquitoes.
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Methods
Study population
We recruited healthy male and female subjects aged 18 to 35 years, adhering to inclusion 
and exclusion criteria as described previously [7]. All subjects had an estimated 10-year risk 
of developing a cardiac event smaller than 5% as estimated by the systematic coronary 
evaluation system [12]. Baseline ophthalmologic examination revealed no abnormalities 
on fundoscopy that might preclude treatment with chloroquine.
 Subjects gave written informed consent before inclusion. The trial was conducted in 
accordance with Good Clinical Practice and approved by the Central Committee for Research 
Involving Human Subjects of The Netherlands (CCMO NL39541.091.12). An  Investigational 
New Drug application was filed with the U.S. Food and Drug Administration. Clinicaltrials. gov 
identifier: NCT01728701.
Trial design
This prospective, single centre, double-blind, randomized, placebo-controlled clinical trial 
was performed at the Radboud university medical center (Radboudumc), Nijmegen, The 
Netherlands, from September 2012 to February 2014. Thirty subjects were randomly 
assigned to 4 study groups: vaccine groups 1 and 3 (each 10 subjects) and control groups 
2 and 4 (each 5 subjects) (Figure 1). All groups received injections with either cryopreserved 
PfSPZ (strain NF54) or normal saline (NS) under chloroquine cover as described below. 
Sixty days after the last immunization with cryopreserved PfSPZ, groups 1 and 2 received 
a standard CHMI by 5 mosquitoes infected with Pf NF54 SPZ [13]. Protection was defined 
as thick smear negative through day 21 post-CHMI. Subsequent study procedures involving 
groups 3 and 4 were dependent on the rate of protection: if ≥75%, groups 3 and 4 would 
receive CHMI with heterologous Pf NF135.C10-infected mosquitoes [14]; if protection rate 
proved to be <75%, a fourth PfSPZ-CVac immunization would follow with subsequent 
homologous Pf NF54 CHMI.
PfSPZ-CVac immunizations
All subjects received standard chloroquine chemoprophylaxis for a period of 14 weeks (98 
days) as described previously [5]. On days 8, 36 and 64 following initiation of chloroquine 
chemoprophylaxis, vaccine groups received 6 intradermal (ID) 10 µL injections (in the 
deltoid region of both arms) of PfSPZ Challenge, containing a total of 75,000 cryopreserved 
PfSPZ of the Pf NF54 strain. Controls received 6 ID 10 µL injections of NS. The vialed 
cryopreserved PfSPZ in liquid nitrogen vapour phase were thawed and diluted in 
phosphate buffered saline containing 1% human serum albumin and all subjects were 
injected within 30 minutes of thawing. In addition subjects in groups 3 and 4 received a 
fourth injection of PfSPZ Challenge or NS 168 days after the third immunization. 
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On days 5, and 10 to 14 after injections, subjects were checked on an outpatient basis 
by attending physicians and blood was drawn for thick blood smears, standard haema- 
tological and biochemical parameters, markers of myocardial tissue damage, coagulation, 
inflammation, and hemolysis as described previously [7], and retrospective assessment 
of blood-stage parasitaemia by quantitative real-time polymerase chain reaction (qPCR). 
Additional blood samples for qPCR measurements were provided on a voluntary base 
on days 8 and 9 after the second and third immunizations. All signs and symptoms 
(solicited and unsolicited) were recorded and graded as follows: mild/grade 1 (awareness 
of symptoms that are easily tolerated and do not interfere with usual daily activity), 
moderate/grade 2 (discomfort that interferes with or limits usual daily activity), or severe/
grade 3 (disabling, with subsequent inability to perform usual daily activity, resulting 
in absence or required bed rest). Tympanic temperature was measured and recorded 
as fever grade 1 (37.6–38.0°C), grade 2 (>38.0–39.0°C), or grade 3 (>39.0°C). Causality of 
adverse events (AEs) was classified as not-related, possibly, probably or definitely related 
to the trial.
CHMI by mosquito bite
Anopheles stephensi mosquitoes were reared at the Radboudumc insectary and infected 
by feeding on cultured gametocytes of Pf N54 parasites, according to standard procedures 
as described previously [15]. The percentage infected mosquitoes of the batches used for 
challenge infection was 100, and mosquitoes were infected with an average of 75,800 and 
98,000 PfSPZ per mosquito for CHMI #1 (groups 1 and 2) and CHMI #2 (groups 3 and 4), 
respectively.
 Thirty-three days after the last dose of chloroquine, corresponding to 60 days after 
the last immunization with cryopreserved PfSPZ, vaccine group 1 (n=10) and control 
group 2 (n=5) underwent CHMI by the bites of 5 An. stephensi mosquitoes infected with 
the Pf NF54 strain for 10 minutes as described previously [13]. The salivary glands of all 
blood-engorged mosquitoes were dissected to confirm the presence of PfSPZ. When 
necessary, feeding sessions were repeated with fewer mosquitoes until exactly 5 infected 
mosquitoes had fed. Starting from day 5 after CHMI, subjects were checked daily on an 
outpatient basis as described above for PfSPZ-CVac immunizations. Blood sampling for 
thick smear reading and retrospective assessment of parasitaemia by qPCR was performed 
once daily on days 5 and 6, twice daily on days 7–15, once daily on days 16–21, and for 2 
days after initiation of antimalaria treatment for positive thick smears. Antimalaria 
treatment, consisting of a curative regimen of Malarone (1000 mg atovaquone and 400 
mg proguanil) once daily for 3 days, was initiated either as soon as parasites were detected 
on a thick blood smear, or 21 days after CHMI by mosquito bite for those who did not 
become infected. Final follow-up visits were on days 35 and 140 after CHMI by mosquito 
bite.
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On day 14 after CHMI 1 subject in vaccine group 1 was unblinded due to a cardiac serious 
adverse event (SAE) [16]. All other subjects in groups 1 and 2 were unblinded according to 
protocol 24 days after CHMI by mosquito bite.
 Due to the cardiac SAE, the trial was put on hold for 64 days (13 March 2013–16 May 
2013) by the Safety Monitoring Committee and the Central Committee for Research 
Involving Human Subjects of The Netherlands. New safety measures were adopted for 
follow-up after mosquito CHMI of groups 3 and 4. The endpoint of thick blood smear 
positivity for diagnosis of malaria was changed to qPCR positivity. Malarone treatment was 
to be initiated after i) 2 consecutive positive qPCRs when temperature <38.0⁰C, ii) 1 
positive qPCR in the presence of a temperature ≥38.0⁰C, or iii) a positive thick smear 
prepared upon indication during the evening visit. Subjects who underwent standard 
vaccinations within 3 months before start of the trial or were planning to take standard 
vaccinations during the trial period up to 8 weeks after CHMI were excluded. 
Study outcome parameters
The primary study outcome was frequency and magnitude of adverse events. Secondary 
study outcomes included occurrence of Pf parasitaemia after each immunization and 
CHMI, as assessed by microscopy of thick blood smears and/or qPCR. Thick blood smears 
were prepared and read as described previously [7]. qPCR was performed as described 
previously [17] with some modifications. Briefly, 5 µL Zap-oglobin II Lytic Reagent 
(Beckman Coulter, ref no: 7501369-HA) was added to each 0.5 mL blood sample, mixed 
and stored at -80°C. After thawing samples were spiked with Phocine Herpes Virus (PhHV) 
as extraction control and DNA was extracted by a MagnaPure LC isolation instrument. 
Isolated DNA was re-suspended in 50 µL H2O and 5µl was used as template. For the 
detection of Pf the TaqMan MGB probe AAC AAT TGG AGG GCA AG-FAM was used. For the 
quantification of PhHV we used primers and probe as described previously [18]. The 
sensitivity of qPCR was 35 parasites/mL of whole blood. The prepatent period (by qPCR or 
thick smear) was defined as the period between mosquito bite CHMI and the first positive 
qPCR (≥500 parasites/mL) or thick smear result (≥2 unambiguous parasites). The difference 
in the pre-patent period assessed by qPCR compared to thick smear was defined as Δ 
pre-patency.
Immunologic analysis
Plasma and peripheral blood mononuclear cells (PBMCs) were obtained from blood 
collected into citrated BD Vacutainer CPT Cell Preparation Tubes on the following 
time-points: 1 day before initiation of chloroquine prophylaxis (I1-1) for all volunteers, the 
day before the third immunization (I3-1) and CHMI (C-1, 59 days after the third immunization) 
in groups 1 and 2, and 1 day before and 52 days after the fourth injection of PfSPZ/ NS 
injections in groups 3 and 4 (I4-1, I4+52).
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Analysis of antibody responses by ELISA
Plasma concentrations of malaria antigen-specific antibodies were determined against a 
pool of 100 sera from adults living in a highly endemic area in Tanzania (HIT serum [5]) by 
standardized enzyme-linked immunosorbent assay (ELISA). Recombinant proteins of cir-
cumsporozoite protein (PfCSP) and liver stage antigen 1 (PfLSA-1) [19] represent sporozoites 
and liver stages, respectively, while merozoite surface protein 1 recombinant protein 
(PfMSP-1) [20] was used to assess reactivity against late liver and blood stages [21].
 96-well Polystyrene flat-bottom plates (NUNC™ Maxisorp, Thermo Scientific) were 
coated overnight at 4°C with 2 µg/mL of antigen, washed with PBS and blocked for 1.5 
hours at room temperature (RT) with 150 µL of 5% milk in PBS. In all the washing steps that 
followed, plates were washed with PBS + 0.05% Tween (PBST). Serially diluted plasma 
samples (starting at 1:50 to 1:800 in 1% milk in PBST [sample buffer]) were incubated for 3 
hours at RT in a humidified chamber. As a standard, duplicates of pooled HIT serum were 
included on every plate in a 7-point dilution series. Reactivity for each antigen in undiluted 
HIT serum was defined as 100 arbitrary units (AU). Bound immunoglobulin G (IgG) was 
detected using horseradish peroxidase (HRP) conjugated anti-human IgG (Thermo 
Scientific) followed by TMB One Component HRP Microwell Substrate (tebu-bio). The 
reaction was stopped using 0.2M H2SO4 and absorbance measured with a spectro- 
photometer plate reader at 450 nm (Anthos 2020 ELISA plate reader). Optical density (OD) 
values were converted into AUs by four-parameter logistic curve fit using Auditable Data 
Analysis and Management System for ELISA (ADAMSEL-v1.1, http://www.malariaresearch.
eu/content/software). An increase in AU of more than 1 was considered an actual increase. 
Analysis of Plasmodium falciparum sporozoite immunofluorescense 
assay
Two x103 purified PfSPZ suspended in 20 μL PBS with 2% BSA were added to Cel-Line 
(Thermo Scientific) IFA slides as described before [22]. Pre-immune control sera (I1-1) were 
added at a single dilution of 1:50; the post-immune samples of 52 days after the fourth 
injection (I(4)+52) were added at 2-fold dilutions starting at 1:50. Anti-PfCSP monoclonal 
antibody 2A10 [23] was used as positive control. After incubation at 37°C for 1 hour, slides 
were washed and Alexa fluor 488 conjugated goat anti-human IgG (Molecular Probes, cat# 
A11013) (1:250 in 0.2% Evans Blue) was added followed by incubation at 37°C for 1 hour and 
a washing step. Vectashield mounting medium (Vector Laboratories) was added to each 
well, and a cover slip placed on the slide. Samples were assessed with an Olympus BX51 
fluorescence microscope at 400x magnification. The positive control was a serum specimen 
from a volunteer immunized with PfSPZ Vaccine (radiation attenuated PfSPZ) and a malaria 
naive serum sample was used as negative control [22]. The endpoint titer was defined as the 
last serum dilution at which fluorescence intensity was higher than pre-immune sera. A 
post- immunization serum sample was considered positive if it had fluorescence at a dilution 
of 1:50 or higher, and the pre-immunization serum from that volunteer was negative at 1:50.
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Analysis of cellular immune responses by FACS 
For the assessment of Pf-specific immune responses, in vitro re-stimulation assays on 
PBMCs were performed as described previously [24]. Briefly, cryopreserved PBMCs were 
thawed and stimulated in vitro for 24 hours with glycerol-cryopreserved schizont-stage Pf 
NF54 infected erythrocytes (PfRBCs) and purified Pf NF54 sporozoites in the presence of 
anti-human CD107a antibody (Biolegend, Pacific Blue, H4A3) at 100 µL/well (final 
concentrations: 5x106 PBMC/mL; 10x106 PfRBC/well; 1.25x106 PfSPZ/mL). Uninfected red 
blood cells (uRBCs) and medium with 1% HSA (AlbuRx 25, ZLB Behring AG, Switzerland) 
were used as a negative control. For the last 4 hours, Brefeldin A (Sigma, 10 µg/mL) and 
Monensin (Sigma, 2 µM) were added, along with PMA (Sigma, 50 ng/mL) and ionomycin 
(Sigma, 1 µg/mL) in positive control wells. Cells were stained with a viability marker (life/
dead fixable dead cell stain aqua; Invitrogen) and antibodies against CD3 (PerCp, UCHT1), 
IFN-γ (PECy7, 4S.B3) and granzyme B (FITC, GB11; all Biolegend); CD4 (ECD, SFCI12T4D11), γδT 
cell receptor (PE, IMMU510; both Beckman-Coulter), CD8 (BD Biosciences, APC-H7, SK1) and 
CD56 (eBioscience, biotin, MEM188 with eBioscience Streptavidin eFluor 660) [24]. Intracellular 
cytokine staining was performed using the Fixation and Permeabilization buffer kit 
(eBioscience). For every individual subject, all time-points were thawed, stimulated and 
stained within the same experimental round. Flow cytometry was performed on a 9-color 
Cyan ADP (Beckman Coulter) and data were analyzed using FlowJo software (version 9.6.4; 
Tree Star). Gating of cytokine-positive cells was performed automatically, based on the 
geometric Mean Fluorescent Intensity (MFI) of cytokine negative PBMCs for each subject, 
time-point and stimulus. Responses to uRBCs were subtracted from the response to 
PfRBCs for every subject on every time-point.
Analysis of chloroquine and monodesethylchloroquine concentrations
One hundred µL of plasma of volunteers in groups 1 and 2 collected on the day before 
CHMI (C-1) was used to assess chloroquine and monodesethylchloroquine levels. The 
plasma samples were precipitated by methanol (400 µL) containing hydroxychloroquine 
(50 ng/mL). After mixing and centrifugation, supernatants were diluted to half in 
ammonium formate solution 20 mmol/L with formic acid (0.5% v/v) and 15 µL per sample 
was injected into the system. Chloroquine and monodesthylchloroquine were separated 
and quantified by liquid chromatography mass detection (TSQ Quantum Ultra, 
ThermoFisher, France) using an Atlantis DC18 (100 mm x 2.1 mm, 3 µm) column (Waters, 
France) using water/methanol (95/5% v/v) with formic acid (0.1% v/v) as mobile phase. 
The flow rate was 0.30 mL/min and the column temperature was kept at 25°C. Hydroxy-
chloroquine was used as internal standard. Data were acquired in the positive-ion mode 
with an electrospray (ESI) source. Multiple reaction monitoring (MRM) was used for data 
collection.
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Statistical methods
Statistical analyses were performed with GraphPad Prism 5. The difference in AEs between 
2 groups was calculated by unpaired Student t test on the cumulative duration of AEs. 
Differences between groups in pre-patent periods by qPCR, in pre-patency between thick 
smear and qPCR (Δ pre-patency), and in antibody levels were tested by the Mann-Whitney 
test. Differences in antibody concentrations between time points within a group were 
tested by Wilcoxon signed rank test.
Results
Trial overview
Thirty of 65 screened subjects (median age 21 years; range 18–27 years) were included in 
the study (Figure 1). Twenty subjects under chloroquine chemoprophylaxis (groups 1 and 3) 
were immunized by ID injection 3 times at monthly intervals with 75,000 cryopreserved 
PfSPZ, 10 controls (groups 2 and 4) received chloroquine chemoprophylaxis and ID 
injections of NS on the same schedule. Groups 1 and 2 underwent CHMI 60 days after the 
last immunization, corresponding to 33 days after the last chloroquine dose. Two subjects 
(20%) in vaccine group 1 remained thick smear negative through day 21 after CHMI (Table 1). 
One subject in vaccine group 3 who had tetanus vaccination after the third immunization 
session was excluded due to the safety procedures adopted after the first CHMI, because 
of the SAE. Another subject in group 3 was unable to continue participation for the fourth 
immunization due to logistical reasons. According to protocol, 13/15 subjects (8/10 in 
group 3; 5/5 in group 4) received a fourth immunization of 75,000 cryopreserved PfSPZ at 
168 days after the third immunization (Figure 1). Five of these 13 subjects were not able to 
participate in the CHMI by mosquito bite for logistical reasons. Altogether 4 subjects in 
each group underwent CHMI at 109 days after the last chloroquine dose, corresponding 
to 137 days after their last injection of PfSPZ or NS. 
Safety and tolerability during PfSPZ-CVac immunizations
Immunizations were well tolerated. There were no signs of local reactogenicity in 
vaccinees or controls. Eleven of 20 PfSPZ-CVac recipients (7 in group 1 and 4 in group 3) 
reported predominantly mild to moderate probably/possibly solicited AEs (mean duration, 
0.3 ± 0.5 days) beginning on days 1 to 25 after the first 3 immunizations. Six of 10 NS 
recipients (3 in group 2 and 3 in group 4) reported predominantly mild to moderate 
probably/possibly solicited AEs (mean duration, 0.3 ± 0.4 days) beginning on days 1 to 20 
after the first 3 immunizations. The other 9 PfSPZ-CVac and 4 NS inoculated volunteers did 
not report any complaints. There was no difference in the cumulative duration of probably/
possibly solicited AEs per subject between vaccinees (groups 1 and 3) and controls 
(groups 2 and 4) (P=0.52). There were no solicited AEs after the fourth PfSPZ-CVac injection 
in vaccine group 3 and 1 mild headache in control group 4. Overall, the most commonly 
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Table 1   Trial summary table
Group 1 Group 2 Group 3 Group 4
n=10 n=5 n=10
(n=4 received 
CHMI)
n=5
(n=4 received 
CHMI)
Dose  
(number of PfSPZ)
3 x 75,000 0 3 x 75,000 (n=2)
4 x 75,000 (n=8)
0
Route  
of administration
ID ID ID ID
Number of volunteers 
who became TS+
8 5 N/A N/A
Listing of times  
to TS+ (days)
10.5, 10.5, 11, 12, 
12, 14, 14.5, 15
10.5, 10.5, 13.5, 
14, 16
N/A N/A
Geometric mean time 
to TS+ (days)
13.7 12.7 N/A N/A
Listing of parasite 
density by qPCR  
at time of TS+  
(parasites/µL blood)
14, 26, 13, 40, 46, 
66, 24, 27
44, 120, 75, 32, 1 N/A N/A
Geometric mean 
parasite density by 
qPCR at time of TS+ 
(parasites/µL blood)
27.9 26.3 N/A N/A
Number of  
volunteers who  
became qPCR+ (%)
10 (100%) 5 (100%) 4 (100%) 4 (100%)
Listing of times to 
qPCR+ (days)
7.0, 7.0, 7.0, 7.0, 
7.0, 7.0, 9.0, 10.5, 
10.5, 10.5
7.0, 7.0, 7.0, 7.0, 
10.5
7.0, 10.5, 10.5, 
10.5
7.0, 7.0, 7.0, 10.0
Geometric mean time 
to qPCR+ (days)
8.1 7.6 9.5 7.7
Listing of parasite 
densities by qPCR  
at time of qPCR+ 
(parasites/µL blood)
0.08, 1.01, 0.09, 
0.13, 0.25, 0.07, 
0.08, 0.05, 0.05, 
0.08
1,02, 0.47, 0.90, 
0.13, 1.78
0.74, 1.40, 0.08, 
0.06
0.86, 0.36, 0.97, 
0.52
Geometric mean 
parasite density by 
PCR at time of qPCR+ 
(parasites/µL blood)
0.11 0.63 0.27 0.63
ID, intradermal; N/A, not applicable; TS+, thick smear positive; qPCR+, quantitative real-time polymerase chain 
reaction positive.
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reported AE was headache (6/20 vaccine subjects and 3/10 controls, Table 2), which 
occurred once as the single reported grade 3 adverse event.
 After the first PfSPZ-CVac immunization, a remarkable unsolicited AE occurred in 1 
subject in vaccine group 3. Several hours after the fourth chloroquine dose, transitory urticaria 
developed at multiple sites of the body lasting for 3 days (corresponding to days 5–8 after 
PfSPZ Challenge injections). The subject did not receive any treatment for the urticaria. This 
subject had a raised D-dimer level 2 days after resolution of the urticaria (>500 ng/mL; i.e. 
1060 ng/mL) that decreased to 520 ng/mL within the next 4 days. The volunteer continued 
in the study, received 3 immunizations with PfSPZ-CVac and underwent CHMI, but did not 
develop urticaria or any other indication of an allergic reaction. However, the D-dimer 
levels were elevated after each of the 3 following immunizations (range 520–1350 ng/mL).
 None of the 20 PfSPZ-CVac recipients developed parasitaemia, as retrospectively 
detected by qPCR, and all thick smears remained negative. Furthermore, lymphocyte and 
platelet counts did not decline after immunizations.
Protective efficacy after CHMI by P. falciparum-infected mosquitoes
All 5 controls in group 2 became thick smear positive. However, this group showed a wide 
variation in pre-patent periods (median 13.5 days, range 10.5–16 days; Figure 2) and a Δ 
pre-patency of 3.0–9.0 days, which was significantly longer compared to previous studies 
(P=0.006). This wide range is explained by the prolonged parasitaemia below the 
detection limit for microscopy in 2 of the control subjects (represented by the brown and 
pink lines in Figure 3). Retrospective parasitaemia measurement by qPCR revealed a 
Figure 2   Time to thick smear positivity after controlled human malaria infection #1
The time to thick-smear positivity is shown for 10 PfSPZ-CVac recipients (group 1, black line) and 5 
control subjects (group 2, grey dashed line).
CHMI, controlled human malaria infection.
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median pre-patent period of 7.0 days (range 7.0–10.5 days), comparable to previous studies 
[7,24] and (clinicaltrials.gov:) NCT01422954 (P=0.56).
 Eight out of 10 vaccinees developed patent parasitaemia by thick smear (median 12 
days, range 10.5–15 days), while two subjects in group 1 remained negative throughout 
the 21-day follow-up period (Figure 2). On the day before CHMI (C-1), plasma chloroquine 
was deemed to be below the minimum therapeutic concentration in vivo in all 15 subjects 
[25]. However, it is noteworthy that both protected subjects had higher levels of 
chloroquine in plasma (13 µg/L) than all of the non-protected subjects (≤5 µg/L). Their 
monodesethylchloroquine levels (principal metabolite of chloroquine) were not different 
than the other subjects (<5 µg/L). Furthermore, both protected subjects showed positive 
qPCRs peaking on either day 7 post-CHMI (85 and 252 parasites/mL) or day 7.5 (265 
parasites/mL). Finally, the median pre-patent period by qPCR of group 1 was 7 days (range 
7.0–10.5 days) and similar to control group 2 (P=0.55). The combined data suggest that a 
parasite killing effect of residual chloroquine levels cannot be excluded in the 2 protected 
individuals. The second CHMI was administered to groups 3 and 4 after a fourth 
immunization. All 8 subjects became qPCR positive (Figure 4) with a median pre-patent 
period of 10.5 days (range 7–10.5 days) in immunized volunteers (n=4) and 7 days (range 
7–10 days) in controls (n=4), which was not statistically different (P=0.11).
Figure 3   Parasite density after controlled human malaria infection #1
Individual parasite density curves of control subjects (n=5) measured by qPCR are shown up to day 
of treatment, based on diagnosis by thick smear. The grey dotted line indicates the average parasite 
detection limit for microscopy. Four of 5 subjects were first positive on day 7. One subject was first 
positive on day 10.5.
CHMI, controlled human malaria infection.
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Adverse events after CHMI by P. falciparum-infected mosquitoes
All subjects in groups 1 and 2 experienced solicited AEs possibly or probably related to 
CHMI (mean number of AEs per subject in group 1: 6.9, mean duration 0.6 ± 1.2 days; 
group 2: 8.4, mean duration 0.6 ± 0.7 days), with headache (n=29), fever (n=20) and nausea 
(n=19) most commonly reported (Table 3). There was no significant difference between 
the cumulative duration of AEs per subject in group 1 compared to group 2 (3.8 versus 4.7 
days, respectively; P=0.64). One SAE occurred in a subject in vaccine group 1 on day 12 
after CHMI and 2 days after initiation of treatment with atovaquone/proguanil (72 days 
after last PfSPZ-CVac immunization), which was diagnosed as acute myocarditis [16]. 
Abnormal laboratory values normalized without complications in all subjects.
 All volunteers in group 3, except for 1, experienced solicited AEs possibly or probably 
related to CHMI (mean number of AEs per subject in group 3: 4.8, mean duration 0.5 ± 0.6 
days; in group 4: 6.8, mean duration 0.9 ± 1.9 days), with headache (n=15), nausea (n=9) 
and chills (n=7) as most common symptoms (Table 3). The cumulative duration of AEs per 
subject in group 3 was similar to group 4 (2.3 versus 6.0 days, respectively; P=0.051). 
Additionally, there was no significant difference between control groups 2 and 4 (P=0.51), 
although there was a trend towards a lower frequency of AEs in group 4 in which 
antimalarial treatment was initiated after qPCR instead of thick smear positivity.
Figure 4   Parasite density after controlled human malaria infection #2
Parasite densities are shown until the day of treatment, based on diagnosis by qPCR. Each line 
represents a single subject; the grey lines represent subjects of vaccine group 3 (n=4), the black lines 
subjects of control group 4 (n=4).
CHMI, controlled human malaria infection.
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Table 3   Adverse events after mosquito CHMI
CHMI #1 PfSPZ-CVac group 1 (n=10) Control group 2 (n=5)
Any adverse 
eventa
Number of 
volunteers
Mean duration  
± sd (days)
Number of 
volunteers
Mean duration  
± sd (days)
Abdominal pain 2 0.5 ± 0.1 2 0.1 ± 0.1
Chest pain, 
 unspecified
1 0.0 0 N/Ab
Chills 6 0.2 ± 0.1 3 0.4 ± 0.2
Diarrhoea 0 N/A 1 0.1 ± 0.0
Dizziness 1 1.2 2 0.1 ± 0.0
Fatigue 2 4.0 ± 5.2 1 0.4 ± 0.3
Fever 7 0.3 ± 0.3 4 0.6 ± 0.4
Headache 8 0.5 ± 0.4 5 0.9 ± 1.1
Malaise 1 0.3 1 0.5
Myalgia 2 1.2 ± 0.7 3 1.2 ± 0.7
Nausea 5 0.3 ± 0.3 3 0.3 ± 0.4
Vomiting 2 0.0 ± 0.0 1 0.2
Any 10 0.6 ± 1.2 5 0.6 ± 0.7
Grade 3  
adverse event
Fever 3 0.2 ± 0.1 1 0.5
Headache 1 0.4 0 N/A
Nausea 0 N/A 1 0.3
Vomiting 2 0.0 ± 0.0 1 0.2
Any 4 0.1 ± 0.2 2 0.3 ± 0.2
CHMI #2 PfSPZ-CVac group 3 (n=4) Control group 4 (n=4)
Any adverse 
event
No. of  
volunteers
Mean duration  
± SD (days)
No. of  
volunteers
Mean duration  
± SD (days)
Abdominal pain 0 N/A 2 0.3 ± 0.2
Chills 1 0.3 2 0.0 ± 0.0
Dizziness 0 N/A 1 0.1
Fever 1 0.6 2 0.8 ± 1.0
Headache 3 0.4 ± 0.5 3 2.4 ± 3.2
Malaise 1 2.2 0 N/A
Myalgia 1 0.6 ± 0.6 1 1.5
Nausea 3 0.3 ± 0.2 2 0.2 ± 0.1
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Humoral and cellular immune responses
First we addressed whether volunteers immunized with PfSPZ-CVac in group 1 developed 
specific antibodies to PfCSP, PfLSA-1, or PfMSP-1 at 59 days after the third immunization 
and 1 day before CHMI. Five out of 10 subjects showed a greater than 2-fold rise of 
anti-PfCSP antibody titers compared to pre-immunization (P=0.03) ranging from 0.9 to 5.7 
AU (median, 2.66). Antibodies to PfLSA-1 and PfMSP-1 increased non-significantly in 3 and 
2 subjects, respectively (range fold-increase: anti-PfLSA-1, 0.75–1.23; anti-PfMSP-1, 0.52–1.15; 
Figure 5a). Anti-PfCSP antibody titers were comparable in both PfSPZ-CVac groups (1 and 3) 
before the third immunization (P=0.41; Figure 5b).
 Next, we investigated the boosting effect of the third and fourth immunization, 
respectively. The third immunization increased anti-PfCSP antibodies in 7/10 subjects in 
group 1 and in only 1 subject more than 2-fold (I3-1 versus I3+59; median fold increase 
with range: 1.26 [0.79–2.45]; P=0.28). In contrast, anti-PfCSP antibodies were boosted in all 
8 subjects of group 3 and by at least 2-fold in 3 subjects (I4-1 versus I4+52; median fold 
increase with range: 1.43 [1.25–5.74]; P=0.008; Figure 5c). Similarly, 7/8 subjects of group 3 
developed antibodies against PfSPZ by immunofluorescence assay (IFA) after the fourth 
immunization (anti-PfSPZ titers ranged from 50 to 400) in contrast to controls who did not 
develop antibodies (anti-PfSPZ titer <50). While in group 3 the absolute magnitude of 
antibodies to PfCSP was not greater after the fourth dose than in group 1 after the third 
dose (P=0.24), the proportion of responders increased with a fourth dose. These data 
suggest that 4 immunizations increase the number of responders but that absolute 
Table 3   Continued
CHMI #2 PfSPZ-CVac group 3 (n=4) Control group 4 (n=4)
Any adverse 
event
No. of  
volunteers
Mean duration  
± SD (days)
No. of  
volunteers
Mean duration  
± SD (days)
Vomiting 1 0.0 0 N/A
Any 3 0.5 ± 0.6 4 0.9 ± 1.9
Grade 3  
adverse event
Fever 0 N/A 1 0.4
Headache 0 N/A 1 0.1
Vomiting 1 0.0 0 N/A
Any 1 0.0 1 0.3 ± 0.2
a.  Subjects could have more than 1 adverse event. Only solicited adverse events that were possibly or 
probably related to the study are listed. 
b.  N/A, not applicable.
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antibody levels did not increase. Antibodies against PfLSA-1 and PfMSP-1 were not 
significantly increased after the fourth immunization (data not shown, P=0.64 for 
anti-PfLSA-1 and P=0.38 for anti-PfMSP-1).
 In contrast to humoral responses, neither IFN-γ, CD107a, nor granzyme B re-call responses 
to PfRBC or PfSPZ, which were found to be indicative of parasite exposure previously [24,26], 
were induced after 3 PfSPZ-CVac immunizations in any of the T-cell subsets analyzed 
(vaccine group 1 versus control group 2, data not shown). Furthermore, even after the 
fourth PfSPZ-CVac immunization administered in group 3 there were still no measurable 
responses to PfRBC when compared to control group 4 or pre-immunization (data not shown).
Discussion
This first clinical study of the PfSPZ-CVac approach to immunizing healthy malaria-naive 
volunteers showed that the ID immunization regimen of 3 doses of 7.5x104 PfSPZ 
administered at 4-week intervals to subjects taking weekly chloroquine chemoprophylax-
is was safe and well-tolerated, but did not confer protection against a homologous CHMI. 
In contrast, the 3-dose CPS-protocol using PfSPZ-infected mosquitoes for immunizations 
under weekly chloroquine cover at the same 4 week intervals, has induced >90% 
protection in a number of clinical trials [5,7]. 
 Protective efficacy after immunization by CPS is almost certainly due to Pf parasites 
moving from the skin into the vascular system to the liver and then invading and fully 
developing in hepatocytes. In the CPS studies transient qPCR-detected blood-stage 
parasitaemia in particular after the first immunization was observed in the vast majority of 
volunteers. This reflects complete liver maturation followed by rapid chloroquine-mediated 
killing of blood-stage parasites. Under these conditions the host’s immune system is 
exposed to a broad array of antigens for induction of protective pre-erythrocytic immune 
responses [21,27]. In a previous CPS trial dose-dependent sterile protection has been 
observed: 4/5 volunteers were protected after immunization with bites from 3 times 15, 
8/9 volunteers by 3 times 10 and 5/10 volunteers by 3 times 5 infected mosquitoes 
respectively [24]. 
 In this first study of the PfSPZ-CVac approach, we believe that inadequate numbers of 
PfSPZ made the journey from skin through the vascular system into the liver for full 
development. This hypothesis was supported by the lack of protection and the weak 
humoral and absent cellular immune responses against Pf antigens. CPS-induced humoral 
responses have been shown to correlate with the degree of antigen exposure [21]. While 
anti-PfCSP antibody responses after PfSPZ-CVac immunizations were comparable to after 
CPS immunizations [21], indicating exposure to adequate numbers of PfSPZ, anti-LSA-1 
and anti-MSP-1 antibody responses were poor and absent respectively, reflecting very 
limited hepatocyte invasion and liver-stage development. This interpretation was further 
supported by the absence of cellular re-call responses after PfSPZ-CVac immunizations i.e. 
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parasite-specific IFN-γ, CD107a, or granzyme B responses, indicative of parasite exposure 
[24,26] and degranulation of CD4 T cells, associated with protection [24].
 In contrast to CPS-immunization by PfSPZ-infected mosquito bites, PfSPZ-CVac was 
administered ID by needle injection. Murine data have shown that the route of 
administration of fresh and cryopreserved PfSPZ is a key determinant of successful liver 
infection; IV and IM injections result in significantly higher (~50 fold and 2- to 3-fold, 
respectively) liver loads compared to ID and SC injections [28]. Furthermore, Ploemen et 
al. demonstrated that both IM and ID routes increased liver loads when using smaller 
volumes and injections at multiple sites. This method approaches the way anopheline 
mosquitoes successfully administer sporozoites: in some cases before a capillary is found 
the female mosquito probes the dermal skin several times, while injecting tiny bits of 
sporozoite-containing saliva [29]. Increased parasite liver loads in mice after IV inoculation 
of both radiation-attenuated sporozoites and sporozoites in combination with chloroquine 
treatment were associated with augmented cellular immune responses and higher 
protective efficacy after challenge compared to ID inoculation [30].
 Clinical trials of PfSPZ Challenge have also demonstrated that IV administration is 
more efficient than IM, which is more efficient than ID administration. The goals of these 
trials have been to identify the lowest dose of PfSPZ Challenge that gives 100% infection 
rates with a pre-patent period by thick blood smear of 11 to 11.5 days, and a decrease of 
pre-patent period with increasing dose of PfSPZ (e.g. a dose response). One hundred 
percent infection rates have been achieved by IV, direct venous inoculation (DVI), IM, and 
ID administration (Mordmueller, submitted). However, a pre-patent period of <11.5 days 
and a dose response have only been achieved by IV/DVI and IM administration (personal 
communication by SL Hoffman). It takes 23–25 times as many PfSPZ administered IM 
(7.5x104) as IV (3.2x103) to achieve a pre-patent period of <11.5 days (Stephen Hoffman, 
personal communication). Thus far this pre-patent period has not been achieved by ID 
administration. This difference between IV and ID (or SC) administration has also been 
seen with radiation attenuated, aseptic, purified, cryopreserved PfSPZ, PfSPZ Vaccine. Four 
to 6 doses of 1.35x105 PfSPZ of PfSPZ Vaccine SC or ID gave minimal immune responses 
and no protection [22], whereas 5 doses of 1.35x105 PfSPZ IV gave excellent immune 
responses and 100% protection [31].
 The current dose of 7.5x104 PfSPZ-CVac administered ID was well tolerated with 
remarkably few and mild adverse events similar to controls receiving only NS. Once the 
methodology of PfSPZ-CVac administration will be optimized and higher liver loads and 
transient parasitaemia are present, it is to be expected that the frequency and severity of 
AEs will likely match previous CPS trials [5]. However, there was a cardiac SAE 59 days after 
the last dose of PfSPZ Challenge, 12 days after CHMI, and 2 days after initiation of treatment 
with Malarone for a positive blood slide in a subject of vaccine group 1. The subject was 
diagnosed as having acute myocarditis [16], but the pathophysiological basis for this acute 
myocarditis remains unclear and a definitive aetiology could not be established [16].
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Interestingly, there was a discrepancy in the protection against CHMI by mosquito bite as 
assessed by thick smear and retrospective qPCR in group 1. Two of the 10 subjects were 
thick smear negative but positive by qPCR on days 7 and 7.5 post-CHMI in the presence of 
a ~2.5-fold higher chloroquine (13 µg/L) plasma concentration on day 1 before CHMI 
compared to non-protected subjects (≤5 µg/L). This raises the possibility that the early 
parasitaemias in these 2 volunteers could have been cleared by residual chloroquine. 
Another finding suggesting an impact of chloroquine was the significantly prolonged Δ 
pre-patency in control group 2 (Figure 3) compared to controls of recent previous CHMI 
studies. However, it is noteworthy that in a previous CHMI trial where similar plasma 
concentrations were measured (range <5 to 14 µg/L for chloroquine and <5 µg/L for 
monodesethylchloroquine) [5], all 5 controls became thick-smear positive between days 
7 and 11 after CHMI. These plasma concentrations were deemed to be below the minimum 
therapeutic concentration in vivo based on literature [Rombo et al. 1987: min.= 30 µg/L], 
but also because identical blood-stage parasite multiplication kinetics were seen in 
control subjects compared to previous studies suggesting that any residual chloroquine 
levels had no measurable parasiticidal effect [32,33]. 
 In conclusion, this study shows that the dose and ID immunization regimen of 
PfSPZ-CVac used in this trial was safe, but did not provide protection against a homologous 
CHMI by mosquito bite. The lack of protection was almost certainly due to sub-optimal 
parasite exposure, as supported by weak humoral responses and the lack of T-cell 
responses previously shown to be associated with protection. In the next clinical trial 
PfSPZ Challenge will be administered by DVI in order to achieve consistent, high-level liver 
stage infection.
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Abstract
A 23-year-old healthy male volunteer took part in a clinical trial in which the volunteer 
took chloroquine chemoprophylaxis and received 3 intradermal doses at 4-week intervals 
of aseptic, purified Plasmodium falciparum sporozoites to induce protective immunity 
against malaria. Fifty-nine days after the last administration of sporozoites and 32 days 
after the last dose of chloroquine the volunteer underwent controlled human malaria 
infection (CHMI) by the bites of 5 P. falciparum-infected mosquitoes. Eleven days post-CHMI 
a thick blood smear was positive (6 P. falciparum/μL blood) and treatment was initiated 
with atovaquone/proguanil (Malarone®). On the second day of treatment, day 12 
post-CHMI, troponin T, a marker for cardiac tissue damage, began to rise above normal, 
and reached a maximum of 1,115 ng/L (upper range of normal = 14 ng/L) on day 16 
post-CHMI. The volunteer had one ~20 minute episode of retrosternal chest pain and 
heavy feeling in his left arm on day 14 post-CHMI. ECG at the time revealed minor 
repolarization disturbances, and cardiac MRI demonstrated focal areas of subepicardial 
and midwall delayed enhancement of the left ventricle with some oedema and 
hypokinesia. A diagnosis of myocarditis was made. Troponin T levels were normal within 
16 days and the volunteer recovered without clinical sequelae. Follow-up cardiac MRI at 
almost 5 months showed normal function of both ventricles and disappearance of 
oedema. Delayed enhancement of subepicardial and midwall regions decreased, but was 
still present. With the exception of a throat swab that was positive for rhinovirus on day 14 
post-CHMI, no other tests for potential aetiologies of the myocarditis were positive. A 
number of possible aetiological factors may explain or have contributed to this case of 
myocarditis including, i) P. falciparum infection, ii) rhinovirus infection, iii) unidentified 
pathogens, iv) hyper-immunization (the volunteer received 6 travel vaccines between the 
last immunization and the CHMI), v) atovaquone/proguanil treatment, or vi) a combination of 
these factors. Definitive aetiology and pathophysiological mechanism for the myocarditis have 
not been established.
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Introduction
Controlled human malaria infections (CHMIs) have been used for nearly a century for 
treatment of neurosyphilis and for assessing interventions like drugs and vaccines for 
treating and preventing malaria. However, the modern era of CHMIs began in the mid 
1980s, when laboratory reared Anopheles sp. mosquitoes were infected by feeding on 
cultures of Plasmodium falciparum-infected blood [1]. During the past 3 decades CHMI has 
been shown safe, well-tolerated and useful in evaluation of potential new antimalarial 
drugs and vaccines [2]. After exposure to bites of laboratory-reared mosquitoes infected 
with P. falciparum sporozoites (PfSPZ) clinical symptoms and signs of malaria are generally 
mild to moderate and last for a few days. The most commonly reported symptoms are 
headache, fever, myalgia and fatigue, and common laboratory abnormalities include 
clinically insignificant thrombocytopaenia and leukopaenia [3,4]. Subjects, who undergo 
CHMI, are closely monitored and immediately treated with antimalarials upon detection 
of parasitaemia. Due to frequent and intense clinical monitoring, initiation of treatment 
almost always occurs at parasite densities of less than 0.001% and often at 0.0001% [5], a 
density which is more than 1,000-fold lower than parasite densities associated with 
causing severe malaria. 
 Immunization of volunteers taking chloroquine chemoprophylaxis with whole PfSPZ 
administered by mosquito bites resulted in complete and long-lasting protection against 
CHMI with P. falciparum-infected mosquitoes [6,7]. This immunization approach is called 
ChemoProphylaxis with Sporozoites (CPS). Since CPS depends on inoculation of PfSPZ by 
mosquito bites, it cannot be an implementable vaccine. Recently, subjects were infected 
by needle and syringe inoculation of aseptic, purified, cryopreserved PfSPZ, a product 
called PfSPZ Challenge [8,9]. Subsequently, a clinical trial was initiated in which volunteers 
taking chloroquine chemoprophylaxis were injected intradermally (ID) at 4-week interval 
with PfSPZ Challenge, an approach called the PfSPZ-CVac approach (=PfSPZ Chemopro-
phylaxis Vaccine), and then underwent CHMI. 
 Here, a very probable case of acute myocarditis is described in a volunteer who had 
taken chloroquine chemoprophylaxis, was inoculated 3 times at 4-week intervals with 
PfSPZ Challenge, received 6 travel-related routine vaccines after this immunization 
procedure, had CHMI by the bites of 5 PfSPZ-infected mosquitoes 8.5 weeks after the last 
dose of PfSPZ Challenge and 4.5 weeks after the last dose of chloroquine, had a sore 
throat on day 9 after CHMI, developed P. falciparum parasitaemia that was treated 11 days 
after CHMI, and had asymptomatic initial elevation of troponin T levels 12 days after CHMI.
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Case presentation
A 23-year-old healthy male volunteer was enrolled in a double-blind, placebo-controlled 
trial that assessed the safety, tolerability, and protective efficacy against CHMI by 
PfSPZ-infected mosquitoes of ID administration of aseptic purified cryopreserved PfSPZ 
(PfSPZ Challenge) in volunteers taking weekly 300 mg chloroquine prophylaxis, the 
PfSPZ-CVac approach. His medical history was unremarkable, and he did not smoke or use 
illicit drugs. His mother had a history of hypertension and his paternal grandfather had a 
history of heart valve defects and a possible myocardial infarction at the age of 70. At 
inclusion, physical examination was within normal limits with a blood pressure of 139/76 
mmHg, heart rate of 55 beats per minute and a body mass index of 20.2 kg/m2. Electrocar-
diography (ECG) showed a commonly seen normal variant of incomplete right bundle 
branch block (Supporting Information [SI] File 1). Standard laboratory tests at inclusion 
were normal (Table 1). 
 From October to December 2012, he received 3 ID injections at 4-week intervals of 
7.5x104 PfSPZ of PfSPZ Challenge (Pf NF54) diluted in phosphate buffered saline with 1% 
human serum albumin. From day 3 until day 8 after the first immunization he reported a 
sore throat and symptoms of a common cold (i.e., stuffy nose and coughing) with mild chills 
for a few hours. No complaints were reported after the second and third immunizations. 
No clinically significant laboratory abnormalities were found during the immunization 
period. 
 Fifty-nine days after the third and last immunization and 32 days after his last dose of 
chloroquine, he underwent CHMI by the bites of 5 P. falciparum-infected mosquitoes (Pf 
NF54). On day 9 post-CHMI he complained of a sore throat. On day 11 post-CHMI his thick 
blood smear became positive (6 P. falciparum/μL blood; 0.00012% infected erythrocytes) 
and standard treatment with Malarone® (1,000 mg atovaquone plus 400 mg proguanil once 
daily for 3 days) was initiated. Retrospective assessment of parasitaemia by quantitative 
real-time polymerase chain reaction (qPCR) revealed 13,293 parasites/mL (0.00026% 
infected erythrocytes) on day of thick smear positivity. On that day he complained of 
minor chills and headache for a few hours with a highest recorded sublingual temperature 
of 37.5°C. Platelet and lymphocyte counts decreased to 97x109/L (normal range = 
141–400x109/L) and 0.60x109/L (normal range = 1.0–3.5x109/L), respectively, as often seen 
in malaria positive individuals [5,10]. The level of troponin T by a highly sensitive assay was 
normal (i.e., 8 ng/L; upper limit of normal = 14 ng/L). Troponin T is a specific marker for 
myocardial tissue damage. 
 On the second day of Malarone treatment (day 12 post-CHMI) the troponin T level 
was elevated at 45 ng/L and increased to 63 ng/L in the evening. No abnormalities were 
seen on ECG. Apart from mild headache and fatigue on the following day (day 13 post-CHMI) 
the volunteer was asymptomatic, but the troponin T was 197 ng/L in the morning and 
299 ng/L in the afternoon. The blood pressure was 114/60 mmHg and the ECG revealed 
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mild repolarization disturbances with diffuse ST-T-segment elevation, suggestive of 
pericarditis (SI File 2). The echocardiogram showed mild hypokinesia of the inferior wall 
and a slightly diminished global left ventricle (LV)-function (calculated LV ejection fraction 
of 53%; normal range for a young man is >55%). Malarone treatment was completed and 
qPCR for P. falciparum was negative on day 13 post-CHMI. Although the subject did not 
have any cardiac or chest symptoms, he was hospitalized at the cardiology department 
according to safety protocol for telemetric ECG-monitoring and follow-up of troponin T 
levels. 
 That night at ~01:00 AM he experienced retrosternal pain and a heavy feeling in his 
left arm. After approximately 10 minutes sublingual nitroglycerin spray was administered; 
the chest pain did not disappear immediately, but only 10 minutes after administration of 
nitroglycerin. The pain was not related to breathing and there were no concomitant 
complaints or signs of dyspnoea, pyrosis or ructus. The subject never had another episode 
of chest pain. Cardiac MRI several hours later on day 14 post-CHMI showed: i) slightly 
increased T2-weighted signal intensity in the basal- and mid-inferolateral and partly in the 
mid-anterolateral myocardial segments, matching minor oedema (Figure 1a); ii) focal areas 
of subepicardial and midwall delayed enhancement in the basal- and mid-inferior and 
basal- and mid-inferolateral segments after administration of gadolinium contrast (Figure 
1b and c); iii) hypokinesia basal- and mid-inferior and mild hypokinesia basal- and mid- 
inferolateral. These findings were interpreted as indicative of myocarditis. Treatment was 
started on day 14 post-CHMI with a beta-blocker, metoprolol (25 mg twice daily), to 
reduce the chance of cardiac arrhythmia and according to the treatment guidelines for 
patients with reduced LV-function. 
 Troponin T levels continued to rise with a peak of 1,115 ng/L on day 16 after CHMI. The 
following days troponin T decreased and eventually returned to normal 16 days after 
initial increase, corresponding to 28 days post-CHMI. Creatine kinase (CK) showed a similar 
pattern of rising and falling, but returned to normal on day 16 post-CHMI. A biochemical 
marker of cardiac wall stress, N-terminal pro-hormone brain natriuretic peptide (NT-proBNP), 
was slightly elevated on days 15 and 17 post-CHMI, but was normal on day 20 post-CHMI 
(Table 1). A limited rise and fall of aspartate aminotransferase (AST) and lactate 
dehydro-genase (LDH) were found. The nonspecific marker for increased coagulation and 
inflammation, D-dimer, remained within the normal range and was only minimally 
elevated on the first day after thick smear positivity. Similarly, the inflammatory acute-phase 
protein, C-reactive protein (CRP) was only slightly elevated on days 13, 14, and 15 after 
CHMI (Table 1). Four days after admission (day 17 post-CHMI) ECG and echocardiogram 
had normalized (SI File 3; calculated LV ejection fraction was 62%; normal range is >55%) 
and the volunteer was discharged. 
 Apart from the single short episode of chest pain and a longer period of fatigue with 
occasional mild headache during and shortly after hospitalization, no other complaints 
were reported. The fatigue diminished after halving the dose of metoprolol to 25 mg 
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8Figure 1  Cardiac MRI on day 14 and 153 after controlled human malaria infection 
(A) Slightly increased T2-weighted signal intensity was observed in the basal-inferolateral segment 
of the left ventricle on day 14 after CHMI (C+14), which had disappeared on day 153 after CHMI 
(C+153); visualized on the short-axis dark blood STIR (short inversion time inversion recovery) 
recordings. (B and C) After administration of 15 mL gadolinium contrast subepicardial and midwall 
delayed enhancement was observed in the basal-inferolateral and basal-inferior segments of the 
left ventricle on day C+14, which had decreased on day C+153; visualized on the short-axis (B) and 
the 4-chamber (C) PSIR (phase sensitive inversion recovery) recordings.
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once daily on day 23 post-CHMI. The remaining mild fatigue completely disappeared 3 
weeks later on day 44 post-CHMI. After discharge the volunteer did not complain about 
occasional mild headache anymore. 
 The volunteer received pre-travel vaccines for diphtheria, tetanus, polio, typhus, 
hepatitis A and hepatitis B 14 days after the third injection of PfSPZ Challenge (46 days 
before CHMI). He had booster vaccinations for hepatitis A and B 40 days after the third 
injection (20 days before CHMI). 
 Polymerase chain reaction (PCR) analyses of throat smear, faeces and whole blood 
were carried out for viruses and bacteria known to cause myocarditis (Table 2). Throat 
smear PCR was positive for rhinovirus; all other PCR results were negative (Table 2). Virological, 
bacteriological and parasitological serology was performed on samples obtained 3 weeks 
before inclusion and on day 17 post-CHMI (Table 3) with repeat testing 18 days later (day 
35 post-CHMI and 23 days after first elevation of troponin T). All serologic results were 
negative. Furthermore, urine toxicology screening for amphetamine-derivatives, cocaine, 
cannabinoids, diazepam, methadone, tramadol hydrochloride, and opiates was negative 
on day 17 after CHMI.
At almost 5 months after the first MRI, repeat cardiac MRI demonstrated good function of 
the left ventricle (calculated LV ejection fraction of 67%) with persistence of mild hypokinesia 
in the mid-inferior and mid-inferolateral segments of the left ventricle. The oedema had 
Table 2   PCR results for known infectious pathogens of myocarditis
C+14 C+15 C+17
Throat smear tested by PCR for:
Adenovirus, Bocavirus, Coronavirus, Chlamydia Psittaci, 
 Enteroviruses, Metapneumovirus, Mycoplasma, 
 Parechovirus, Parainfluenza 1–4, Rhinovirus, Respiratory 
Syncytial Virus, and Influenza A and B
positive  
for  
Rhinovirus
Faeces tested by PCR for:
Adenovirus (Adenotype 40 and 41), Astrovirus, Bocavirus, 
Enteroviruses, Norovirus, Parechovirus, Rotavirus, and 
Sapovirus
negative
Blood tested by PCR for:
Varicella Zoster Virus, Parvovirus, Epstein-Barr Virus, 
Cytomegalovirus, Q fever, and HIV load
negative
PCR results for known virological and bacteriological causes of myocarditis based on samples taken on day 
14, 15, and 17 after CHMI (C+14, C+15, and C+17, respectively).
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Table 3   Serology results for known infectious pathogens of myocarditis
Sera tested for 
antibodies to:
Screening visit
(paired with
C+17)
C+17 C+17
(paired with
C+35)
C+35
Echovirus pool 20 < 10 (negative) < 10 (negative) 10
(Types 4, 6, 9, 14, 24, and 30)
Coxsackie virus pool 20 10 10 20
(Types A9, B1–B6 )
Poliovirus 20 10 20 40
Adenovirus Ig 20 < 10 (negative) 20 20
Parvovirus IgM negative negative
Parvovirus IgG 64 64
Mycoplasma 
pneumoniae IgM
negative negative negative
Mycoplasma 
pneumoniae IgA
negative negative negative
Mycoplasma 
pneumoniae Ig
< 10 (negative) < 10 (negative) < 10 (negative) < 10 (negative)
Chlamydia including 
Psittacosis Ig
< 10 (negative) < 10 (negative) < 10 (negative) < 10 (negative)
Q fever phase 2 IgM negative negative negative
Q fever Ig < 10 (negative) < 10 (negative) < 10 (negative) < 10 (negative)
Hepatitis B s-antigen negative negative
Hepatitis B anti-HBc negative negative
Hepatitis C Ig negative negative
Borrelia blot IgM negative negative
Borrelia blot IgG negative negative
Legionella 
serotype 1–7 IgM
negative negative negative
Legionella 
serotype 1–7 IgG
negative negative negative
Syphilis IgG negative negative
Toxoplasma IgG negative negative
Serology results for known virological, bacteriological and parasitological causes of myocarditis based on 
samples taken at the screening visit, on day 17, and 35 after CHMI (C+17 and C+35, respectively). Paired 
serologic analysis was performed with serum drawn at the screening visit (3 weeks before the start of the 
trial) for a number of pathogens. To detect potential delayed immune responses serologic analysis was 
repeated on day C+35. Again, paired serologic analysis was performed with serum drawn on day C+17 for a 
number of pathogens.
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disappeared completely (Figure 1a) and concomitantly the delayed enhancement had 
decreased, mostly in the basal-inferolateral segment (see Figure 1b and c). However, 
patchy midwall and subepicardial delayed enhancement was still present in 4 myocardial 
segments (i.e., the basal-inferolateral, mid-inferolateral, basal-inferior, and mid-inferior 
segments). Follow-up ECG did not show any abnormalities except for a minimally widened 
QRS complex compared to the pre-trial ECG and the persistence of incomplete right 
bundle branch block (SI File 4). In addition, ECG during a cardiac stress test did not show 
ST-T-segment changes, rhythm abnormalities, or other changes with respect to the 
pre-trial ECG. The cardiac stress test used a cycling protocol starting at 50 watt and with 
increasing steps of 20 watt per minute. He reached a maximally achieved power of 270 
watt (i.e., 122% of expected for his age group and gender). He had an adequate increase 
in blood pressure and heart rate. His heart rate pressure product was 35,854 mmHg/min 
(normal is >25,000 mmHg/min). Metoprolol 25 mg once daily was stopped and the 
volunteer has remained without complaints in good condition. 
Discussion
Clinically suspected acute myocarditis with typical MRI characteristics is reported in a 
healthy volunteer participating in a PfSPZ-CVac approach phase 1 clinical trial. The first 
myocarditis manifestations occurred 71 days after the last dose of PfSPZ Challenge, 44 
days after the last dose of chloroquine, 57 and 31 days after receiving pre-travel vaccines, 
12 days after CHMI by P. falciparum-infected mosquito bites, 3 days after the onset of a 
sore throat, and 1 day after diagnosis of P. falciparum malaria and initiation of treatment for 
malaria. The retrosternal chest pain [11], kinetics of increased troponin T plasma 
concentrations, ECG and echocardiogram findings, and MRI findings, which are consistent 
with the guidelines of the International Consensus Group on MR Diagnosis of Myocarditis 
[12], support the diagnosis of acute myocarditis. Moreover, improved myocardial function, 
disappearance of oedema and reduced delayed enhancement after almost 5 months 
correspond to the natural course of acute myocarditis; the residual delayed enhancement 
is consistent with contrast retention in fibrous tissue [13]. In addition, BNP and NT-proBNP 
were temporarily elevated and their elevation has also been found in patients with 
myocarditis and is associated with reduced left ventricular function [14,15]. 
 The occurrence of the cardiac event relates in time with residual parasitaemia during 
curative Malarone treatment post-CHMI that might be suggestive of a causal relationship. 
A few cases of malaria and concomitant myocarditis have been reported in the literature, 
albeit restricted to patients with severe or fatal infection with P. falciparum [16-22] and 
Plasmodium vivax malaria [23]. In literature, myocarditis has never been reported in patients 
with uncomplicated P. falciparum malaria, even in those patients who present with P. 
falciparum parasite densities 20 to 30 times higher than the parasite density in this 
volunteer. In addition, troponin T plasma concentrations have never shown elevations 
161
Acute myocarditis during treatment for malaria infection
8
above background in an unselected group of 167 volunteers when daily measured after 
CHMI using a highly sensitive assay [personal communication by RW Sauerwein (Radboud 
University Medical Center, The Netherlands)]. Consistent with this finding, troponin T was 
very rarely (0.6%) elevated when assessed retrospectively in patients with uncomplicated 
P. falciparum malaria [24]. In contrast, 31–80.5% of African children with severe and/or fatal 
P. falciparum malaria exhibited high to very high levels of circulating cardiac proteins 
indicating myocardial injury and impaired left ventricular function [25]. 
 Previously, a cardiac serious adverse event was reported in a female volunteer who 
participated in a phase 1 clinical trial in which she was immunized with a subunit, 
recombinant protein malaria vaccine (PfLSA3), underwent CHMI by mosquito bites, 
developed malaria, and was treated with Riamet® (artemether/lumefantrine) [26]. She was 
diagnosed with acute coronary syndrome 2 days after completing treatment, but 
myocarditis was considered a possible alternative diagnosis. Apart from 1 confirmed 
myocardial infarction in a male volunteer with an increased cardiovascular risk, who 
underwent CHMI but did not develop parasitaemia [3], there have been no other reports 
of cardiac complications in the approximately 2,000 subjects who have undergone CHMI 
since the 1986 report by Chulay et al. [1]. 
 In the current case the cardiac event occurred during the 3 days when the subject 
was receiving curative Malarone treatment for P. falciparum malaria. There are no previous 
data indicating that antimalarial treatment with atovaquone/proguanil (Malarone®), or its 
metabolite cycloguanil causes myocarditis or any other significant cardiovascular toxicity 
[27]. Furthermore, the product monograph of Malarone does not mention cardiotoxicity 
or myocarditis, only palpitations and tachycardia. 
 The most common cause of acute myocarditis in a healthy young individual is a viral 
infection [28]. Numerous infectious pathogens can cause acute myocarditis [29,30]. 
Enteroviridae (including Coxsackie B) were responsible for 25–30% of cases in the past [31], 
but more recently, other viruses (including adenovirus, parvovirus B19, and hepatitis C) 
have also emerged as important cardiotropic pathogens [32]. In the current volunteer, 
diagnostic tests for the most common infectious causes of myocarditis were negative 
(Table 2 and 3). However, negative convalescent antibody titers do not exclude a post-in-
fectious myocarditis. Furthermore, a throat swab, taken 2 days after the initial increase in 
troponin T contained rhinovirus, and rhinovirus has been occasionally associated with 
myocarditis [33,34]. Noteworthy, rhinovirus is often detected by PCR in asymptomatic 
subjects and a causal inference with symptomatic patients should, therefore, be made 
with caution [35]. 
 The pathogenesis of myocarditis can be due to direct infection of the myocardium by 
a replicating pathogen, the host’s specific immunologic response to such an infection 
[36], or a nonspecific immunologic response in a susceptible individual that could have 
been triggered in this case by the malaria infection. In most such cases one would expect 
to find markers of inflammation elevated. However, markers for nonspecific inflammation 
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and haemolysis, D-dimer, CRP, and LDH, were normal or only slightly elevated when the 
troponin T levels were highest (Table 1). Nonetheless, it is possible that an overall hyper-
reactivity induced by the 6 standard vaccines (i.e., diphtheria, poliomyelitis, tetanus, 
parenteral typhoid fever, hepatitis A and hepatitis B) the volunteer received between the 
immunization period and CHMI, and the subsequent CHMI could have generated a hyper-
sensitivity myocarditis. Such post-vaccination myocarditis has been rarely reported for the 
administered vaccines and usually manifests with fever and/or other nonspecific 
inflammatory symptoms within several days of the hyperimmunizations [37], which did 
not occur in this volunteer. Nonetheless, this explanation cannot be ruled out. 
 No systemic allergic reactions or local adverse events have occurred in the 20 
volunteers, who have now received 3 intradermal (ID) injections of 7.5x104 PfSPZ of PfSPZ 
Challenge. Moreover, there have been no systemic allergic reactions among the 184 
subjects who have received single doses of PfSPZ Challenge by the ID (n=84), intramuscular 
(IM) (n=70), and intravenous (IV) (n=30) routes in order to study the safety and infectivity 
of PfSPZ Challenge [8,9, and personal communication by SL Hoffman (Sanaria Inc., USA)], 
or among the 120 volunteers who have received up to 6 doses of 1.35x105 radiation-atten-
uated PfSPZ (PfSPZ Vaccine) ID (n=40), subcutaneously (SC) (n=40), or IV (n=40) [38,39]. 
Thus, it seems extremely unlikely that the parenterally administered PfSPZ or the 
phosphate buffered saline or human serum albumin with which the PfSPZ are administered 
contributed to the myocarditis or contain an immunologically sensitizing agent. 
 Myocarditis may also be triggered by toxins, alcohol, cocaine, chemotherapeutics, 
antibiotics, metabolic abnormalities, and other factors [29,30]. However, the volunteer 
denied excessive use of alcohol, and urine drug tests for cocaine, amphetamines and 
cannabinoids were negative, making such factors an unlikely explanation. Alcohol intake 
was not quantified during follow-up visits after CHMI, but volunteers were repetitively 
instructed to restrict alcohol intake. Since the urine drug test was performed 5 days after 
the first rise in troponin T, the detection of metabolites of cocaine and amphetamines 
after single use is quite limited at this time and could have been missed [40]. 
 In conclusion, there are different possible causes for the myocarditis but a definitive 
cause in this case cannot be established. It is also possible that a combination of the 
above-discussed potential aetiological factors could have contributed to the development 
of this case of acute myocarditis.
Consent
Informed consent for publication of this case report was obtained from the volunteer who 
participated in this clinical trial.
163
Acute myocarditis during treatment for malaria infection
8
Acknowledgements
We thank the Safety Monitoring Committee (T.B. Nutman, P.F. Weller, and A.J.M. Rennings) 
for their advice and expert reviews. We thank Dr. Maureen van der Vlugt for the preparation 
and interpretation of the MRI-scans, and Dr. Foekje Stelma for interpretation of PCR and 
serology results.
164
Chapter 8
References
1. Chulay JD, Schneider I, Cosgriff TM, Hoffman SL, Ballou WR, et al. (1986) Malaria transmitted to humans by 
mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg 35: 66–68.
2. Sauerwein RW, Roestenberg M, Moorthy VS (2011) Experimental human challenge infections can accelerate 
clinical malaria vaccine development. Nat Rev Immunol 11: 57–64.
3. Verhage DF, Telgt DS, Bousema JT, Hermsen CC, van Gemert GJ, et al. (2005) Clinical outcome of experimental 
human malaria induced by Plasmodium falciparum-infected mosquitoes. Neth J Med 63: 52–58.
4. Epstein JE, Rao S, Williams F, Freilich D, Luke T, et al. (2007) Safety and clinical outcome of experimental challenge 
of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. J Infect Dis 196: 145–154.
5. Church LW, Le TP, Bryan JP, Gordon DM, Edelman R, et al. (1997) Clinical manifestations of Plasmodium 
falciparum malaria experimentally induced by mosquito challenge. J Infect Dis 175: 915–920.
6. Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, et al. (2009) Protection against a malaria challenge 
by sporozoite inoculation. N Engl J Med 361: 468–477.
7. Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN, et al. (2011) Long-term protection against 
malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 377: 1770–1776.
8. Roestenberg M, Bijker EM, Sim BK, Billingsley PF, James ER, et al. (2013) Controlled human malaria infections by 
intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 88: 5–13.
9. Sheehy SH, Spencer AJ, Douglas AD, Sim BK, Longley RJ, et al. (2013) Optimising controlled human malaria 
infection studies using cryopreserved P. falciparum parasites administered by needle and syringe. PLoS One 
8:e65960.
10. Richards MW, Behrens RH, Doherty JF (1998) Hematologic changes in acute, imported Plasmodium falciparum 
malaria. Am J Trop Med Hyg 59: 859.
11. Sarda L, Colin P, Boccara F, Daou D, Lebtahi R, et al. (2001) Myocarditis in patients with clinical presentation of 
myocardial infarction and normal coronary angiograms. J Am Coll Cardiol 37: 786–792.
12. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, et al. (2009) International Consensus Group 
on Cardiovascular Magnetic Resonance in Myocarditis: Cardiovascular magnetic resonance in myocarditis: A 
JACC White Paper. J Am Coll Cardiol 53: 1475–1487.
13. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ (2005) Delayed enhancement cardiovascular magnetic 
resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 26: 1461–1474.
14. Ogawa T, Veinot JP, Kuroski de Bold ML, Georgalis T, de Bold AJ (2008) Angiotensin II receptor antagonism 
reverts the selective cardiac BNP upregulation and secretion observed in myocarditis. Am J Physiol Heart Circ 
Physiol 294: H2596–2603.
15. Panagopoulou V, Deftereos S, Kossyvakis C, Raisakis K, Giannopoulos G, et al. (2013) NTproBNP: an important 
biomarker in cardiac diseases. Curr Top Med Chem 13: 82–94.
16. Mohsen AH, Green ST, West JN, McKendrick MW (2001) Myocarditis associated with Plasmodium falciparum 
malaria: a case report and a review of the literature. J Travel Med 8: 219–220.
17. Wichmann O, Loscher T, Jelinek T (2003) Fatal malaria in a german couple returning from Burkina Faso. 
Infection 31: 260–262.
18. Costenaro P, Benedetti P, Facchin C, Mengoli C, Pellizzer G (2011) Fatal myocarditis in course of Plasmodium 
falciparum infection: case report and review of cardiac complications in malaria. Case Rep Med 2011: 202083.
19. Horstmann RD, Ehrich JH, Beck J, Dietrich M (1985) Fatal complications of tropical malaria in non-immune 
patients. A retrospective clinico-pathologic analysis of 25 cases. Dtsch Med Wochenschr 110: 1651–1656.
20. Goljan J, Nahorski WL, Wroczynska A, Felczak-Korzybska I, Pietkiewicz H (2006) Severe malaria–analysis of 
prognostic symptoms and signs in 169 patients treated in Gdynia in 1991–2005. Int Marit Health 57: 149–162.
21. Sanklecha M, Mehta N, Bagban H (2012) Varied presentation of complicated falciparum malaria in a family. 
Indian Pediatr 49: 413–414.
22. Greenfield I (1947) Myocarditis in malignant tertian malaria. N Y State J Med 47: 1895.
23. Kim SA, Kim ES, Rhee MY, Choi SI, Huh HJ, et al. (2009) A case of myocarditis associated with Plasmodium vivax 
malaria. J Travel Med 16: 138–140.
24. Günther A, Grobusch MP, Slevogt H, Abel W, Burchard GD (2003) Myocardial damage in falciparum malaria 
detectable by cardiac troponin T is rare. Trop Med Int Health 8: 30–32.
165
Acute myocarditis during treatment for malaria infection
8
25. Ehrhardt S, Mockenhaupt FP, Anemana SD, Otchwemah RN, Wichmann D, et al. (2005) High levels of circulating 
cardiac proteins indicate cardiac impairment in African children with severe Plasmodium falciparum malaria. 
Microbes Infect 7: 1204–1210.
26. Nieman AE, de Mast Q, Roestenberg M, Wiersma J, Pop G, et al. (2009) Cardiac complication after experimental 
human malaria infection: a case report. Malar J 8: 277.
27. Gupta RK, Van Vugt M, Paiphun L, Slight T, Looareesuwan S, et al. (2005) Short report: no evidence of 
cardiotoxicity of atovaquone-proguanil alone or in combination with artesunate. Am J Trop Med Hyg 73: 267–268.
28. Cooper LT Jr (2009) Myocarditis. N Engl J Med 360: 1526–1538.
29. Calabrese F, Thiene G (2003) Myocarditis and inflammatory cardiomyopathy: microbiological and molecular 
biological aspects. Cardiovasc Res 60: 11–25.
30. Cooper LT (2013) Etiology and pathogenesis of myocarditis – UpToDate. [http://www.uptodate.com]. Ref Type: 
Report.
31. Rotbart HA, Martino TA, Liu P, Petric M, Sole MJ (1995) Enteroviral Myocarditis And Dilated Cardiomyopathy: A 
Review Of Clinical And Experimental Studies. In Human Enterovirus Infections. Edited by Rotbart HA. 
Washington, DC: American Society for Microbiology Press 291–352.
32. Mahrholdt H, Wagner A, Deluigi CC, Kispert E, Hager S, et al. (2006) Presentation, patterns of myocardial 
damage, and clinical course of viral myocarditis. Circulation 114: 1581–1590.
33. Spencer MJ, Cherry JD, Adams FH, Byatt PH (1975) Supraventricular tachycardia in an infant associated with a 
rhinoviral infection. J Pediatr 86: 811–812.
34. Grist NR, Reid D (1993) Epidemiology Of Viral Infections Of The Heart. In Viral Infections Of The Heart. Edited by 
Banatvala JE. London: Hodder and Stoughton: 23–31.
35. Jansen RR, Wieringa J, Koekkoek SM, Visser CE, Pajkrt D, et al (2011) Frequent detection of respiratory viruses 
without symptoms: toward defining clinically relevant cutoff values. J Clin Microbiol 49: 2631–2636.
36. Liu PP, Mason JW (2001) Advances in the understanding of myocarditis. Circulation 104: 1076–1082.
37. Barton M, Finkelstein Y, Opavsky MA, Ito S, Ho T, et al. (2008) Eosinophilic myocarditis temporally associated 
with conjugate meningococcal C and hepatitis B vaccines in children. Pediatr Infect Dis J 27: 831–835.
38. Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, et al. (2011) Live attenuated malaria vaccine designed to 
protect through hepatic CD8+ T cell immunity. Science 334: 475–480.
39. Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, et al. (2013) Protection against malaria by intravenous 
immunization with a nonreplicating sporozoite vaccine. Science 341: 1359–1365.
40. Ellenhorn MJ, Schonwald S, Ordog G, Wasserberger J (1997) Ellenhorn’s Medical Toxicology: Diagnosis And 
Treatment Of Human Poisoning. 2nd edition. Baltimore, MD: Lippincott Williams & Wilkins.
166
Chapter 8
Supporting Information
SI
 F
ile
 1
   E
le
ct
ro
ca
rd
io
gr
am
 a
t s
cr
ee
ni
ng
 v
isi
t b
ef
or
e 
st
ar
t o
f t
he
 c
lin
ic
al
 tr
ia
l (
10
-S
EP
-2
01
2,
 1
0:
59
 A
M
) s
ho
w
in
g 
a 
no
rm
al
 v
ar
ia
nt
 o
f a
n 
in
co
m
pl
et
e 
rig
ht
 b
un
dl
e 
br
an
ch
 b
lo
ck
.
167
Acute myocarditis during treatment for malaria infection
8
SI
 F
ile
 2
   E
le
ct
ro
ca
rd
io
gr
am
 o
n 
da
y 
13
 a
ft
er
 C
H
M
I (
18
-F
EB
-2
01
3,
 0
7:
41
 P
M
) s
ho
w
in
g 
m
ild
 re
po
la
ris
at
io
n 
di
st
ur
ba
nc
es
 w
ith
 d
iff
us
e 
ST
-T
-s
eg
m
en
t e
le
va
tio
n.
168
Chapter 8
SI
 F
ile
 3
   E
le
ct
ro
ca
rd
io
gr
am
 o
n 
da
y 
16
 a
ft
er
 C
H
M
I (
21
-F
EB
-2
01
3,
 1
2:
13
 P
M
) s
ho
w
in
g 
no
rm
al
iz
at
io
n 
of
 th
e 
re
po
la
ris
at
io
n 
di
st
ur
ba
nc
es
 
co
m
pa
re
d 
to
 th
e 
pr
ev
io
us
 E
CG
 o
f 1
8-
FE
B-
20
13
.
169
Acute myocarditis during treatment for malaria infection
8
SI
 F
ile
 4
   E
le
ct
ro
ca
rd
io
gr
am
 o
n 
da
y 
15
3 
af
te
r C
H
M
I (
08
-J
U
L-
20
13
, 0
9:
48
 A
M
) s
ho
w
in
g 
no
 a
bn
or
m
al
iti
es
 e
xc
ep
t f
or
 th
e 
kn
ow
n 
in
co
m
pl
et
e 
rig
ht
 b
un
dl
e 
br
an
ch
 b
lo
ck
 a
nd
 a
 m
in
im
al
ly
 w
id
en
ed
 Q
RS
 c
om
pl
ex
 c
om
pa
re
d 
to
 th
e 
pr
e-
tr
ia
l E
CG
.

Chapter 9
GENERAL DISCUSSION  
AND FUTURE PERSPECTIVES

173
General discussion and future perspectives
9
The main objective of this thesis was to evaluate currently available and experimental 
treatment and vaccination strategies that have the potential to support malaria control, 
elimination, and eradication efforts now and in the future. The work described in this 
thesis focused on three main strategies:
1.  Improving access and accuracy of diagnosis using 
malaria rapid diagnostic tests
Presumptive treatment of suspected malaria cases was a justified approach to combat malaria 
in a time when many regions were affected by high malaria risk and limited availability of 
diagnostic tools. When chloroquine and sulphadoxine-pyrimethamine were first-line 
antimalarial drugs, presumptive treatment of suspected malaria cases was also financially 
attractive because they were cheaper than the cost of malaria diagnosis. I examined the 
consequences of this approach now malaria prevalence and mortality are decreasing [1-6]. 
 Countries in the east and south of sub-Saharan Africa have recorded patterns of 
decreasing malaria transmission [3,7,8] and malaria mortality rates dropped by 33% in the 
WHO African Region between 2000 and 2010 [9]. In general, and especially in the context 
of this changing malaria epidemiology, health workers may not always apply treatment 
according to test results in those sub-Saharan settings where microscopy is available 
[10-13]. Malaria rapid diagnostic tests (RDTs) are becoming increasingly available and may 
form an attractive alternative to microscopy to improve access to and accuracy of 
diagnosis and thereby support rational treatment of malaria.
 In the study described in Chapter 2, we observed an immediate and evident effect of 
a policy change by the Tanzanian Ministry of Health and Social Welfare, comprising the 
provision of RDTs and advice to restrict antimalarial treatment to RDT-positive individuals. 
The significant reduction in antimalarial prescriptions after RDT implementation in two 
Designated District Hospitals (DDH) situated in low to very-low malaria endemic areas, 
was also observed in other studies particularly those where RDTs were introduced 
in presumptive treatment settings (Chapter 3). In general, the advantages of RDT 
implementation are harder to define when RDTs are introduced in settings that have used 
microscopy examination of blood smears (Chapter 3).
 Our findings in Chapter 2 are in line with the widely observed phenomenon that 
health workers often do not apply treatment according to test result [10-13]. This is often 
associated with the fear of missing low density infections that may later result in fulminant 
disease, although the limited available evidence indicates that withholding antimalarial 
therapy in febrile children with negative test results by microscopy, is likely to be safe [14]. 
In Sumve DDH and Rubya DDH (before RDT-implementation) clinicians frequently 
requested blood slides, but also frequently ignored negative slide results. In these 
hospitals up to 81% of the slide-negative individuals were treated with antimalarials. In 
Biharamulo DDH 79% of the children were treated with antimalarials without parasitological 
174
Chapter 9
confirmation, illustrating the persisting effects of long-held WHO-guidelines that promoted 
presumptive treatment of malaria in cases of fever [15]. 
 At first instance it was encouraging to see an increase in antibiotic prescriptions after 
RDT-implementation, indicating consideration of alternative diagnoses and treatment 
options by medical staff. One may, however, question whether the observed rise in 
antibiotic use is proportionate or simply illustrates the replacement of irrational antimalarial 
use by irrational antibiotic use [16]. This phenomenon of (disproportionally) increased 
antibiotic use was seen in all studies where antimalarial prescription rates were reduced in 
malaria-negative patients [10,17-19] (Chapter 3), illustrating the considerable challenges to 
assist alternative diagnosis and treatment strategies for RDT-negative patients. Currently, 
there is little data on the spectrum of infections in patients presenting with symptoms of 
suspected malaria but a considerable part is probably self-limiting [20,21]. One study 
showed that the majority of febrile (≥38°C) patients younger than 10 years of age attending 
outpatient clinics in Tanzania were most likely suffering from a viral illness [22], while 
another study showed that the majority (90%) of febrile RDT-negative children recovered 
safely without antibiotic treatment [23]. Thus, sending such patients home without antimalarial 
or antibiotic treatment in the absence of severe clinical signs could be a reasonable 
suggestion. It remains, however, a considerable challenge to distinguish between patients 
who are at risk for severe disease and therefore need antibiotic treatment and/or referral, 
and those where antibiotic treatment could be safely withheld. Development and supply 
of cheap and easy to use point of care tests for bacterial infections or biomarkers of severe 
infections, as are now increasingly available for malaria in the form of RDTs, will support 
medical personnel to rationally prescribe both antimalarials and antibiotics preventing 
spread of antimalarial as well as antimicrobial resistance.
 In addition to the challenges of alternative diagnosis and treatment in RDT negative 
patients, the largest challenge for successful RDT implementation will be assuring and 
sustaining their supply at all levels of the health system. Particularly, areas where implementation 
of RDTs has shown a significant impact on antimalarial prescription rates are at risk of 
situations where health staff will regress to their former diagnostic and drug-prescribing 
behaviour when RDTs are irregularly supplied. With the increasing number of low endemic 
settings following successful malaria control, adequate and sustained coverage of RDTs is 
mandatory for rational antimalarial treatment.
 In Rubya DDH, situated in a remote, rural, very-low malaria endemic area, we observed 
that RDTs provided by the Tanzanian government were out of stock shortly after initial 
roll-out (Chapter 2). Unfortunately, this is not uncommon. Particularly in rural areas, where 
access to services is often low but demand for services is highest [9], drug stock-outs are 
common [12,24-26] and supply is one of the biggest challenges facing the health system. 
Only few studies have examined supply chain characteristics and factors that affect stock 
levels and availability of essential health commodities at health centres. Main drivers of 
RDT stock-outs are most probably suboptimal supply, inaccurate inventory of existing 
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stock in stock cards, and poor system design [27]. RDT stock-outs will not only affect 
health centres, but also practice of community health workers (CHWs) who increasingly 
use RDTs and rely on nearby health facilities for their RDT stock supply [28]. 
 A constant supply of RDTs is a massive and costly logistical undertaking and although 
RDTs are more robust than ever before, they are perishable items which need to be 
delivered under strict storage and transport conditions to allow efficient use. Furthermore, 
it is important that the private for-profit sector is included into this undertaking. This 
sector plays a key role in delivering services across most of Africa and the majority of 
suspected malaria episodes are initially treated by private health workers [29,30]. Data 
from a limited number of countries suggest that neither microscopy nor RDTs have 
penetrated the private healthcare sector [9,31], hampering the implementation of the 
new parasite-based policy.
 Simply making RDTs available in all health care sectors will not directly lead to high 
uptake of the tests or adherence to results by health workers [32]. Health workers are often 
insufficiently trained and may distrust negative test results, have little confidence or 
resources to treat alternative causes of fever, and are influenced by the perception of 
patients demanding for antimalarial drugs (Chapter 3). These challenges seem to persist 
even when highly sensitive and specific RDTs are used [16] and when evidence suggests 
that adhering to RDT results does not have a negative effect on health outcomes [32]. 
Training and regular retraining using proven supportive interventions which take staff 
turnover into account, alongside education of community members is urgently needed.
 However, there is little evidence on how to optimally design health worker training 
to improve adherence to current malaria treatment guidelines including use of RDTs. Only 
few studies have assessed interventions intended to change health workers practice 
when introducing RDTs. Recent evidence from a cluster randomized trial in Cameroon 
shows that a mindset-oriented, interactive training approach results in a significant 
reduction in antimalarial overtreatment and increases the percentage of febrile patients 
being tested for malaria, compared to the “standard” conventional, knowledge-based and 
skills-oriented, didactic training approach. The new training approach covered three 
additional modules targeting improvements in quality of care. These modules focussed 
on how to adapt to a change in policy, on discussions about professionalism, and on 
improving communication skills to patients including managing patients’ expectations 
[33]. Novel interactive training methods like the one described in this study are the way 
forward to bring about the behaviour change needed to support the rollout of RDTs.
 If positive trends continue and malaria transmission will continue to decrease in many 
sub-Saharan areas, the number of (very) low transmission and elimination settings will 
increase. These settings present new challenges that will demand new diagnostic tools 
more sensitive than current RDTs and new strategies, i.e. a change from passive case 
detection to “active” case detection to detecting the highest possible fraction of infections 
in the general population. 
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In low endemic settings the proportion of malaria-infected individuals who harbour 
parasites at densities below the microscopic threshold for detection is considerable [34] 
and the currently available RDTs do not detect all malaria-infected individuals. Research 
aimed towards increasing the sensitivity of existing RDTs may not change this because of 
the limitations of the currently available technology. In low endemic and elimination 
settings, the diagnostic sensitivity (the proportion of target cases detected by the test) for 
passive as well as active case detection should be ≥99%, and the analytic sensitivity (the 
detection threshold against the marker of the infective agent in controlled conditions) 
should be <1 parasites/µL, particularly for active case detection [34,35]. 
 One operationally attractive approach to use RDTs, with shortcomings in sensitivity to 
detect asymptomatic infections, would be to use RDTs to identify geographical clusters of 
malaria infections. RDT-positive cases are likely to be surrounded by (sub-patent) infections 
[36] and RDT-positive individuals can thus form sentinel cases for mass screening and 
treatment using new diagnostics that can detect very low levels of Plasmodium in the 
blood (1 parasite/µL) of asymptomatic individuals who may contribute to continuing 
malaria transmission [37,38]. 
 With the current focus on malaria elimination and the increasing awareness of the 
contribution of low density infections to onward malaria transmission, the need for more 
sensitive field-ready diagnostic tools for mass screening and surveillance to monitor 
transmission reduction and ensure elimination, is increasing. Detecting circulating parasites 
by demonstrating parasite DNA through amplification of ribosomal RNA genes by PCR 
assays is currently the most sensitive diagnostic method. However, PCR capacity is limited 
in resource-poor settings due to the need to avoid contamination which leads to 
false-positive results, requiring a very high standard of laboratory practice [39,40]. The use 
of centralized PCR-specialized labs where field samples obtained by active or passive case 
detection are sent and analyzed, should be evaluated, with a particular focus on logistics 
(sample transfer, time to test result and feedback to field team, communication between 
centralized lab and field team). 
 Another molecular detection method based on DNA amplification is loop-attenuated 
isothermal amplification (LAMP). This promising method, which amplifies DNA (usually 
mitochondrial) with a single thermal cycle, has the potential to reduce the training and 
infrastructure requirements of molecular diagnosis [41-43]. LAMP would allow the timely 
feedback of results needed for case management, but could also be used for mass 
screening and surveillance detecting very low parasite densities. However, LAMP has not 
yet been adequately field tested for wide-scale use or developed in a format suitable for 
the processes of high sample numbers, and sensitivity could be further optimised. In a 
remote Ugandan clinic LAMP achieved sensitivity similar to that of single-well nested PCR, but 
showed false-negative results at parasitaemia levels detectable by 3-well nested PCR [44].
 In conclusion, expanding access to RDTs on the scale needed to achieve universal 
coverage requires retraining of public, private, and retail sector providers as well as sustained 
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supplies and quality assurance. In the increasing number of (very) low transmission and 
elimination settings RDTs will not (and may probably never) be able to detect all 
(asymptomatic) malaria infections. Therefore, new diagnostic tools capable of identifying 
very low parasite densities should be developed for case management, mass screening 
and surveillance, and use of currently available highly-sensitive tools like PCR should be 
evaluated in resource-poor settings. Furthermore, as malaria case incidence will drop, 
research is required into diagnostics for non-malarial febrile diseases and into the 
integration of these tests into health systems.
2.  Mosquitocidal additions to current antimalarial 
treatment to prevent transmission
Gains in malaria control over the last decade are severely threatened by widespread 
insecticide resistance in Anopheles vectors [45-47] and emerging artemisinin-resistant P. 
falciparum [48,49], posing a major challenge to worldwide control and elimination. New 
vector-targeted interventions that reduce malaria transmission are needed, in particular a 
broader range of insecticides with novel modes of action and control methods that target 
vector species regardless of their biting habits, i.e. act against outdoor feeding and resting 
vectors [50]. Moreover, the high vectorial capacity [51] of malaria vectors in sub-Saharan 
Africa should be reduced [50,52]: decreasing Anopheles daily survival rates will show the 
greatest effect on malaria transmission [53,54]. Our findings in Chapters 4 and 5 address 
these issues and show great potential of ivermectin (IVM) as a powerful new addition to 
the toolbox of antimalarial measures.
 Results of animal studies (Chapter 4) show a pronounced effect of IVM on mosquito 
mortality: 70-100% of mosquitoes died within 72 hours after taking a blood meal within 2 
days after IVM treatment. This strong, short-lived mosquitocidal effect supports several 
previous observations of IVM [55-57], with more detailed daily assessments and a larger 
number of mosquito observations. The short period of killing activity suggests that IVM 
may be less attractive as a stand-alone drug for mass drug administration (MDA) 
campaigns that aim to reduce malaria transmission. IVM may, however, be a potent 
addition to antimalarial drugs in MDA campaigns or to prevent transmission shortly after 
treatment of symptomatic malaria cases by reducing the likelihood that mosquitoes that 
feed on gametocytaemic human hosts live long enough to become infectious to other 
humans. With this rationale, we designed a clinical trial, described in Chapter 5, in which 
IVM was added as transmission-blocking drug to artemisinin-combination therapy (ACT). 
Findings confirmed our hypothesis: the survival of two major malaria vectors in 
sub-Saharan Africa, An. gambiae and An. funestus was significantly reduced in the study 
groups receiving AL-IVM. The mosquitocidal effect of IVM was apparent three to seven 
days after a single dose depending on volunteer gender with a more pronounced effect 
when mosquitoes fed on blood from female participants. 
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This trial was the first ever to formally confirm the safety profile of IVM in combination with 
ACT - in this case AL - in a small group of malaria-infected individuals. The AL-IVM 
combination was safe without evidence that co-administration of IVM affected the bio-
availability of lumefantrine. IVM already had an established safety profile which allowed its 
use in MDA campaigns for onchocerciasis and treatment of lymphatic filariasis in Africa 
[58]. The mode of action of IVM as mosquitocidal drug depends on IVM activating gluta-
mate-gated chloride channels in neuronal and neuromuscular tissues of invertebrates, 
thereby causing flaccid muscle paralysis that can lead to death of the insect [59-61]. Gluta-
mate-gated chloride channels do not exist in humans and orthologous mammalian 
channels are distantly related and found only in the human central nervous system, where 
the blood-brain barrier limits drug access [62,63]. No significant association has been 
found between IVM plasma levels and adverse events [64], and doses up to 10 times the 
approved limit are well tolerated by healthy volunteers [65], providing little concern for 
drug toxicity even at high doses. This may be beneficial for future use, since our findings 
indicate that higher, repeated doses or sustained presence of IVM may be needed for 
maximal mosquitocidal effect. Modelling results indicate that increasing the duration of 
the mosquitocidal effect of IVM will have a greater impact than increasing the magnitude 
of the mosquitocidal effect on reducing infectious vector density and host parasite 
prevalence [66].
 Adverse events related to IVM have been usually associated with intensity of 
microfilarial infection and primarily characterized as classical (mild) Mazzotti reactions to 
degenerating microfilariae [67]. However, in persons with high levels of Loa loa microfilar-
aemia (>30,000 microfilaria/mL) IVM can induce excessive forms of the normally expected 
Mazzotti reactions, i.e. serious (neurological) adverse events including encephalopathy 
and coma [67-69]. This is a drawback if ACT-IVM were to be implemented in countries 
where loiasis is or may be endemic (Angola, Cameroon, Central African Republic, Congo, 
DR Congo, Equatorial Guinea, Gabon, and potentially parts of Chad, Ethiopia, Nigeria and 
Sudan). On the other hand, prevalence of this parasitic disease is still very low even in 
these countries [70] and prior screening using efficient and sensitive methods such as the 
RAPLOA assessment tool developed by the World Health Organization [71] and parasito-
logical assessment by microscopic examination of a blood film [69] could be feasible.
 The activation of glutamate-gated chloride channels does not only provide an 
excellent safety profile but also represents a novel model of action [59] circumventing the 
issue of emerging resistance to other currently used insecticides. Furthermore, as a 
systemic drug, IVM is ingested by all biting mosquitoes and so it will equally target indoor 
and outdoor-biting mosquitoes, as well as those with crepuscular activity, thereby 
avoiding the selective survival of outdoor biters that has been observed after the 
wide-scale deployment of bed nets [72]. Finally, the activity of IVM targets the most 
influential variable of vectorial capacity, the probability of mosquito survival through one 
day [53,54].
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Use of single IVM-only MDAs is not expected to have a long-term effect on malaria parasite 
transmission [56,73]. Field data only show significantly increased mortality of wild A. 
gambiae for up to six days [56] and large reductions in sporozoite rates for at least 2 weeks 
after IVM MDA [73]. Modelling results suggest that IVM MDAs might only be able to 
significantly reduce malaria parasite transmission in a community if given once a month or 
more frequently, and probably only in areas with seasonal malaria transmission, such as 
the Sahel, or during epidemics [63]. 
 We envisage a complementary role of IVM in malaria control, elimination and 
eradication efforts by combining it with antimalarials such as ACT, which rapidly clears 
asexual parasites and developing gametocytes but leaves mature P. falciparum 
gametocytes largely unaffected; a proportion of P. falciparum parasite carriers may 
transmit malaria after successful ACT treatment [74,75]. IVM could be an extremely valuable 
and safe alternative for or in addition to gametocytocidal drugs to reduce malaria 
transmission post-ACT to prevent the spread of artemisinin-resistant parasites throughout 
the world [76]. The most powerful approach to implement ACT-IVM in community 
campaigns to reduce malaria transmission depends on the previously mentioned 
challenges in identifying all malaria-infected individuals who contribute to malaria 
transmission. With the large proportion of submicroscopic infections in all settings, 
especially low endemic settings [34], restricting ACT-IVM to RDT positive individuals may 
have negligible sustained effects on malaria transmission [66]. There are three options to 
use ACT-IVM to bring down community transmission intensity: i) ACT-IVM may be 
distributed to parasite positive individuals in a mass screening and treatment (MSAT) 
approach where molecular diagnostics are used to screen individuals regardless of 
symptoms; ii) RDTs are used to identify high density parasite positive individuals who are 
indicative of clusters of asymptomatic (often submicroscopic) infections that can then be 
identified by more costly and laborious molecular diagnostics and treated with ACT-IVM; 
iii) a MDA approach where ACT-IVM is distributed to the entire community regardless of 
malaria diagnosis or symptoms. Although ACT-IVM MDA will result in unacceptable costs 
and drug-pressure on parasite populations if repeatedly performed, it may play a role in 
selected settings where elimination has nearly been achieved or where drug resistance 
needs containment [66,77]. Modelling results suggest that including mass IVM 
administration alongside mass screening and treatment (MSAT) or MDA with an ACT can 
substantially increase reductions in P. falciparum malaria transmission. This transmission 
effect is obtained through the effect IVM has on vector mortality [66]. 
 Before IVM can be recommended for malaria control, further studies must be 
conducted to provide definitive evidence of its role in any type of malaria control strategy 
(Table 1). The ultimate evidence will come from cluster-randomized community trials with 
single or repeated IVM MDA preferably with addition of antimalarial MSAT or MDA. More 
modest studies to provide further evidence on the potential role(s) of IVM should directly 
compare membrane feeding with skin feeding, since cumulative mosquito mortality may 
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be higher after direct skin feeding [55]. There is evidence that IVM concentrations in 
different tissues may vary [78], but it is currently unknown if the observed difference in 
mosquito mortality between membrane and skin feeding is due to different IVM 
concentrations in capillary versus venous blood. Furthermore, it was recently suggested 
that sublethal IVM concentrations may affect sporogony in colonized An. gambiae s.s. 
mosquitoes infected with cultured P. falciparum parasites [79]. We did not observe a 
sporonticidal effect in our study, neither in vivo or in vitro. Since the attractiveness to use 
IVM will be also dependent on a possible sporonticidal effect that may reduce malaria 
transmission for a longer period than predicted based on anti-mosquito effects alone, it 
will be necessary to clarify the reasons for these conflicting results and potentially validate 
the results of the study by Kobylinski and colleagues with natural P. falciparum isolates and 
wild-caught anophelines. 
Successful implementation of any type of IVM MDA would require good understanding of 
the transmission intensity and seasonality pattern of the particular target area to ensure 
that treatment rounds are conducted at optimal times and that interruption of transmission 
is feasible. Effects of (any type of) IVM MDA will have to be compared in diverse habitats 
containing different vectors and malaria ecologies. Since IVM is of utmost importance for 
control of onchocerciasis, lymphatic filariasis and treatment of some soil-transmitted 
helminthes [80], increased exposure of these parasites to IVM might lead to resistance and 
threaten the success of control programmes. Therefore, surveillance strategies must be 
established in areas where IVM is introduced as a malaria control measure. Combining IVM 
with a second antihelmintic drug might be effective to delay resistance development in 
soil-transmitted helminthes.
Table 1   Challenges and future research for implementation of IVM
Large-scale  
community trials
- Single or repeated IVM MDA + antimalarial MSAT or MDA
- Effect of IVM MDA in diverse habitats containing different vectors and 
malaria ecologies
IVM dosage  
determination  
and spacing
- Comparing membrane feeding with (human) skin feeding
- Simultaneous mosquito feeding and measurement of IVM concentration 
in human plasma 
- Development of a safe, single-encounter, long-lasting IVM formulation
IVM resistance - Establishment of resistance-surveillance in communities where IVM will 
be introduced for malaria control
- Explore combination of IVM with a second antihelmintic
IVM, ivermectin; MDA, mass drug administration; MSAT, mass screening and treatment.
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3.  Protection against malaria by inoculation of  
whole sporozoites 
In 1967, Nussenzweig et al. reported the first successful proof-of-concept studies of a live 
attenuated, metabolically active sporozoite vaccine in a rodent malaria model [81]. This 
landmark finding formed the basis for whole sporozoite immunization, which proved to 
provide protection against malaria challenge infection in humans in the 1970s [82-89]. 
Results by Hoffman et al. expanded these findings, showing protection against challenge 
infection in 24 of 26 volunteers immunized by irradiated mosquitoes carrying P. falciparum 
sporozoites [90]. This sterile protection most likely was based on pre-erythrocytic immunity 
acquired by irradiated sporozoites that arrest early after liver cell invasion providing 
liver-stage antigen exposure [90]. However, the requirement of a minimum of 1,000 bites 
by irradiated mosquitoes during five or more immunization sessions in order to successfully 
induce sterile immunity in humans precluded this method from routine immunization 
and the pursuit of a whole sporozoite malaria vaccine was largely abandoned.
 In the past years, there has been renewed interest in the whole sporozoite immunization 
as a result of the cryopreservation of sporozoites by Sanaria Inc. [91] and the highly 
effective CPS (ChemoProphylaxis and Sporozoites) immunization model [92,93]. Using the 
CPS-approach, healthy malaria-naive volunteers can be fully protected against a mosquito 
challenge infection with a homologous P. falciparum strain for up to more than two years 
after three immunizations under chloroquine prophylaxis by bites from 12–15 P. falciparum 
sporozoite-infected mosquitoes at monthly intervals [92,93]. The unprecedented efficacy 
of the CPS immunization model is represented by the low dose sufficient to induce 
protection compared with the irradiated sporozoite approach [90]. In the latter approach, 
asexual blood stages never occur and the apparent lack of blood-stage immunity was 
firstly shown in the 1970s in a single irradiated sporozoite-immunized volunteer challenged 
with blood-stage parasites [85].
 In CPS immunization, transient low-level blood-stage parasitaemia does occur [92], 
because chloroquine only kills developing blood stages of P. falciparum without affecting 
sporozoites or liver stages [94]. Consequently, the host’s immune system is exposed to a 
relatively broad repertoire of antigens, including sporozoite, liver-stage, and blood-stage 
antigens [92,95] of which many are shared between stages [96]. As well as posing the 
question whether this great array of antigens is the main reason for the potency of CPS-im-
munization, the exact mode of protective action remains uncertain: protection may be 
mediated by immune responses against liver stage parasites, blood stage parasites or a 
combination thereof [97]. 
 In Chapter 6 we have shown that CPS immunization does not protect against an 
intravenously administered challenge with P. falciparum-infected erythrocytes. This 
complete absence of apparent functional blood-stage immunity emphasizes the need for 
a 100% effective liver-stage immunization if this model is to be translated into an actual 
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vaccine. Especially in people without natural immunity, a single surviving parasite caught 
in an endemic area may be sufficient for the infection to proceed to the blood stage 
causing clinical disease. A selective group of non-immune subjects, such as military and 
travellers, is expected to be the primary target group for a CPS-based vaccine in the near 
future. Thus, even when a CPS-based vaccine would provide a high rate of sterile 
protection, the absence of functional blood-stage immunity may cause safety concerns 
and warrant a continued need for antimalarial prophylaxis. Another issue to deal with is 
co-administration of the antimalarial drug. Currently this is chloroquine, although 
mefloquine was recently shown to be equally effective in the CPS immunization model (E. 
Bijker et al., submitted). It is crucial that full attenuation is independent from compliance 
and pharmacokinetics of the blood-stage killing drug used and that the drug formulation 
should have a sufficient half-life. Finally, extensive post-vaccination follow-up might be 
necessary due to the inability to carry out viability checks before the vaccine is administered. 
However, progress in the development of in vitro hepatocyte assays to reliably and 
repeatedly check the potency of sporozoites should solve this issue. 
 The biggest impediment for direct practical application of CPS-immunization is its 
dependence on inoculation of sporozoites by mosquito bites. The first study ever to 
address this issue is described in Chapter 7 where we replaced mosquito bites by intradermal 
needle and syringe injections containing sporozoites, an approach called PfSPZ-CVac 
(PfSPZ-Chemoprophylaxis Vaccine). We used the PfSPZ Challenge product of the 
biotechnology company Sanaria Inc. (USA) which consists of infectious, aseptic, purified, 
vialed, cryopreserved Pf sporozoites manufactured according to Good Manufacturing 
Practice [98,99].
 Results of this first phase I trial showed that the current intradermal immunization 
regimen of PfSPZ-CVac immunization was safe and well tolerated. Furthermore, a cardiac 
SAE occurred from which the definitive aetiology could not be established (Chapter 8). 
The current immunization regimen did not confer protection against a homologous 
challenge infection in healthy malaria-naive volunteers. In contrast to previous CPS studies 
[92](Chapter 6), parasitaemia was never observed after an immunization in any of the 
PfSPZ-CVac recipients, plausibly reflecting insufficient liver stage maturation and 
presumably sub-optimal parasite exposure. Under these conditions the host’s immune 
system is underexposed to the broad array of antigens necessary for induction of 
protective pre-erythrocytic immune responses [100,101]. Differences in efficiency of 
administration (route/method) and infectivity/fitness of sporozoites between CPS and 
PfSPZ-CVac immunization are likely responsible for the observed absence of blood-stage 
parasitaemia as a reflection of unsuccessful liver-stage maturation. 
 With the application of multiple intradermal injections of sporozoites by needle and 
syringe we tried to approach the way anopheline mosquitoes successfully deliver sporozoites: 
before a capillary is found the female mosquito probes the dermal skin several times, 
while injecting tiny bits of sporozoite-containing saliva [102]. Evidence supporting multiple 
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intradermal injections was derived from murine data demonstrating that both 
intramuscular and intradermal routes increased liver loads when using smaller volumes 
and injections at multiple sites [103]. However, despite the apparent similarity to mosquito 
bite delivery it is evident that the current method of 6 intradermal sporozoite injections is 
still clearly different from natural conditions: i) mosquitoes deliver a proportion of sporozoites 
intracapillary and a proportion intradermally [104]; ii) sporozoites are embedded in 
mosquito saliva when inoculated, a component that may improve infectivity [105]; and iii) 
the volume of injections by mosquito is considerably lower than will ever be reached by 
needle and syringe. Injecting smaller volumes of e.g. 1 µL in future trials may prevent 
sporozoites from ‘swimming’ in pools of intradermally injected fluid, providing them with 
the possibility to adhere to dermal cells and subsequently migrate to capillaries and 
lymphatic vessels [106]. Furthermore, increasing the number of injections may improve 
chances that sporozoites find a dermal capillary. For this a novel injecting device should 
be designed that simultaneously or consecutively injects very small volumes of 
sporozoites. Apart from optimizing route and method of immunization, increasing the 
infectivity of cryopreserved sporozoites by Sanaria Inc. and consequently optimizing 
effective dose will be key for clinical development of PfSPZ-CVac.
 It will take more time to translate CPS-immunization into an effective and implementable 
malaria vaccine. Apart from impediments mentioned before, the genetic variation of 
parasite clones in the field may form an obstacle [107]. There is some evidence from the 
1970s and 1990s that whole sporozoite immunization induces protection against 
heterologous P. falciparum challenge: heterologous P. falciparum infection by mosquito 
bite, after immunization with radiation attenuated P. falciparum sporozoites by the bites of 
>1,000 mosquitoes, was performed 7 times in 4 volunteers with protection in all 4 
volunteers [90]. Furthermore, we have recently obtained supportive evidence for existence 
of heterologous protection after CPS immunization. Two out of 12 subjects, who had 
previously received CPS immunization with 3x5, 3x10 or 3x15 infected bites and were 
homologously challenged, were protected against heterologous re-challenge with significant 
delays in pre-patent period in most of the volunteers previously protected against the 
homologous challenge (R. Schats et al., submitted). To confirm these promising data and 
understand the reasons for cross-protection and failure to achieve cross-protection, a new 
clinical CPS-trial primarily aimed at assessing heterologous protection has been designed.
 Apart from CPS-immunization, sporozoites attenuated by targeted gene disruption, 
of which the favourite candidates are genetically attenuated late liver-stage-arresting 
parasites, are being evaluated as whole-parasite vaccines [108]. In mice, this type of 
vaccine induced high levels of cross-species protection and complete protection when 
administered by intradermal or subcutaneous routes [109]. Such results still need to be 
generated in humans. 
 Another way of using the CPS-immunization model in the future, would be to 
translate it into a natural immunization strategy in malaria endemic areas. Here, chloroquine 
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administration would not only have a direct prophylactic effect, but could also provide 
protective efficacy to malaria after cessation of the drug. Ideal areas to test the feasibility 
and efficacy of this strategy would be those with a short but intense malaria transmission 
season with similar inoculation rates as challenge infections [110]. Particularly in these 
areas, where the exposure to pre-erythrocytic antigens will be high while blood-stage 
infections are controlled by chloroquine, protective efficacy could be assessed in the next 
peak transmission season by measuring incidence of clinical malaria, prevalence of malaria 
parasitaemia and parasite densities.
 A major roadblock for the applicability of natural immunization is the prevalence of 
parasite populations with resistance to chloroquine [111], necessitating alternatives to 
chloroquine monotherapy. Murine immunization studies with P. berghei in combination 
with pyrimethamine or primaquine prophylaxis show promising results [108]. Furthermore, 
use of an ACT like dihydroartemisinin-piperaquine is potentially interesting and could be 
assessed in the lab and in the field. Dihydroartemisinin kills Plasmodium blood-stages by 
targeting the food vacuole in which the parasite concentrates haem [112]; the mechanism of 
action of piperaquine is currently unknown, but it is believed to resemble that of chloroquine. 
 Although the natural immunization approach might be more feasible for the near 
future, a CPS-based (or other type of) vaccine would probably hold larger promise to 
support malaria elimination initiatives. In (very) high transmission areas sporozoite 
inoculation rates may rapidly reach the threshold for a natural immunization strategy. 
In moderate, low and elimination areas, natural immunization could also be applied but 
should be accompanied by regular immunizations with sporozoites to enhance rapid 
development of herd immunity.
Conclusion
Each of the treatment and vaccination strategies described in this thesis has the potential 
to make a significant contribution to malaria elimination (and eventually eradication). To 
achieve malaria elimination, i) access to highly sensitive and accurate diagnosis is essential 
in order to find all malaria-infected individuals, and diagnostics should be suitable for 
mass screening, ii) parasite positive individuals should be treated and onwards transmission 
should be prevented, and iii) gains should be sustained and herd immunity should be 
induced in low endemic and elimination areas. Strategies described in this thesis, could be 
applied into this three-step approach: i) RDTs could increasingly be used to identify 
geographical clusters of malaria infections ii) that could then be targeted with IVM-ACT 
MSAT or MDA to prevent the spread of (resistant) parasites to surrounding populations, 
and eventually iii) a whole-sporozoite vaccine (once developed) could protect the 
population against future malaria outbreaks.
 Interrupting malaria transmission worldwide is one of the greatest challenges for 
international health and development communities. Even though substantial progress 
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has been made in reducing malaria prevalence, further scaling up of control with currently 
available knowledge, tools and strategies will most likely fall short of eliminating malaria in 
most endemic settings [113]. The efficient transmission of malaria, with a single malaria 
infection giving rise to dozens or even hundreds of new malaria cases [114], makes it 
tremendously challenging to achieve and sustain local malaria elimination. To eliminate 
malaria from all regions of the world, i.e. malaria eradication, additional challenges exist 
with a major role for operational limitations (e.g. underperforming health services/
systems, insufficient human resources, inadequate tools to interrupt transmission in high 
transmission areas, political unrest) and heterogeneity in malaria transmission between 
areas (e.g. different vector, parasite, social and environmental factors) indicating that there 
is no single strategy that works everywhere. Furthermore, the parasite and the vector are 
always evolving, indicating that there are - and always will be - significant threats to the 
progress made. Examples are the emergence of artemisinin resistance, the consequent 
need for more vigorous containment measures [76], and the increased mosquito resistance 
to insecticides warranting the need for new vector control strategies [46]. 
 Continued financial and political support to prevent resurgence of malaria in countries 
that have brought the malaria burden down as well as development of new and improved 
tools and strategies, and their implementation in various settings is crucial to achieve 
eradication, hence the impetus to explore transmission-blocking and live attenuated 
parasite vaccines as well as anti-vector measures targeting novel processes. The Plasmodium 
parasite and the Anopheles vector offer many targets for intervention that are currently still 
unknown. A better insight into the genome sequences of both will provide a better 
understanding of host-parasite interactions and enable us to design new interventions. 
The future of malaria control and eradication efforts will be highly dependent on how well 
the scientific and public health communities, policy makers and local governments can 
work together to extend the effective life span of our existing tools while discerning new 
interventions that interrupt the complex life cycle of Plasmodium parasites.
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Interrupting malaria transmission worldwide is one of the greatest challenges for international 
health and development communities. Even though substantial progress has been made 
in reducing malaria prevalence, further scaling up of control with currently available 
knowledge, tools and strategies will most likely fall short of eliminating malaria in most 
endemic settings. This is partly due to constant threats to current progress, such as 
emergence of antimalarial drug resistance and vector mosquito resistance to insecticides. 
Consequently, need for more potent tools to contain dissemination of resistant parasites 
and accelerated development of vaccines that can impact on malaria incidence, disease, 
and death remains a high priority.
In this thesis, I evaluate currently available and experimental treatment and vaccination 
strategies that have the potential to support malaria control, elimination, and eradication 
efforts now and in the future. The work described in this thesis can be grouped into three 
main sections. 
A. Improving access and accuracy of diagnosis using malaria rapid diagnostic tests, 
a current strategy 
B. Mosquitocidal additions to current antimalarial treatment to prevent transmission, 
a near future strategy
C. Protection against malaria by inoculation of whole sporozoites, a future strategy 
In Section A we show that malaria rapid diagnostic tests (RDTs) can support rational 
treatment of malaria, as they provide parasite based diagnosis in presumptive treatment 
settings and are an attractive easy-to-use alternative to microscopy. In Chapter 2 we 
observed an immediate and evident effect of a policy change by the Tanzanian 
government, comprising the provision of RDTs and advice to restrict antimalarial treatment 
to RDT-positive individuals. There was a significant reduction in antimalarial prescriptions 
after RDT implementation in two district hospitals situated in low to very-low malaria 
endemic areas in Tanzania. In Chapter 3 we show that this reduction was also observed in 
other studies, particularly those where RDTs were introduced in presumptive treatment 
settings, but that the advantages of RDT implementation are harder to define when RDTs 
are introduced in settings that have used microscopy examination of blood smears. 
Furthermore, we highlight the World Health Organization’s (WHO) initiative T3: Test. Treat. 
Track, which centres on the use of RDTs to address the widespread problem of poor access 
to diagnostic testing and antimalarial treatment. We argue that the biggest challenge in 
RDT implementation will be to provide adequate and sustained supplies of RDTs and 
appropriate training to all health workers in endemic areas.
In the Section B we present an alternative approach to prevent post-treatment malaria 
transmission. The transmission of malaria parasites from humans to mosquitoes (and 
subsequently to other humans) depends on the presence of mature sexual parasite forms 
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(gametocytes) in the peripheral blood. Gametocytes are relatively insensitive to current 
first line antimalarial drugs that therefore need to be supported by specific transmission- 
blocking drugs. The search for malaria transmission-blocking drugs has so far focused 
on drugs that clear gametocytes. We discovered that ivermectin (IVM, a drug widely 
used against onchocerciasis) can prevent post-treatment malaria transmission in an 
unconventional way: by killing the vector, the Anopheles mosquito, instead of killing the 
gametocyte. In animal studies described in Chapter 4 we discovered a pronounced but 
short-lived mosquitocidal effect of IVM. In Chapter 5 we confirm these findings in humans 
by performing a double-blind, placebo-controlled trial in Burkina Faso, in which we show 
that the combination of IVM with the current first line antimalarial drugs is safe and 
significantly reduces the survival of malaria-transmitting Anopheles mosquitoes. The 
mosquitocidal effect of one and two doses of IVM in combination with first line antimalarial 
drugs resulted in 27% and 35% reductions, respectively, in estimated malaria transmission 
potential during the first week after initiation of treatment. We argue that IVM can be 
recommended for malaria control in the near future, but that further studies must be 
conducted to provide definitive evidence of its role in any type of malaria control strategy. 
The ultimate evidence will come from cluster-randomized community trials with single 
or repeated IVM mass drug administration preferably with addition of mass drug 
administration of first line antimalarial drugs.
In the Section C we describe two controlled human malaria infection studies in which we 
immunized malaria naive volunteers under chloroquine chemoprophylaxis with Plasmodium 
falciparum sporozoites (CPS). In Chapter 6 we assessed the life-cycle stage-specificity of 
CPS-induced protection and show that CPS immunization does not protect against an 
intravenously administered blood-stage challenge infection. The absence of protection 
against P. falciparum-infected erythrocytes indicates that CPS immunization only provides 
functional immunity against parasite liver-stages, emphasizing the need for a 100% 
effective CPS liver-stage immunization if this model is to be translated into an actual 
vaccine. In Chapters 7 and 8 we determined the safety and tolerability of intradermal 
administration of cryopreserved P. falciparum sporozoites to volunteers taking chloroquine 
chemoprophylaxis, and its protective efficacy against infectious mosquito bites. We show 
that the current intradermal immunization regimen is safe and well tolerated, although it 
did not confer protection against infectious mosquito bites. This is in contrast to previous 
CPS studies in which volunteers were protected against infectious mosquito bites after 
CPS immunization. We believe that differences in efficiency of administration and 
infectivity of sporozoites between the regular CPS immunization and the currently used 
intradermal injections are likely responsible for the observed differences. 
Each of the treatment and vaccination strategies described in this thesis has the potential 
to make a significant contribution to malaria elimination (and eventually eradication). To 
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achieve malaria elimination, i) access to highly sensitive and accurate diagnosis is essential 
in order to find all malaria-infected individuals, and diagnostics should be suitable for 
mass screening, ii) parasite positive individuals should be treated and onwards transmission 
should be prevented, and iii) gains should be sustained and herd immunity should be 
induced in low endemic and elimination areas. Strategies described in this thesis, could be 
applied into this three-step approach: i) RDTs could increasingly be used to identify 
geographical clusters of malaria infections ii) that could then be targeted with IVM and 
first line antimalarial drugs in a mass drug administration approach to prevent the spread 
of (resistant) parasites to surrounding populations, and eventually iii) a whole-sporozoite 
vaccine (once developed) could protect the population against future malaria outbreaks.
 The future of malaria control and eradication efforts will be highly dependent on how 
well the scientific and public health communities, policy makers and local governments 
can work together to extend the effective life span of our existing tools while discerning 
new interventions that interrupt the complex life cycle of Plasmodium parasites.
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Samenvatting
Het terugdringen van malariatransmissie wereldwijd is één van de grootste uitdagingen 
voor de internationale gezondheidszorg. Hoewel er aanzienlijke vooruitgang is geboekt, 
zullen de momenteel beschikbare kennis, middelen en strategieën in de meeste endemische 
gebieden waarschijnlijk niet leiden tot eliminatie van malaria. Dit is deels te wijten aan 
de toenemende resistentie van Anopheles-muggen tegen insecticiden en de verminderde 
gevoeligheid van de Plasmodium-parasiet voor diverse antimalariamiddelen. Om de 
verspreiding van resistente Plasmodium-parasieten tegen te gaan, zullen krachtigere 
middelen nodig zijn. Ook hebben de ontwikkeling en distributie van een werkzaam 
vaccin dat invloed heeft op malaria-incidentie, -ziektelast, en -mortaliteit hoge prioriteit.
In dit proefschrift evalueer ik momenteel beschikbare en experimentele behandelings- en 
vaccinatiestrategieën die malariabeheersing, -eliminatie, en -eradicatie nu en in de toekomst 
zouden kunnen ondersteunen. Mijn proefschrift bestaat uit drie delen.
A. Verbetering van de beschikbaarheid en nauwkeurigheid van diagnostiek met behulp 
van malaria-sneltesten, een momenteel toegepaste strategie
B. Toevoeging van muggendodende middelen aan de bestaande malariabehandeling 
om transmissie via de mug te voorkomen, een strategie voor de nabije toekomst 
C. Bescherming tegen malaria door inoculatie met sporozoïeten, een strategie voor de 
toekomst
In Deel A laten wij zien dat malaria-sneltesten (rapid diagnostic tests, RDTs) kunnen 
bijdragen aan een rationele behandeling van malaria. In gebieden waar men uitsluitend 
behandelde op basis van klinische symptomen maakt een RDT het mogelijk om de 
diagnose malaria te stellen door detectie van specifieke Plasmodium-antigenen. In 
Hoofdstuk 2 zagen wij een direct effect van een beleidswijziging van de Tanzaniaanse 
overheid, waarbij er RDTs werden verstrekt aan ziekenhuizen en malariabehandeling 
alleen mocht worden gestart na een positieve RDT-uitslag. Na deze beleidswijziging 
verminderde het aantal voorgeschreven antimalariamiddelen aanzienlijk in de twee 
regionale ziekenhuizen waar onze observatie plaatsvond. In Hoofdstuk 3 tonen wij dat 
deze trend ook is waargenomen in andere studies, met name daar waar men voorheen 
uitsluitend behandelde op basis van klinische symptomen. Invoering van RDTs blijkt 
echter minder effect te hebben indien microscopische diagnose van malaria reeds 
plaatsvond. Ook belichten wij het T3: Test, Treat, Track initiatief van de Wereldgezondheids-
organisatie dat zich richt op het gebruik van RDTs. Wij zijn van mening dat adequate en 
permanente bevoorrading met RDTs alsmede een gedegen opleiding voor al het ge-
zondheidszorgpersoneel de grootste uitdagingen vormen voor RDT-implementatie in 
endemische gebieden.
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In Deel B tonen wij een nieuwe manier om de transmissie van parasieten tussen mens en 
mug na standaard malariabehandeling te verhinderen. Deze transmissie is het gevolg van 
de aanwezigheid van gametocyten (seksuele stadia van de parasiet) in humaan bloed. 
Gametocyten zijn relatief ongevoelig voor eerstelijns antimalariamiddelen die daarom 
ondersteund moeten worden met middelen die transmissie voorkomen. De zoektocht naar 
deze transmissieblokkerende middelen heeft zich tot op heden gericht op middelen die 
gametocyten doden. Wij hebben aangetoond dat ivermectine (IVM, een geneesmiddel dat 
op grote schaal wordt gebruikt voor behandeling van rivierblindheid) malaria transmissie op 
onconventionele wijze kan verhinderen: IVM doodt de vector van de  malariaparasiet, de 
Anopheles mug, in plaats van de gametocyt. Uit dierstudies beschreven in Hoofdstuk 4 
blijkt dat IVM een kortdurend maar evident muggendodend effect heeft. In Hoofdstuk 5 
observeerden wij in een dubbelblinde, placebo-gecontroleerde trial in Burkina Faso 
eenzelfde effect in de mens. In deze trial laten wij zien dat de combinatie van IVM met de 
huidige eerstelijns antimalariamiddelen veilig is en de overleving van Anopheles muggen 
significant verkleint. Het muggendodende effect van één en twee doses IVM resulteerde in 
dalingen van respectievelijk 27% en 35% van het malariatransmissiepotentieel tijdens de 
eerste week na start van behandeling. Wij zijn van mening dat deze combinatietherapie in 
de nabije toekomst kan worden gebruikt voor de bestrijding van malaria. Er dienen echter 
aanvullende studies te worden uitgevoerd om de precieze rol van IVM in elk type malaria-
beheersingsstrategie te bepalen. Het definitieve bewijs zal moeten worden geleverd door 
cluster-gerandomiseerde community trials waarin een eenmalige of herhaalde dosis IVM bij 
voorkeur met een eerstelijns antimalariamiddel aan de hele populatie wordt gegeven.
In de Deel C beschrijven wij twee gecontroleerde humane malaria-infectiestudies waarin 
gezonde proefpersonen terwijl zij chloroquine innemen, worden blootgesteld aan 
Plasmodium falciparum sporozoïeten via muggenbeten (de conventionele CPS-immunisatie) 
of via injecties (een alternatieve wijze van CPS-immunisatie). Op deze manier proberen wij 
hen immuun te maken voor een nieuwe malaria-infectie. In Hoofdstuk 6 laten wij zien 
dat CPS-immunisatie wél bescherming biedt tegen met sporozoïeten geïnfecteerde 
muggenbeten, maar niet tegen intraveneus toegediende bloedstadiumparasieten. Het 
ontbreken van bescherming tegen deze bloedstadiumparasieten duidt erop dat CPS- 
immunisatie alleen bescherming biedt tegen de leverstadia van de parasiet. In Hoofdstuk 
7 en 8 hebben wij bekeken of proefpersonen die intradermaal sporozoïeten krijgen 
toegediend en chloroquine innemen, immuun worden voor infectieuze muggenbeten. 
We concluderen dat het huidige intradermale immunisatiebeleid veilig is en goed 
verdragen wordt. Het biedt echter geen bescherming tegen infectieuze muggenbeten, 
in tegenstelling tot eerdere CPS-immunisatiestudies waarin proefpersonen immuun werden. 
Wij denken dat het verschil tussen de conventionele CPS-immunisatie en de intradermale 
injecties te verklaren is door een andere toedieningswijze en de mate waarin sporozoïeten 
infectieus zijn.
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Elk van de behandelings- en vaccinatiestrategieën beschreven in dit proefschrift heeft de 
potentie om een belangrijke bijdrage te leveren aan malaria-eliminatie (en uiteindelijk 
eradicatie). Om malaria-eliminatie te bereiken, i) is toegang tot zeer gevoelige en 
nauwkeurige diagnostiek essentieel om alle malariageïnfecteerde individuen op te sporen 
en moet diagnostiek geschikt zijn voor massale screening, ii) dienen malariageïnfecteerde 
individuen te worden behandeld en moet verdere transmissie worden voorkomen, en iii) 
dient gemaakte progressie te worden gewaarborgd en immuniteit op populatieniveau te 
worden opgewekt in laagendemische gebieden en eliminatiegebieden. De strategieën 
beschreven in dit proefschrift kunnen worden toegepast in deze drietraps-aanpak: i) RDTs 
kunnen worden gebruikt om geografische clusters van malaria-infecties op te sporen ii) 
waar vervolgens zoveel mogelijk individuen met IVM en eerstelijns antimalariamiddelen 
worden behandeld om verspreiding van (resistente) parasieten naar omringende 
populaties te voorkomen en iii) uiteindelijk zou een vaccin gebaseerd op sporozoïeten 
(eenmaal ontwikkeld) de populatie kunnen beschermen tegen toekomstig uitbraken van 
malaria. 
 De toekomst van malariabeheersings- en eradicatie-inspanningen zal sterk afhangen 
van de mate waarin wetenschap, volksgezondheidsorganisaties, beleidsmakers en lokale 
overheden samenwerken om de levensduur van bestaande beheersingsmaatregelen te 
verlengen en nieuwe interventies te ontwikkelen.
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Appendix II - Dankwoord
Hèhè.... Zo, dat is af!
Robert en Teun, jullie zijn beiden ontzettend belangrijk geweest voor het traject dat ik 
in de afgelopen jaren heb doorlopen. Wat heb ik veel geleerd! 
Robert, ik herinner me nog mijn eerste afspraak met jou, waarschijnlijk kwam ik over als 
een enthousiast maar ongeleid projectiel. Jij hebt me in die vier jaar dat ik onder je hoede 
was, geleerd om altijd kritisch naar zaken te kijken, geen genoegen te nemen met een 
halfslachtig antwoord en dingen tot de bodem uit te zoeken. Dit zal ik de rest van mijn 
leven meenemen. Aangezien jij mij dikwijls kwijt was “Robert was op zoek naar je”, stel ik 
voor dat je mij voortaan gewoon op mijn mobiel kunt bellen.
Teun, als geneeskundestudent kwam ik al met jou in contact. Ik wilde graag onderzoek 
doen tijdens mijn laatste coschap in Tanzania en jij zag mogelijkheden. Uiteindelijk bleek 
dit de start van een vruchtbare samenwerking die hopelijk nog een hele tijd voortduurt. 
Het voorlopige hoogtepunt was toch wel het artikel in de Donald Duck, uhm... ik bedoel 
De Telegraaf. Wij delen de passie voor veldwerk. Daardoor begrijp jij daadwerkelijk welke, 
soms bizarre problemen er in het veld kunnen spelen. Jij komt altijd met een oplossing, 
je bent echt de eeuwige optimist!
Maurits, wat hebben wij veel gelachen! Ondanks alle heisa rondom de SAE, het memorabele 
interview met de ANS en al het andere TIP5 gedoe, kijk ik met veel plezier op deze tijd 
terug. Zonder jou was het zeker weten een stuk zwaarder geweest. Tevens hebben wij 
bewezen een turbo-efficiënt team te zijn: ik begon om 6:30 uur met werken en stopte 
eind van de middag, jij begon ergens in de middag en werkte door tot midden in de nacht. 
Resultaat: 23 uur per dag productie! Ik zou ons meteen aannemen als arts-microbioloog- 
turboteam. Je bent in de loop der jaren een goede vriend geworden waarmee ik nog 
veel zal gaan lachen, drinken en ouwehoeren en die ik nog vaak genoeg in de rede zal 
moeten vallen.
Anja, you are really my humoral-cellular-rescue-goddess! I don’t know what I would have 
done without you. As you know, I´ m not really the cellular type of guy but you managed 
to make me enthusiastic about immunology. I learned a lot from you and I´ m sure we´ll 
keep seeing each other as one married couple to another.
Je voudrais remercier mes bons collègues et amis de Burkina Faso (Centre National de 
Recherche et de Formation sur le Paludisme) pour les moments agréables: André Lin, 
Sabine, Faye-Ann et Jade pour la grande hospitalité et la bonne musique gangster rap 
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dans la voiture; Roland et Amad pour les soirées avec de la bière et le poulet; dr Tiono, 
dr Sirima, dr Alphonse, dr Barry, Edith, Issa, dr Coulibaly et dr Maurice pour l’aide pendant 
les études; et Nicolas, Paul, Azara, Toé et Nelson pour le séjour inoubliable à Banfora.
I would like to thank my dear colleagues from the London School of Hygiene and 
Tropical Medicine for their expertise, help, and above all pleasant company (in real life, 
via e-mail or via Skype) during field trial activities. Dear Chris, Bronner and Beth, I hope 
we’ll be designing and conducting many more field studies in the future. 
I would like to thank the collaborators from Sanaria. Dear Steve, Kim Lee, Eric, Pete and 
Anusha, it has been a pleasure to work with you. I enjoyed coming over to Maryland to 
have a look at your facility and it was a great pleasure to receive you in Nijmegen. I admire 
your absolute dedication to the production of a malaria vaccine and I hope progress will 
be made quickly. 
Dear staff from the Rubya, Biharamulo and Sumve Designated District Hospitals, 
asante sana for your hospitality and help to conduct and complete the rapid diagnostic 
test study. Dear Seif, thanks for your help with the ethics and logistics. Ook jou, Monique, 
wil ik hartelijk danken voor je hulp bij het uitvoeren van deze studie.
Ook wil ik natuurlijk al mijn fantastische MMB-para collega’s bedanken. 
Else, met jou heb ik een groot deel van mijn eerste promotiejaar doorgebracht met als 
resultaat de succesvol voltooide EHMI-9 studie. We hebben veel lol gehad en waren een 
goed team. Jorien, jij bent een rots in de branding geweest voor de momenten dat ik er 
echt geen zin meer in had. Jij was altijd opbeurend en leverde mij snoep als ik behoefte 
had aan emotie-eten. Ook de bed and breakfast in huize Jorien beviel mij prima. Rob, 
altijd de figuurlijke én letterlijke hand op de schouder, een echte lab-papa. Theo, ik wil jou 
en je team bedanken voor alle dikke druppels die jullie hebben bekeken. Gelukkig ga ik de 
komende jaren nog veel met je samenwerken en veel van je leren. Geert-Jan, ik betwijfel 
of er iemand bestaat die in zijn leven meer (gezonde!) muggen heeft gekweekt dan jij. 
Mijn basisschoolleraar zou zeggen: ga zo door! Wouter, jonge, BAM, jonge, BAM!!! Helmi, 
many thanks for giving me the opportunity to spit in a saliva sample kit for kids in 
Ouagadougou. You not only made me discover a whole new skill, but also that I’m not a 
G6PD A+ A- or Mediterranean carrier, yeah! Annemieke, jij bent de sterkste schakel op de 
afdeling. Jij zit nooit om een (humoristisch) praatje verlegen dus ik hoop dat ik je nog vaak 
lastig mag komen vallen. Ook alle andere collega´s, Marga, Rianne, Maarten, Martijn, 
Ben, Koen, Sanna, Judith, Karin, Maarten, Jona, Isaïe, Will, William, Anne, Karina, Ivo, 
Marije, Kjerstin, Amrish, Fitsum, Joshua, Wieteke en Richard wil ik bedanken voor 
de gezellige koffiemomentjes, nuttige werkbesprekingen en flexibiliteit gedurende de 
klinische studies. 
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André, Quirijn en dr Pop, jullie stonden altijd voor ons klaar. Mede door jullie betrokkenheid 
bij het welzijn van de vrijwilligers zijn de klinische trials tot een goed einde gebracht. 
Ik hoop jullie in de komende jaren nog vaak tegen te komen in de kliniek.
Beste vrijwilligers, ook jullie wil ik hierbij hartelijk danken voor jullie deelname aan de 
trials. Chères volontaires, je voudrais vous remercier pour votre participation dans les 
études.
Remko, Leo, Matthew, Linda en Meta, mijn malariacollega’s uit het ganse land, wil ik 
bedanken voor de leuke samenwerking. 
Dear Toby, many thanks for your help and expertise in writing the RDT policy paper. You 
were a great supervisor. Dear colleagues from ICIPE, I’ve had a great time on one of the 
most beautiful research sites on earth, on the shores of Lake Victoria. Beste prof. dr. 
Roscam Abbing en prof. dr. Merkx, door de mogelijkheden die jullie mij hebben 
geboden (buiten de gebaande paden!), ben ik op het punt beland waar ik nu ben. Beste 
Ronald, erelid der TTT, als hoofd van het StIP maakte jij mijn leven een stuk makkelijker. 
Dear Peter Braker, thanks for your help during my stay in Tamale. Ook Harry van 
Bockhoven en Bèr van Schijndel, bedankt!
Flexkamer-henkies, wat heb ik een mooie tijd gehad in dat muffe hok! Graswodka, 
hertjes spotten, knettersterke koffie lurken, het illegaal uitschakelen van de imbeciele schuifdeur 
en het feuten van de deurbassies. Al het geouwehoer hielp de boel te relativeren, merci! 
Beste collega AIOS en supervisoren van het Radboud en Rijnstate, de eerste maanden 
van de opleiding tot arts-microbioloog bevallen mij heel goed, mede door de warme 
ontvangst en de motiverende werksfeer.
Michiel, Bas en Sabel. Wij hebben een verleden. Michiel, jou ken ik nondezèk al 27 jaar. 
Bas en Sabel, jullie ken ik al zo’n 12 jaar. Wij hebben intussen alles wel zo’n beetje meegemaakt: 
van Pimp my Room en Calella tot het bellen van 112. INTENSO is daarom het woord dat 
onze vriendschap al jarenlang typeert. Ik hoop dat ik het tijdens Valencia 2015 allemaal 
richtig gesjèft krijg.
Geachte heeren der TTT, Sjoerd, Erik, Paul en Roddy, sinds de studietijd zijn wij een 
hechte groep die al nodig feest op z’n kop heeft gezet, van Pinkpop tot Rowwen Hèze. 
Ook de vakantie in Tunesië en de jaarlijkse TTT-weekenden waren top! Dat er nog 
vele mogen volgen, met of zonder de TTT-bitches, Martje, Wendy en Gemma en de 
TTT-aanhang, Jan, Marleen, Saar, Sandra en Tanja en alle kids.
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Erik, waar zou ik nu zijn zonder jou?! Het begon allemaal na de eerste werkgroep van 
geneeskunde, waar we beiden geen zak aan vonden. Al snel hadden we het plan om in 
het derde jaar geneeskunde naar het buitenland te vertrekken. Na veel geregel stapten wij 
uiteindelijk in augustus 2005 in het vliegtuig naar Ghana. De rest is geschiedenis! Ik vind 
het echt super dat we jou, Tanja en Sarah konden opzoeken in Zuid Afrika en ook Eveline 
en Liselot al aan elkaar hebben kunnen voorstellen. Als jullie weer in Nederland zijn, zullen 
we elkaar zeker weten weer veel zien mét whisky en sigaeren.
Lieve Klaas, Wil, Frank en Saskia, de schoonfamilie heb je niet voor het uitzoeken, maar 
in mijn geval boeit dat ook helemaal niet! Ik kom al jaren met veel plezier bij jullie over de 
vloer en heb me vanaf het begin thuis gevoeld. Bedankt voor de gezelligheid, goede 
woordgrappen en de zuurkool. We denken dat Liselot dit ook zal gaan waarderen.
Lieve Lucie en Guido, of moet ik zeggen tante Lucie en ome Guido? Het is al jarenlang 
een feest als we bij elkaar zijn. Nu jullie definitief in Mestreech zullen blijven, zullen we 
onze carnavalsoutfits maar weer uit de kast halen!
Lieve papa en mama. Jullie hebben alle ups en downs van mijn leven wel zo’n beetje 
meegemaakt en mij altijd onvoorwaardelijk gesteund. Ik kom nog altijd graag naar het 
zuiden. Niet alleen voor de vlaai, maar ook om lekker bij te kletsen met een kopje koffie in 
de zon. En aanstaande zomer kunnen jullie lekker genieten van jullie kleinkind spelend 
op het gras! 
Lieve schat, wij kennen elkaar nu al meer dan 9 jaar. Normale mensen zouden zich misschien 
al lang kapot vervelen, maar wij blijven maar praten! Jij hebt mijn promotie ups en downs 
van dichtbij meegemaakt, steunde me op de moeilijke momenten, hielp me te relativeren 
en vierde feest met mij op de mooie momenten. Afgelopen december hebben wij er een 
supermooi cadeautje bij gekregen toen onze dochter Liselot werd geboren. Ik heb nu al 
zin om met jullie door Burgers´  Zoo te banjeren. Ik hou van jullie, kus!
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Guido Joseph Henri Bastiaens was born on the 11th of February 1984 in Heerlen, The 
Netherlands. In 2002 he passed his Gymnasium exam at the Bernardinuscollege in Heerlen 
and started studying Biology at the Radboud University Nijmegen. After receiving his 
propaedeutic diploma, Guido switched to study Medicine in 2003. 
 In 2005 he worked as a medical student in various health facilities in Tamale, Ghana 
(Bruham Clinic, Free and Fair Pharmacy and SDA Hospital) where he also conducted 
a public health-oriented research (prof. dr. E. Roscam Abbing). In 2007 he conducted 
a research on maxillofacial trauma in the department of Maxillofacial Surgery of the 
Muhimbili Medical Centre in Dar es Salaam, Tanzania (prof. dr. M.A. Merkx and dr. E.N. 
Simon). In this period he was (vice-)chairperson of the student branch of the Nijmegen 
Institute for International Health and he followed the Interdisciplinary Honours Programme 
at the Radboud University Nijmegen from which he graduated in 2008. In 2009 Guido 
followed an internship in Tropical Medicine in northern Tanzania (dr. M. Keuter), where he 
also conducted his first malaria research in three district hospitals (dr. T. Bousema, dr. S.A. 
Shekalaghe). Upon returning to the Netherlands, he obtained his medical degree in 2010 
and started working as a resident in the department of General Surgery of the Slingeland 
Hospital as part of the training in Tropical Medicine.
 Guido started his PhD in the department of Medical Microbiology of the Radboud 
University Medical Center in 2011, of which the research is described in this thesis (prof. dr. 
R.W. Sauerwein and dr. T. Bousema). During this period he conducted clinical malaria trials 
in the Netherlands and Burkina Faso, and fieldwork in Kenya. Since 2011 he is also a 
member of Uniting Streams, the working group for young field researchers of the Dutch 
Society of Tropical Medicine.
 As of October 2014, Guido is working as a resident in Medical Microbiology at the 
Radboud University Medical Center.
 Guido is married to Else Bastiaens-Eleveld and they have one daughter, Liselot, born 
on the 13th of December 2014.
De ASN Bank zet zich in om de duurzaamheid van de samenleving te bevorderen en laat zich daar 
in haar economisch handelen door leiden. Economische groei mag volgens de ASN Bank niet 
ten koste gaan van het milieu, de natuur, kwetsbare bevolkingsgroepen of anderszins worden 
 afgewenteld op toekomstige generaties. In Nederland is de ASN Bank sinds 1960 voorloper 
op het gebied van duurzaam bankieren. De bank is actief op het gebied van beleggen, sparen, 
 betalingsverkeer en duurzame financieringen. De ASN Bank heeft ruim 600.000 klanten en een 
 totaal beheerd vermogen van € 12 miljard.
Via de ASN Foundation ondersteunt de ASN Bank projecten over de hele wereld.
Het doel van de ASN Foundation is geld beschikbaar te stellen aan organisaties en projecten om 
duurzame initiatieven mogelijk te maken.
De ASN Bank maakt deel uit van SNS REAAL. Meer informatie vindt u op www.asnbank.nl of 
www.asnbank.nl/foundation.


